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Non-syndromic cleft lip/palate (nsCL/P) is a congenital birth defect 
characterised by cleft(s) of the upper lip with or without a cleft of the palate. The 
aetiology of nsCL/P is complex with both genetic and environmental risk factors. In 
this thesis, I applied Mendelian randomization (MR) and polygenic risk scoring (PRS) 
to explore the aetiology of nsCL/P and possible consequences of the phenotype.  
In Chapter 3, strong evidence was found for nsCL/P having a highly 
polygenic architecture with a substantial SNP heritability suggesting that PRS are 
likely to be effective genetic proxies for nsCL/P.  
In Chapter 4, three putative loci were identified where the effect of nsCL/P 
genetic risk variants on disease liability may be mediated by DNA methylation, 
although conclusions are limited by possible tissue specific effects.  
In Chapter 5, nsCL/P genetic risk variants were shown to have a consistent 
additive effect on philtrum width in the general population suggesting that liability to 
nsCL/P causes decreased philtrum width which supports a polygenic threshold 
model of inheritance for nsCL/P.  
In Chapter 6, nsCL/P genetic variants were shown to not be strongly 
associated with adverse developmental outcomes that are common in nsCL/P 
cases. These findings suggest that the adverse outcomes tested are unlikely to be 
related to underlying liability to nsCL/P.  
In Chapter 7, nsCL/P PRS were found to predict increased risk of oral 
cavity/oropharyngeal cancer (OC/OPC). Follow-up analyses suggested the 
relationship was non-causal and that nsCL/P and OC/OPC likely share risk factors, 
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Chapter 1: Introduction  
The focus of this doctoral thesis is non-syndromic cleft lip/palate (nsCL/P), a 
subtype of orofacial clefts (OFCs). Previous research has established that nsCL/P 
has a complex aetiology with both genetic and environmental risk factors. Although 
nsCL/P does not typically present with major anomalies independent from the facial 
cleft structure, there is growing evidence for phenotypic differences between nsCL/P 
cases and the general population, such as lower educational attainment amongst 
nsCL/P cases.  
Despite recent advances in nsCL/P research there remains limited or partial 
understanding in specific areas, such as; the characteristics of nsCL/P-related 
genetic variation (genetic architecture), the aetiological role of epigenetic processes 
for nsCL/P, the nature of the shared genetics between nsCL/P and facial 
morphology, and the mechanisms underlying the increased incidence of 
developmental and disease outcomes in nsCL/P cases. In this chapter, I introduce 
the nsCL/P phenotype and the research questions of interest before discussing the 
advantages of applying Mendelian randomization (MR) and polygenic risk scoring 
(PRS) approaches to explore correlation and causality to increase understanding of 
the phenotype. 
1.1 Non-syndromic cleft lip/palate 
 In this section, I give an overview of what is currently known about nsCL/P, 
including information relevant to the aetiology, phenotypic consequences and public 





1.1.1 Facial development and orofacial clefts 
OFCs refer to a subtype of facial clefts, primarily affecting the upper lip and 
the palate 1. The facial region begins to form in the fourth embryonic week; bilateral 
cellular structures called pharyngeal or branchial arches create processes that 
coordinate facial development. The upper lip and upper jaw are formed by the fusion 
of the medial nasal and maxillary processes, the lower jaw is formed by the 
mandibular process while the philtrum is formed by the fusion of the two medial 
nasal processes 2,3. The palate begins to form by the sixth week and is formed by 
several palatine processes. A cellular mass developing between the surfaces of the 
maxilla forms the primary palate while the second palate is formed by the remaining 
hard and soft palate 4. Even minor developmental anomalies may prevent process 
fusion, which results in the formation of a cleft at the boundary 3. Therefore, clefts 
can form at any point where merging or fusion occurs during development; a 
complete cleft is characterised by the complete absence of merging or fusion while 
some merging or fusion is found in incomplete clefts 5.  
1.1.2 Incidence and subtypes of orofacial clefts 
 OFCs have an estimated incidence of around 1 in 700 individuals, with the 
incidence varying across different ethnic groups 1,6. OFCs are often divided into the 
subtypes; cleft palate only (CPO) and cleft lip with/without cleft palate (CL/P). The 
subtypes are sexually dimorphic, with CL/P more common in males and CPO more 
frequent amongst females 1. The argument for the division into CPO and CL/P is that 
embryology and genetic research suggest mechanistic differences between the 
development of clefts of the primary palate and lip with development of clefts 
affecting only the secondary palate 7. However, there is also emerging evidence of 





A – Unilateral cleft lip only (CLO or CL/P) 
B – Bilateral cleft lip only (CLO or CL/P) 
C – Unilateral cleft of the secondary palate only (CPO) 
D – Unilateral clefts of the primary and secondary palates (CPO) 
E – Bilateral cleft of the secondary palate (CPO) 
F – Bilateral clefts of the primary and secondary palates (CPO) 
G – Unilateral clefts of the lip and primary palate (CLP or CL/P) 
H – Unilateral clefts of the lip and primary/secondary palates (CLP or CL/P) 
I – Bilateral clefts of the lip and primary palate (CLP or CL/P) 
J – Bilateral clefts of the lip and primary/secondary palates (CLP or CL/P) 
cleft palate (CLP) and cleft lip only (CLO), suggesting that these subtypes should 
also be considered separately when possible 8,9. The different cleft subtypes can 
also occur unilaterally, i.e. affects one side of the lip or palate, or bilaterally, affects 
both sides of the lip or palate. Figure 1 below shows 10 common OFC subtypes and 
demonstrates the heterogeneity within the different OFC sub-classifications (e.g. 
CL/P, CPO).  
Figure 1: Cleft lip and palate – subtypes and classifications 


















1.1.3 Syndromic and non-syndromic orofacial clefts 
OFCs can present as a symptom of a Mendelian disorder, traits with 
inheritance controlled by a single locus. One of the most common OFC syndromes is 
Van der Woude syndrome, which is caused by mutations in the IRF6 gene 10. There 
are over 400 genetic syndromes that may present with an OFC, among other 
symptoms 11, including Pierre-Robin sequence/syndrome, median facial dysplasia 
and Velocardiofacial syndrome 12. Approximately 70% of OFCs are non-syndromic, 
presenting with the facial cleft structure but no other apparent developmental or 
physical abnormalities 7. Diagnosis of a non-syndromic OFC is typically based on 
family history and the absence of other abnormalities. The focus of this thesis project 
is nsCL/P. 
1.1.4 Aetiology of nsCL/P 
While syndromic forms of cleft are caused by genetic variation in a single 
locus, nsCL/P has a more complex aetiology with multiple distinct genetic risk factors 
and several proposed environmental risk factors 13.  
1.1.4.1 Genetic risk factors 
Linkage analysis 14, an early genetic risk mapping method, was relatively 
successful for identifying regions relevant to syndromic OFCs 15,16 but was largely 
ineffective for nsCL/P. Multiple regions were found across different studies to co-
segregate with nsCL/P 17-19 but the findings often did not replicate 20. The lack of 
clear segregation within pedigrees demonstrated the complex genetic aetiology of 
nsCL/P. 
Genome-Wide Association Studies (GWAS) were more successful in 
identifying risk loci for nsCL/P. Different study designs, including parent-offspring 





nsCL/P and the genome. Subsequent meta-analyses of GWAS results from 
independent data-sets, across distinct ethnic backgrounds, have been used to 
identify over 40 distinct genetic risk loci for nsCL/P 9,21-30. The characteristics of 
nsCL/P genetic risk variants, such as allele frequency and effect sizes, have 
important implications for aetiological understanding of the phenotype as well as for 
study design. The genetic architecture of nsCL/P as well as relevant implications and 
methodologies (e.g. GWAS) are discussed and explored in more detail in Chapter 3. 
Follow-up of nsCL/P risk loci demonstrated that the majority of risk regions 
contain only one common variant signal 31 and that a major nsCL/P risk locus may 
affect disease liability through gene expression pathways 32. Epigenetic processes 
such as DNA methylation may play a role in the aetiology of nsCL/P 8,33-36 through 
gene expression. DNA methylation is of particular epidemiological interest to nsCL/P 
because it can be altered by environmental exposures. The aetiological relevance of 
DNA methylation to nsCL/P is the primary focus of Chapter 4. 
1.1.4.2 Environmental risk factors 
Environmental risk factors for nsCL/P are not as well-characterised as the 
genetic risk factors. The in-utero and maternal environment are the primary routes of 
exposure for a birth defect, and the effects of certain maternal environmental risk 
factors on embryology are well characterised. For example, maternal alcohol intake 
is known to have a teratogenic effect on the developing foetus 37,38 and maternal folic 
acid supplementation has been shown in randomised controlled trials (RCTs) to be 
protective against neural tube defects 39-41. Other potential maternal risk factors 
during pregnancy, include; cigarette smoking, which is associated with increased risk 
of adverse outcomes such as low birth-weight 42-46, and obesity, which is associated 





Previously studied maternal environmental risk factors for nsCL/P include; 
folic acid 50-66, obesity 48,67-69, smoking 70-76, alcohol consumption 74,77-80, cholesterol 
81,82, low plasma zinc 83-85, vitamin B6 54,86,87 and vitamin A 88. In general, the 
evidence for association between proposed exposures and risk of nsCL/P is largely 
inconsistent, particularly for folic acid 57, but a recent meta-analysis found consistent 
evidence for an association between maternal adiposity and cleft palate with or 
without cleft lip (CP/L) 67. It is also important to note that it is possible that the 
paternal environment may play an aetiological role via interaction effects with the 
mother or via sperm 89.  
 A major limitation of reviewing the epidemiological literature to infer 
aetiological relationships is that studies reporting null results may be less likely to be 
published, which can skew the literature evidence and affect meta-analyses 90. A 
further limitation is that observational epidemiological studies may be susceptible to 
confounding (discussed in the next section). Reliably identifying maternal risk factors 
for nsCL/P could have important implications for prevention and also improve 
biological understanding. An MR framework, which will be discussed in the next 
section, has the potential to accurately investigate possible maternal risk factors for 
nsCL/P. However, an investigation of maternal risk factors for nsCL/P is greatly 
limited by the available data sources (data sources are described in Chapter 2), 
which lack sufficient sample sizes and suitable control groups. This is discussed in 
more detail in Chapter 8. 
1.1.5 Phenotypic consequences 
Typically, the treatment for an OFC involves surgical corrections to repair the 
lip and/or palate of the affected child, at a young age. However, post-surgery, there 





the general population. Examples of phenotypic differences between nsCL/P cases 
and controls that will be discussed in more detail in this section, include: facial 
morphological differences distinct from the OFC, dental anomalies and difficulties 
with speech 1. More concerning is the evidence suggesting that individuals with 
nsCL/P may have a reduced quality of life and higher mortality up until the age of 55 
13,91,92.  
1.1.5.1 Facial morphology 
Syndromes including an OFC often present with additional craniofacial 
anomalies, but nsCL/P does not usually present with major facial anomalies distinct 
from the OFC. However, there are several lines of evidence suggesting a possible 
relationship between the genetics of nsCL/P and facial morphology. Firstly, the 
genetic overlap between OFC syndromes and nsCL/P suggests the potential for 
some overlap in phenotypic presentation, independent of the facial cleft structure 
93,94, secondly, the identification of pleiotropic genes implicated in both nsCL/P and 
facial variation 95, and thirdly, the observation of sub-clinical differences in facial 
morphology in individuals with nsCL/P and their unaffected relatives 93,96-98. Facial 
development and the formation of an OFC are largely synchronous, so improved 
understanding of shared genetics may have important aetiological implications. The 
relationship between genetic variants associated with nsCL/P and facial morphology 
is explored and discussed in more detail in Chapter 5. 
1.1.5.2 Adverse developmental outcomes 
Adverse outcomes with evidence for increased incidence in nsCL/P cases, 
include; impaired growth 99-101, dental anomalies 102-109, auditory problems 110-113, 
speech impediments 114-116, behavioural problems 117-120 and lower educational 





with an OFC may have reduced quality of life 13,91. It is currently unclear which 
outcomes are related to an individual’s underlying liability to nsCL/P (the liability 
concept is discussed in more detail in the next section) and which outcomes are 
caused by the physical presence of an OFC and/or the corrective surgery. 
Discerning which of the two possibilities is more likely may have important 
implications for treatment and follow-up of nsCL/P cases. In Chapter 6, the 
association between genetic risk variants for nsCL/P and adverse developmental 
outcomes is investigated. 
1.1.5.3 Increased risk of cancer? 
Previous research has suggested that congenital anomalies and cancer may 
have shared aetiology 122. Specifically for nsCL/P, there is largely inconsistent 
evidence for increased risk of cancer amongst cases and their unaffected family 
members 122-126 but several genes have been implicated in the aetiology of both 
phenotypes 127-129. 
Cancers of the oral cavity and pharynx (OC/OPC) are strong candidates for 
having shared genetic aetiology with nsCL/P and this potential relationship has not 
been previously investigated. Shared genetics between nsCL/P and OC/OPC would 
suggest that nsCL/P cases may have increased risk of OC/OPC and that the two 
phenotypes may share common biological pathways or environmental risk factors. In 
Chapter 7, I investigate the possibility of shared genetic aetiology between OC/OPC 
and nsCL/P. 
1.2 Epidemiology, the genome, polygenic risk scores & Mendelian 
randomization 
The research questions of this doctoral thesis are epidemiological in nature, 





Here I discuss different epidemiological techniques and explain the relevance of the 
genome in an epidemiological context. MR and PRS are recurring themes 
throughout this thesis, both are utilised in the majority of results chapters and so are 
described in detail.  
1.2.1 Correlation & Causation 
Epidemiology refers to the study of the effects and causes of disease. One of 
the most important public health applications of epidemiology is to inform 
preventative interventions, which aim to reduce the incidence of a disease in a 
population or a sub-sample of a population. Interventions may take a number of 
forms, including medical advice, drug prescriptions or government policy. For 
example, based on evidence that red meat may be carcinogenic, the World Health 
Organisation recommended reduced consumption of red meat 130.  
The premise of a preventative intervention is that on a population level, the 
intervention will cause a beneficial change, and so prevention is heavily reliant on 
genuine causal relationships. Correlation does not necessarily imply causation, 
distinct traits can be phenotypically correlated, i.e. two traits can often occur together 
in the same individuals, but this does not mean that modifying one trait would directly 
impact the other. One possibility is that two traits are correlated because of shared 
causes of the traits; for example, yellow fingers and lung cancer are correlated 
because they are both caused by cigarette smoking. Alternatively, this correlation 
could be because one of the traits is causally linked to the other, as in the genuine 
causal relationship between tobacco smoking and risk of lung cancer 131.  
1.2.2 Randomised controlled trials 
The gold standard for testing causality is the RCT. RCTs aim to enact a 





with study participants and personnel blinded to treatment group allocation. Study 
participants are then followed up over time, to determine the effects of the treatment 
on predetermined outcomes. When designed appropriately and well-powered, RCTs 
provide reliable causal estimates but trials cannot be used to test every potential 
causal relationship because they are expensive, time consuming and often unethical. 
1.2.3 Observational epidemiological studies 
One epidemiological tool that can help to identify causal relationships is 
observational epidemiology. Observational epidemiology studies involve observing 
and collecting data from a sub-sample of a population and extrapolating the results 
in order to make population-wide level inferences. Case-control, cross-sectional and 
prospective cohort studies are among the most frequently employed designs.  
1.2.3.1 Observational study designs 
Case-control studies are often retrospective; cases for a particular disease 
are recruited and compared to controls (individuals without the disease), purported 
causal attributes are compared between the two groups to identify factors that may 
contribute to disease incidence. Case-control studies are very useful for studying 
rare diseases or events but the potential for bias, especially sampling bias, is a major 
limitation. A cross-sectional study involves extracting data from a population at a 
single time point in order to determine the prevalence - the number of cases in a 
population - at a specific time-point. Cross-sectional studies can investigate multiple 
outcomes but because data are only extracted at a single time-point, cannot easily 
distinguish between cause and effect. Prospective cohort studies involve recruiting a 
representative sample from the population and following study participants up over 
time, to determine if they develop outcomes of interest. Cohort studies are an often-





may alleviate the possibility of reverse causation, where the outcome of interest 
actually affects the exposure of interest. However, prospective cohort studies are 
often expensive, time-consuming and may be biased by confounders 132. A notable 
successful prospective cohort study was the British Doctor’s study which provided 
evidence supporting the causal link between lung cancer and smoking 131.  
1.2.3.2 Limitations of observational studies 
The primary limitation of observational studies is that they are not controlled 
experiments, like RCTs. To determine the causal effect of an exposure on a disease 
outcome, we ideally want to ensure that study participants are identical in every 
regard other than levels of the exposure. In general, across populations this does not 
hold; lifestyle and dietary factors are heavily interlinked. For example, individuals 
who have a diet low in selenium are likely to differ in other ways (e.g. in relation to 
other dietary factors or lifestyle), to individuals with a diet high in selenium. This 
leads to difficulties with inferring causality from observational studies because of the 
potential for confounding. Despite the best efforts to account for confounders in 
analysis, observational studies are still highly susceptible to unmeasured residual 
confounding. The difficulties of inferring causality from observational studies are 
highlighted by the discordance between observational studies and RCTs; for 
example, observational studies found increased beta-carotene intake was 
associated with decreased risk of cardiovascular disease but RCTs found weak 
evidence for a protective effect of beta-carotene supplementation 133. The differing 
results may be explained by confounding or they may be explained by differences in 
the measured exposure (short term supplementation against circulating levels). 





analyses are often unreliable at robustly identifying causal risk factors, meaning that 
when RCTs are not possible, there are limited options for causal inference.  
1.2.4 The use of genetic data in an epidemiological context: Polygenic risk 
scores and Mendelian randomization  
An alternative approach to observational epidemiology is to use genetic data 
in an epidemiological context (genetic epidemiology) to explore correlation and 
causality. In this section, I will discuss two relevant methodologies, PRS and MR. 
PRS are scores consisting of multiple genetic variants associated with a trait that can 
be used for either risk prediction or for the detection of shared genetic factors 
influencing two distinct traits (which could suggest a possible causal relationship). 
MR is an instrumental variable (IV) approach using genetic variants associated with 
an exposure to formally examine the causal relationship between that exposure and 
an outcome.  
1.2.4.1 Polygenic risk scores  
PRS include genetic variants that are associated with the phenotype of 
interest, often identified in GWAS, and are used as genetic predictors or proxies of 
the phenotype of interest. PRS are determined for each individual using either an 
unweighted score, where the number of risk alleles are summed, or a weighted 
score where GWAS effect sizes are used to weight the contribution of each genetic 
variant to the score. PRS have the potential to be useful in risk prediction; a disease 
PRS derived from one study can be tested for prediction of risk of the same disease 
in an independent sample. Although PRS often explain a substantial proportion of 
phenotypic variation (~40% for height 134), the use of PRS for risk prediction is still 
largely in its infancy. PRS can also be used to detect shared genetic risk factors 





phenotype in an independent sample, then this suggests that the association is likely 
attributable to genetic factors 135. A further application of PRS is to formally estimate 
genetic correlation, which will be detailed in Chapter 3. 
 PRS have had success as genetic proxies for complex traits where there are 
few individual genetic variants reaching genome-wide significance and where many 
common variants are thought to contribute to disease risk, i.e. highly polygenic traits 
136. By including a large number of genetic variants, PRS often have increased 
power to detect shared genetic aetiology compared to scores which include only 
genome-wide significant variants. The utility of using PRS to detect shared genetic 
aetiology between nsCL/P and other phenotypes, will be explored in Chapter 3.  
However, a strong association between a PRS for trait A with trait B could 
imply either correlation or causality. The relationship could be non-causal; trait A and 
trait B have shared genetic aetiology. Alternatively, the relationship could be causal; 
if trait A has a causal effect on trait B, then the genetic risk factors for trait A will also 
influence trait B, or vice-versa. The likelihood and interpretation of the different 
possibilities is largely dependent on the specific traits of interest and relevant factors 
such as temporality and liability (which will be discussed later on in the chapter). 
1.2.4.2 Premise of Mendelian randomization 
PRS can consist of hundreds or thousands of genetic variants and so, are 
often well-powered to detect associations. However, as described above, when there 
is an association between a PRS and an observed phenotype it can be difficult to 
distinguish between correlation and causality. Similar to PRS methods, MR analyses 
utilise genetic variants but under certain conditions, which will be detailed below, MR 
can be used to evaluate causality. Important differences between the two methods 





second, that MR analyses often include sensitivity analyses to test assumptions 
required for inferring a causal relationship.  
The primary strength of using an MR approach to evaluate causality over 
observational epidemiological methods is that genetic variation may be less prone to 
reverse-causation and confounding than the measured phenotype itself. Reverse-
causation is largely ruled out because an individual’s genotype is fixed from birth 137, 
while it follows from the first two laws of Mendelian genetics that genetic variants are 
unlikely to be associated with confounding factors on a population level. Mendel’s 
first law of segregation states that allele pairs segregate during meiosis and 
randomly recombine at conception suggesting that each segregated allele has an 
equal chance of being present in a zygote. An extension of this law is that the 
probability of each segregated allele being present in a study participant can be 
assumed to be independent of environmental factors. While Mendel’s second law of 
independent assortment states that alleles for different traits assort independently of 
one another, suggesting that the inheritance of a trait is independent of the 
inheritance of other traits 137,138. 
If genetic variation leads to phenotypic differences which in turn affect disease 
risk, then the genetic variation should be related to the disease risk to the extent of 
the effect of the genetic variation on the phenotypic differences. The random 
inheritance of alleles and independent assortment of alleles relevant to an MR 
analysis offers parallels to the random allocation of treatment groups in an RCT, 












1.2.4.3 MR in a parent-offspring trio  
MR can be illustrated by considering the pattern of inheritance within a parent-
offspring trio; assuming one parent is heterozygous at a locus and the other is 
homozygous, then the offspring has a 50% chance of inheriting each of the alleles 
from the heterozygous parent. Therefore, if the genotype at this locus is causally 
related to a disease, we would expect a higher proportion of disease cases to have 
been transmitted the disease risk allele from heterozygous parents than for controls. 
If an over-transmitted risk allele is known to be related to increased LDL cholesterol, 
this suggests that LDL cholesterol may be a risk factor for the disease. However, in 
practice, MR analyses are seldom applied to parent-offspring trios because of the 
Figure 2: Comparison between a Randomised Controlled Trial (left) and a Mendelian 





difficulties recruiting large cohorts of trios and the lower statistical power compared 
to case-control studies 137.  
1.2.4.4 MR in association studies and one/two-sample MR 
Therefore, MR analyses mostly utilise data from genetic association studies of 
individuals who are not closely related. MR in this context can be thought of as an 
approximation to a parent-offspring framework because the case-control design may 
be susceptible to potential sources of bias such as assortative mating and dynastic 
effects, which a parent-offspring design is robust to. Potential sources of bias in MR 
studies will be discussed later in the chapter. 
MR analyses can be one-sample, where the association between the genetic 
instruments with the exposure and outcome are measured in the same individuals, 
or two-sample, where these associations are measured in non-overlapping samples. 
A major advantage of two-sample MR is that the exposure and outcome do not need 
to be measured in the same data-set. Instead, GWAS summary statistics for the 
exposure and outcome can be used to estimate the causal effect. Two-sample MR is 
particularly useful for the analyses in this thesis because a primary research 
question regards the causal effect of nsCL/P risk variants (derived from nsCL/P 
cases and controls) on outcomes in the general population. However, two-sample 
MR requires careful harmonisation of genetic instruments and the assumption that 
genetic instruments for the exposure are also valid instruments for the exposure in 
the outcome data-set 139.   
1.2.4.5 Assumptions of Mendelian randomization 
MR is not, however, a panacea to every epidemiological question. The 
method relies on several assumptions, which are required for causal inference. 





significant), secondly, the variants cannot influence the outcome through a pathway 
independent of the exposure and thirdly, the variants should not be associated with 
confounders of the relationship between the exposure and the outcome 140.  
The first assumption requires the identification of genetic variation robustly 
associated with the exposure of interest in the population of study, often from 
GWAS, ideally replicated. Population stratification may lead to violations of the first 
assumption. The second and third assumptions may be violated for a number of 
different reasons, including; survival bias, pleiotropy, assortative mating, dynastic 
effects and canalisation 141. 
1.2.4.6 Survival bias 
Survival bias can affect the estimate of the gene-outcome relationships in a 
GWAS, which may violate the second and third assumptions. An illustrative example 
of where survival bias could potentially affect the gene-outcome estimate is in the 
context of tobacco smoking and Alzheimer’s disease. A previous MR study, found 
that a genetic variant in CHRNA5, which is strongly associated with the quantity of 
cigarette smoking, is protective against Alzheimer’s 142. If smoking worsens the 
progression of Alzheimer’s resulting in increased mortality amongst cases, then this 
would mean that cases with the smoking-related variant may be underrepresented in 
study populations. This underrepresentation could then induce a spurious inverse 
association between the smoking-related variant and Alzheimer’s incidence.  
1.2.4.7 Population stratification 
Population stratification refers to genetic variants being spuriously associated 
with a trait when they are instead ancestral markers. If we assume that a disease, 
say type 2 diabetes (T2D), is much more prevalent in a particular ancestral group 





ancestral markers will be associated with T2D for reasons unrelated to T2D 143. For 
this reason, GWAS are generally performed within relatively homogeneous 
populations and methods such as principal components analysis (PCA) or linear 
mixed models (LMM) are further used to account for population differences between 
individuals. 
1.2.4.8 Pleiotropy 
Pleiotropy refers to a genetic variant being associated with multiple 
independent phenotypes. There are two types of pleiotropy; vertical or mediatory 
pleiotropy and horizontal pleiotropy (which can lead to balanced or directional 
pleiotropy in an MR context). Vertical or mediatory pleiotropy refers to the instance 
where a genetic variant affects the exposure, which in turn affects the outcome (i.e. 
the exposure and the outcome are on the same pathway and there is a causal 
relationship). Horizontal pleiotropy refers to the instance where a genetic variant 
affects the exposure and outcome through independent pathways. Balanced 
pleiotropy refers to the instance when genetic variants are horizontally pleiotropic, 
but across all genetic variants, the net bias in an MR analysis from pleiotropy is null 
144, while directional pleiotropy refers to the instance when horizontal pleiotropy 
biases the causal estimate.  
Wide-spread pleiotropy across the genome is thought to be the norm rather 
than the exception 145. However, the effect of wide-spread pleiotropy on the validity 
of MR analyses is dependent on whether the pleiotropy is balanced or directional. A 
previous study found that for two highly polygenic traits, height and bone mineral 
density, there is no evidence of directional pleiotropy 146. MR-Egger 147 can be used 
to formally test for unbalanced horizontal pleiotropy while comparisons between the 





median 148 and the weighted mode 149 can also be used to infer unbalanced 
horizontal pleiotropy.  
1.2.4.9 Assortative mating 
Assortative mating refers to the non-random mating of individuals according to 
a particular phenotype, characterised by a higher phenotypic correlation amongst 
spouse-pairs than in non-spouse pairs. For example, if we assume that a phenotype 
is influenced by both environmental and genetic factors, then assortative mating on 
the phenotype will result in spousal correlation for both environmental and genetic 
factors relating to the phenotype. In any resulting offspring, environmental and 
genetic factors relating to the phenotype will then be correlated. Genetic factors 
being associated with environmental factors, which are common confounders, 
violates the third IV assumption. There is strong evidence that many complex traits 
such as educational attainment and height influence mate selection and so care 
must be taken when using these phenotypes in an MR study 150-152.  
1.2.4.10 Dynastic effects 
In some instances, MR analyses may be biased by the genotype of the 
parents, otherwise known as dynastic effects. If we are trying to disentangle whether 
alcohol consumption reduces intelligence, then maternal genotype is a potential 
confounder. This is because if the mother has a variant influencing their alcohol 
consumption, then this will affect the genotype of the offspring, potentially the social 
environment for the offspring via alcohol consumption, potentially the drinking 
behaviour of their offspring through a shared environment and also potentially affect 
the IQ of the offspring because of the teratogenic impact of alcohol. 
Effects of assortative mating and dynastic effects are alleviated when using 





However, as discussed previously, in practice complete genotype data on large 
numbers of offspring and their parents is often unavailable and so, MR frequently 
utilises genetic instruments derived in genetic studies of unrelated individuals. 
1.2.4.11 Canalisation 
Canalisation refers to the degree to which phenotypic development is 
unaffected by genetic and environmental variation on a population level 153. 
Canalisation may have important implications for MR because developmental 
compensation for the effect of a genetic variant may distort the estimate of the gene-
outcome relationship 141.  
1.2.4.12 Applications of Mendelian randomization 
The conventional use of MR is for testing causal relationships between 
modifiable continuous exposures and disease outcomes (e.g. cholesterol or alcohol 
on cardiovascular disease 154,155). Beyond determining the effects of continuous 
environmental exposures on disease outcomes, the principles of MR can be used 
more generally to infer the likely direction of causality. For example, in the context of 
DNA methylation. DNA methylation is an epigenetic process, which unlike the 
genome, varies across the life course. Therefore, DNA methylation can be a cause 
or consequence of a phenotype and so the principles of MR can be used to 
investigate temporal relationships; DNA methylation may be on the causal pathway 
to a phenotype or DNA methylation could be a consequence of a phenotype 
(reverse-causation). The use of MR in the context of DNA methylation and nsCL/P, 
will be discussed in more detail in Chapter 4.  
An example of a non-conventional application of MR is when estimating the 
causal effect of liability to a disease on an outcome. The inheritance of dichotomous 





a population, liability to a disease can be assumed to be normally distributed; 
individuals over a liability threshold have the trait and individuals under do not 156. 
The liability scale is easily demonstrated with psychiatric traits such as schizophrenia 
and autism, which are highly continuous traits but can be dichotomised into cases 
and non-cases. Psychiatric tests can be thought to be an estimate of disease liability; 
sub-clinical variation in psychiatric traits is present across the general population and 
threshold cut-offs are used for diagnosis of clinical cases. There is some evidence 
that sub-clinical liability to psychiatric traits may have beneficial effects, which could 
explain the evolutionary persistence of clinical psychiatric disorders. For example, 
genetic variants associated with autism spectrum disorder (ASD) have been shown 
to be associated with increased cognitive ability in the general population while 
genetic variants associated with increased educational attainment have been shown 
to be over-transmitted to children with ASD 157,158.  
The liability model may be particularly relevant to nsCL/P because unaffected 
family members have been observed to have increased incidence of related sub-
phenotypes 95. Whether a liability model of inheritance is appropriate for nsCL/P will 
be discussed in more detail and explored in Chapter 3. In the context of 
demonstrating a causal relationship between liability to a trait and an outcome in an 
MR analysis, identified genetic variants associated with the trait are used as a 
genetic proxy for the genetic and non-genetic contributions contributing to liability. A 
consistent effect of genetic risk variants for the exposure on the outcome would 
support the liability hypothesis. However, if the effect of genetic risk variants for the 
exposure on the outcome is heterogeneous, then this suggests that the association 
may be driven by shared risk factors, such as environmental factors or specific 





of MR to infer causal effects of liability to nsCL/P on phenotypes will be employed 
and discussed in Chapters 5 and 7.  
1.3 Summary and overview of thesis aims 
Under the right conditions, PRS and MR can be effective tools for answering 
epidemiological questions relevant to nsCL/P. However, both the use of PRS to 
detect genetic overlap, and the non-conventional use of MR to test the causal effect 
of liability to nsCL/P on phenotypes rely on certain assumptions about the 
dimensionality and genetic architecture of nsCL/P. Therefore, in Chapter 3, the aim 
is to explore the different components of the genetic architecture of nsCL/P and 
estimate the proportion of phenotypic variation explained by single nucleotide 
polymorphisms (SNPs), base-pair changes with a minor allele frequency (MAF) 
greater than 1%, on the genotyping chip. 
In later chapters, the aim is to use PRS and MR to tease apart correlation and 
causality. In Chapter 4, epigenetic and genetic data are used in conjunction with MR 
to test the hypothesis that DNA methylation may mediate the effect of genetic risk 
variants for nsCL/P. In Chapter 5, PRS and MR are used to disentangle the shared 
genetics of nsCL/P and normal-range variation in facial morphology. In Chapter 6, 
PRS are used to explore if nsCL/P genetic risk variants explain the increased 
incidence of developmental outcomes amongst children with an OFC. Finally, in 
Chapter 7, PRS and MR are used to investigate shared genetic aetiology between 













Chapter 2: Data sources 
2.1 Introduction 
The work in this doctoral thesis utilises a range of different data types, 
obtained from many different studies and populations (Table 1). Many data sources 
are used in multiple chapters, so the purpose of this chapter is to give an overview of 
the different studies used in analyses and discuss primary data sources in detail for 
reference when reading subsequent chapters. Methodology that is specific to 
particular chapters will be described in the relevant chapter.  
Table 1: Summary of data sources 




Orofacial cleft parent-offspring 
trio study 
Individual level genotype data 
Case-control phenotyping 
Avon Longitudinal Study 
of Parents and Children 
Cohort study Individual level genotype data 
DNA methylation data 
Phenotype data 
UK Biobank Cohort study Individual level genotype data 
Phenotype data 
Oral cavity and 
oropharyngeal cancer 
case-control data-set 
Cancer case-control GWAS 
study 
Individual level genotype data 
Case-control phenotyping 
Bonn-II study Orofacial cleft case-control 
GWAS study 
GWAS summary statistics 
Genetics of Overweight 
Young Adults 
Case-cohort study of extreme 
BMI 
Individual level genotype data 
DNA methylation data 
The Cleft Collective Orofacial cleft family study DNA methylation data 
Case-control phenotyping 
methWAS cohort Orofacial cleft case-control 
study of DNA methylation 
Summary statistics  
Genotype-Tissue 
Expression project 
Study of genotypic effects on 
gene expression 
Summary statistics 
NESDA NTR Conditional 
eQTL catalog 
Study of genotypic effects on 
gene expression 
Summary statistics 
3D Facial Norms 
Database 
Genetics of facial morphology 
study in the general population 
Summary statistics 
Individual level data 









2.2 International Cleft Consortium (ICC)  
2.2.1 Background 
The International Cleft Consortium (ICC) is a large, publicly available (via 
dbGAP study accession: phs000094.v1.p1 159,160) database of genetic data relevant 
to OFCs. The data-set consists predominantly of OFC cases and their parents, 
sampled across a wide array of geographical locations in North America, Europe and 
Asia. Phenotype data consists of OFC subtype classifications as well as information 
on measured common maternal exposures (available in a subset of the sample). In 
total, the available data-set with complete genotype data includes 2,029 parent-
offspring trios, 401 parent-offspring pairs, 88 singletons and 25 assorted extended 
families. Of the 2,543 individuals with a diagnosed OFC; 1,988 were classified as 
nsCL/P cases, 582 were classified as CPO cases and 21 presented with an 
unknown cleft subtype. Individuals were recruited from across 13 different centres 





Table 2: Recruitment centres and self-reported ethnicity of the ICC sample 







   
Chengdu  0  452 0 452 
Denmark  148  0 0 148 
Iowa  288  1 2 291 
Korea  0  198 0 198 
Maryland  451  6 52 509 
Norway  1173  14 9 1196 
Philippines  0  0 292 292 
Pittsburgh  407  0 5 412 
Singapore  27  332 4 363 
Taiwan  0  916 0 916 
Utah  736  6 36 778 
Weifang  0  843 0 843 
Wuhan  0  691 0 691 
Total  3230  3459 400 7089 
Percent  45.6%  48.8% 5.6% 100% 






OFC cases were classified as having CLO, CL/P or CPO through either a 
treatment centre or population-based registry. A subset of parents were interviewed 
regarding family history and maternal exposures during the peri-conceptual period (3 
months prior to conception through the first trimester) and information was derived 
on the offspring’s exposure to maternal smoking, alcohol consumption and 
multivitamin use during pregnancy 160. 
2.2.3 Genotyping and quality control (QC) 
ICC tissue samples were collected from whole blood (83.1%), buccal 
brush/swab (11.0%), saliva (2.8%), mouthwash (1.8%) and dried blood spots (1.2%). 
DNA samples were extracted using methods varying across recruitment centre and 
tissue source. DNA samples were genotyped using the Illumina Human610 
Quadv1B array and the BeadStudio calling algorithm at the John Hopkins Center for 
Inherited Disease Research (CIDR).  
Of 7,347 DNA samples from study subjects genotyped using the Illumina 
Human610 Quadv1B array SNP genotyping platform, scans from 7,089 subjects 
passed QC for unexpected relatedness, gender errors (where self-reported gender 
estimated from X chromosome heterozygosity rates is inconsistent with the genotype 
sample) and missingness (>5%). This sample was released on dbGAP. Pre-dbGAP 
release, SNPs in sample-chromosome combinations with a chromosomal anomaly 
(e.g. aneuploidy) were also excluded. Post dbGAP release, SNPs were excluded for 
missingness (>5%), MAF (<5%) and deviation from Hardy-Weinberg Equilibrium 





2.2.4 Strengths and limitations 
Two major characteristics of the ICC data-set are the study design (i.e. 
parent-offspring trios) and the ancestral heterogeneity of study participants. The 
sampling of parent-offspring trios has advantages regarding the effect of population 
stratification bias and allows the testing of parent of origin effects. However, relevant 
to analyses, the recruitment of trios is largely a disadvantage because many planned 
analyses required an unrelated control group for comparison.  
The ancestral heterogeneity of the ICC data-set is a major advantage in that it 
allows replication in different ancestral groups, which was utilised in Chapter 3. 
However, for the purposes of analyses the heterogeneity, even amongst self-
reported Europeans, increased the difficulty of case-control matching in Chapter 3. 
Similarly, many analyses in this thesis required nsCL/P variants identified in 
European populations, so the non-European ICC samples were not included in many 
analyses. 
Beyond the limitations regarding my analyses, the ICC is a rich resource for 
exploring the genetics of OFCs. The ICC is currently the largest publicly available 
collection of OFC cases and family members, including both phenotype and 
genotype data on over 2,500 OFC cases. 
2.2.5 Analysis subsets 
2.2.5.1 European nsCL/P parent-offspring subsets 
 A subset, of European nsCL/P cases and parental controls, was created for a 
pedigree analysis in Chapter 3 Firstly, the subset was restricted to pedigrees 
consisting of an offspring with an OFC with at least one parent in the data-set. 
Secondly, the subset was restricted to pedigrees where the offspring were 





self-reported European descent. The final sample consisted of 638 parent-offspring 
trios and 178 parent-offspring pairs. The meta-analysis GWAS summary statistics 
generated using this sample were used in all five subsequent results chapters. 
 For a specific analysis in Chapter 3 requiring parent-offspring data, parents 
with a diagnosed OFC were also removed from analysis. The final sample consisted 
of 604 parent-offspring trios and 198 parent-offspring pairs. 
2.2.5.2 Asian nsCL/P parent-offspring subset 
 For a specific analysis in Chapter 3, parent-offspring samples of East Asian 
descent were required. As for the European subsets, a sample of Asian nsCL/P 
cases and parental controls was created by restricting the data-set to pedigrees of 
self-reported East Asian descent where the offspring were phenotyped as CL/P or 
CLO and removing parents with a diagnosed orofacial cleft. The final sample 
consisted of 759 parent-offspring trios and 159 parent-offspring pairs. 
2.2.5.3 European nsCL/P cases only subset 
 A European nsCL/P case only sample was utilised in matched case-control 
analysis in Chapter 3. The subset was restricted to individuals of self-reported 
European descent with a CL/P or CLO phenotype. The final sample consisted of 838 
nsCL/P cases.  
2.3 Avon Longitudinal Study of Parents and Children 
2.3.1 Background 
The Avon Longitudinal Study of Parents and Children (ALSPAC) is a 
longitudinal birth cohort study based in the former county of Avon in the United 
Kingdom that recruited pregnant women with expected delivery dates between 1 





14,541, which resulted in 14,062 live births and 13,988 children alive at the age of 1. 
When the oldest children in the study were around 7 years of age, the initial sample 
was boosted with eligible cases who had failed to join the study originally. Data from 
ALSPAC participants were used in Chapter 5 and Chapter 6. 
2.3.2 Phenotyping 
ALSPAC is a deeply phenotyped cohort, with self-report questionnaires and/or 
clinic sessions used to collect phenotype data from the mother and her partner (both 
during pregnancy and post birth) and the children (post birth), at many different time-
points. The phenotypes of relevance for this thesis are outcomes potentially relevant 
to nsCL/P. Facial phenotypes derived from 3D facial scans of ALSPAC participants 
in a clinic session at age 15 were utilised in Chapter 5. Hearing assessment 
phenotypes (audiometry and tympanometry), speech assessment, anthropometric 
measures and dental outcomes were utilised in Chapter 6. 
2.3.3 Genotyping and QC 
9,912 ALSPAC children were genotyped using the Illumina HumanHap550 
quad genome-wide SNP genotyping platform. Individuals with gender errors, 
excessive or minimal autosomal heterozygosity (where the proportion of genotyped 
markers with different alleles is higher or lower than expected, which may suggest 
possible sample contamination), disproportionate levels of individual missingness 
(>3%), unexpected relatedness (>10%) or evidence of non-European ancestry 
(which was determined by comparing study participants to individuals of European 
ancestry from the HapMap 2 reference panel) were excluded from analysis.  
The samples were pre-phased, which involves statistically estimating 
individual’s haplotypes, using ShapeIT (v2.r644) 162 a programme that utilises 





genotypes are estimated using a reference panel, to the 1000 Genomes (Phase 1, 
Version3) 163, which is described in Chapter 2.6.8, using IMPUTE3 V2.2.2 against 
the reference panel. After QC for SNPs on imputation quality (INFO< 0.8) and MAF, 
8,099,747 SNPs and 8,860 individuals were available for analysis. ALSPAC 
genotype data were used in Chapter 5 and Chapter 6 to construct nsCL/P PRS.  
2.3.4 DNA methylation 
As part of the Accessible Resource for Integrated Epigenomic Studies 
(ARIES) project 164, genome-wide DNA methylation data were generated for 1,018 
ALSPAC mother-child pairs at five different time-points. Bisulfite sequencing, which 
converts non-methylated cytosine nucleotides to uracil allowing detection of 
methylated cytosines, was used in conjunction with the Illumina Infinium 
HumanMethylation450K BeadChip assay to quantify DNA methylation at over 
480,000 CpG (where a cytosine nucleotide is followed by a guanine nucleotide) sites 
across the genome. After QC and normalisation 165, data were reported as 
methylation beta values, ranging from 0 (completely unmethylated) to 1 (completely 
methylated). Analyses in Chapter 4 used the ARIES methylation data generated 
from the offspring cord blood samples, which were collected at birth.  
2.3.5 Strengths and limitations 
The main advantage of the ALSPAC cohort is the availability of detailed data 
on a wide-range of phenotypes, along with both genetic and DNA methylation data. 
The availability of hearing, speech and facial morphology phenotypes (all derived by 
specialists) is relatively unique and allows for the testing of genetic overlap between 
these phenotypes and nsCL/P. Arguably, a disadvantage of ALSPAC, is the modest 
sample size compared to large Biobanks, because genetic analyses can often 





2.4 UK Biobank 
2.4.1 Background 
The UK Biobank is a large-scale cohort study of 502,655 participants aged 
between 40-69 years. Study participants were recruited from 22 recruitment centres 
across the United Kingdom between 2006 and 2010 166. Data from UK Biobank 
participants were used in Chapter 3 and Chapter 7.  
2.4.2 Phenotyping 
 Questionnaires completed at baseline were used to extract information on a 
wide-range of phenotypes for the majority of study participants. Phenotypes relevant 
to my analyses were; ICD10 codes from hospitalisation events, and self-reported 
alcohol consumption/tobacco smoking phenotypes which were used in analyses in 
Chapter 7.  
2.4.3 Genotyping and QC 
 488,377 UK Biobank participants were assayed using two very similar 
genotyping arrays, the UK BiLEVE Axiom™ Array by Affymetrix1 (N= 49950) and the 
closely-related UK Biobank Axiom™ Array (N= 438427). Directly genotyped variants 
were pre-phased using SHAPEIT3 167 and then imputed using Impute4 using the 
UK10K 168, Haplotype Reference Consortium 169 and 1000 Genomes Phase 3 163 
reference panels. Post-imputation, data were available on approximately ~96 million 
genetic variants 166,170. For the purposes of analyses undertaken in Chapter 3, 
152,249 individuals from the first genotype data release in May 2015 were used. For 
analyses in Chapter 7, the full sample from the second genotype data release in 





2.4.4 Strengths and limitations 
The main strength of the UK Biobank is the size of the data-set; genotype 
data and phenotype data on almost 500,000 individuals is unprecedented, with 
obvious advantages for the statistical power of analyses. UK Biobank study 
participants are mostly of western European descent, which limits the possibility of 
matching Biobank controls to cases of non-European descent, but the large sample 
size allows the potential for accurate case-control matching for cases of recent 
European ancestry in Chapter 3. Two limitations of the UK Biobank relevant to my 
analyses are the absence of phenotypes relating to nsCL/P related outcomes, and 
the potential for selection bias. The UK Biobank study participants are middle-aged, 
so phenotypes related to outcomes in children such as speech and hearing are not 
available, while selection into the study has been proposed as a potential source of 
bias 171.  
2.5 Oral cavity and oropharyngeal cancer (OC/OPC) data-set  
2.5.1 Background 
The OC/OPC data-set refers to an amalgamation of OC/OPC cases and 
controls from different studies, used in a previous GWAS 172. The data-set includes 
6,034 cases and 6,585 controls from 12 epidemiological studies, mostly hospital-
based case-control samples, from North America, South America and Europe. The 
majority of participants were from the International Head and Neck Cancer 
Epidemiology Consortium (INHANCE), the European Prospective Investigation into 
Cancer and Nutrition (EPIC) or the Head and Neck 5000 (HN5000). OC/OPC data 
were used in Chapter 7, where potential genetic overlap between nsCL/P and 






OC/OPC is a heterogeneous phenotype, including cases with cancer of the 
oral cavity, oropharynx, hypopharynx, or at multiple sites. The OC/OPC subtypes 
(oral cavity, oropharyngeal, hypopharyngeal and overlapping at multiple sites) were 
identified using ICD codes from hospitalisation events 172. 
2.5.3 Genotyping and QC 
Genotyping and QC has been described in detail previously 172. In brief, DNA 
from blood or buccal cells was genotyped using the Illumina OncoArray, a custom 
cancer array. The majority of the samples were genotyped using a specific oral and 
pharynx cancer OncoArray but some of the shared controls were genotyped using a 
Lung OncoArray. Genotype calls were made using GenomeStudio software and a 
standardized cluster file for OncoArray studies. PLINK 161 was first used to exclude 
samples and SNPs with excessively high missingness (>20%). After the initial 
exclusions, in a second round of QC, samples and SNPs with missingness (>5%) 
were removed. Next, samples with chromosomal errors, excessive or minimal 
autosomal heterozygosity, unexpected relatedness (estimated relatedness > 0.3) 
and expected experimental duplicate pairs were also removed (the removal of 
controls was prioritised over cases). After QC, data on 513,311 genetic variants 
remained. 
 The study population was highly heterogeneous, with samples from Europe, 
North American and South America. Therefore, the data-set was divided into the 
three geographic regions and SNPs deviating from HWE (P<1x10-7) were removed. 
Principal-components analysis (PCA), a statistical method of identifying trends in 
data which is discussed in more detail in Chapter 3, was used on a set of 





outliers, which were removed. STRUCTURE 2.3.4 174 was used in conjunction with 
samples from the HapMap reference panel to determine the relevant ancestry (e.g. 
the code CEU refers to individuals of northern European ancestry sampled from 
Utah in the USA) for each individual. Finally, the directly genotyped data were 
imputed using the Michigan Imputation Server. SHAPEIT 175 was used for pre-
phasing, with Minimac3 176 used for imputation and the Haplotype Reference 
Consortium panel 169 used as a reference panel.  
2.6 Secondary data sources 
2.6.1 Bonn-II study 
 The Bonn-II study 23 was a central European based, case-control GWAS of 
nsCL/P, which including 401 nsCL/P cases and 1,323 controls genotyped using 
Illumina BeadChips (the Human610-Quad and the HumanHap 550k). GWAS 
summary statistics on 496,240 SNPs from the post quality-control, discovery sample 
of 399 nsCL/P cases and 1,318 controls were kindly made available by the principal 
investigators of the study. In Chapter 3, these summary statistics were meta-
analysed with data from the ICC to attempt to replicate the summary statistics from a 
previous meta-analysis GWAS 24. The summary statistics were used in subsequent 
analyses in all results chapters. The Bonn-II data were also used in Chapter 3 to 
explore genetic architecture using PRS. 
2.6.2 Genetics of Overweight Young Adults 
 The Genetics of Overweight Young Adults cohort (GOYA) 177 used a case-
cohort sampling design to sample cases with extreme BMI scores and compared 
them to controls randomly sampled from the same cohort. Participants were sampled 
from the Danish National Birth cohort and the draft board examination cohort for 





children. Epigenetic and genotype data as well as estimated cell counts estimated 
using the Houseman method 178,179, ancestry principal components and DNA batch 
were available for 889 children. GOYA data are used in Chapter 4 as a replication 
cohort for analyses in in ALSPAC. 
2.6.3 The Cleft Collective birth cohort study 
The Cleft Collective birth cohort study (CC) 180 recruited children born with an 
OFC in the UK between 2013 and 2016. Family members were invited to take part 
and data were collected on demographics and lifestyle via questionnaires. Blood and 
non-discarded lip and palate samples were collected during surgery. Surgical forms 
were used to phenotype OFC cases as CPO, CLP or CLO.  
A subsample of 150 OFC cases (with no other known anomalies) were 
randomly selected and stratified by subtype: 50 CLP, 50 CPO and 50 CLO. Children 
have not been classified as syndromic because they have not been diagnosed as 
having any other anomaly, although because of the young age of the children, the 
non-syndromic status cannot be confirmed. The orofacial tissue type was dependent 
on the OFC subtype; lip samples were available for children with CLO and palate 
samples were available for children with CPO. Of the 50 children with CLP, 43 
contributed a lip sample and 7 contributed a palate sample. Genome-wide DNA 
methylation was measured using the Illumina Infinium HumanMethylation450 
BeadChip platform and functional normalisation was performed on the blood and 
tissue samples together. Of the original 300 samples, three blood and two lip 
samples failed QC. Surrogate variables were generated using the sva package in R 
to capture variation in the methylation data associated with technical batch and 
cellular heterogeneity 181 8. Methylation data from the CC was used in Chapter 4 to 





2.6.4 methWAS cohort 
The methWAS cohort included samples from 67 individuals diagnosed with 
nsCL/P and 59 age and sex matched controls, all of Brazilian ancestry. The average 
age at sampling was 5.29 years for cases and 6.45 years for controls. Whole-blood 
DNA was extracted from by the North Thames Regional Genetics Service with a 
subset of the sample (N=18) having available lip tissue samples recovered from 
surgery. DNA samples from the methWAS cohort were subjected to bisulfite 
conversion using the EpitectBisulfite Kit (QIAGen) and genome-wide DNA 
methylation was measured using the Illumina HumanMethylation 450 K Bead-Array 
platform. An epigenome-wide association study (EWAS), which estimates the 
association between DNA methylation and a phenotype of interest, was performed 
using the methWAS methylation data, with 11 CpG sites targeted for replicated in an 
independent UK sample of 171 cases and 177 controls 36. Data from the methWAS 
cohort was used in Chapter 4 to compare probes of interest from primary analysis 
with the results in the EWAS. 
2.6.5 The Genotype-Tissue Expression project 
The Genotype-Tissue Expression (GTEx www.gtexportal.org)) project is a 
resource database and tissue bank developed to aid the understanding of the 
relationship between genetic variation and gene expression in humans. The 
database includes information on expression quantitative trait loci (eQTL), which are 
genetic variants associated with gene expression, generated using genotype and 
RNA sequencing gene expression data from 43 distinct tissue types from 175 
individuals 182,183.  In Chapters 4 and 5, SNPs of interest were looked up in GTEx to 





2.6.6 NESDA NTR Conditional eQTL Catalog 
The NESDA NTR Conditional eQTL Catalog (NNC) is a repository of eQTL in 
whole blood, generated using genotype and gene expression microarray data from 
4,896 individuals across two Dutch biobanks. Conditional eQTL analysis, which 
involves accounting for the correlation between nearby SNPs to estimate likely 
causal variants, was applied to distinguish between dependent and independent 
eQTL 184. The catalogue is available at 
(https://eqtl.onderzoek.io/index.php?page=info). In Chapter 4, SNPs of interest were 
looked up in the NNC to explore potential biological mechanisms related to gene-
expression. 
2.6.7 3D Facial Norms Database 
The 3D Facial Norms Database (3DFN) is a database of controls for 
craniofacial research with genetic data on 2,447 individuals, aged between 3 and 40 
years of recent European descent. 2,272 individuals were recruited from Pittsburgh, 
Seattle, Houston or Iowa City as part of the 3DFN and the remaining 175 individuals 
were recruited as healthy controls for a separate study at Pittsburgh on orofacial cleft 
genetics. Study participants were screened for a history of craniofacial conditions 
and 3D-derived anthropometric measurements, 3D facial surface images and 
genotype data were derived from each participant 95,185. Notably a GWAS of normal-
range variation in facial morphology was published using the 3DFN cohort 95. 3DFN 
data were used in Chapter 5 as a replication cohort for facial morphology related 
analysis in ALSPAC. 
2.6.8 Reference panels: The 1000 Genomes reference panel 
Several different reference panels (HapMap2, 1000 Genomes, Haplotype 





genotype data and QC. Reference panels typically consist of a number of deeply 
sequenced individuals from different ancestral populations. There are several 
important uses of reference panels; first, it is useful to compare genotyped 
individuals to individuals from a reference panel to infer ancestry, second, reference 
panels can be used in genomic imputation to estimate markers that were not directly 
genotyped, and third, reference panels can be informative about linkage 
disequilibrium (LD), a characteristic of the genome where nearby markers are often 
correlated on a population level, which can be informative for identifying a proxy SNP 
for an unavailable SNP.  
 In several subsequent chapters, I use the 1000 Genomes 163 (which 
published results in 2015) as a reference panel. The 1000 Genomes data-set 
includes 2,504 deeply sequenced individuals from 26 different world-wide 
populations with genotypic data on over 88 million genetic variants 163. Applications 
in later chapters, used the CEU individuals and the GBR individuals (Individuals of 
European descent from Great Britain) to estimate the MAF of specific variants in a 
European population and estimate LD to identify proxy SNPs and generate 








Chapter 3: Exploring the genetic 
architecture of nsCL/P 
3.1 Abstract 
Understanding of the heritability and genetic architecture of nsCL/P is an 
important prerequisite for the interpretation of analyses in future chapters. Therefore, 
in this chapter I use available data-sets in conjunction with a variety of distinct 
statistical methods to estimate the SNP heritability of nsCL/P and make inferences 
about the genetic architecture.  
Triangulating the results from different methods, strong evidence was found 
that nsCL/P is a highly polygenic trait, with common genetic variation on genotyping 
chips estimated to contribute between 20 and 33% of the phenotypic variance. The 
evidence for polygenic architecture suggests that PRS may be effective genetic 
proxies for liability to nsCL/P and supports phenotypic dimensionality of nsCL/P. 
Beyond implications for the genetic architecture of nsCL/P, analyses in this chapter 
have implications for the utility of case-control matching and for the use of different 
SNP heritability estimation methods. Firstly, ancestral matching of cases to controls 
from different studies was shown to be a non-trivial undertaking and should be 
considered carefully. Secondly, results and simulations suggested that the different 
SNP heritability estimation methods vary in effectiveness for samples affected by 
batch.  
3.2 Introduction 
In later chapters, I use genetic proxies for liability to nsCL/P in MR and PRS 
analyses in order to investigate possible causes and effects of nsCL/P. At the time of 





there was limited knowledge about the genetic architecture of nsCL/P and no 
published SNP heritability estimates. As will be discussed in this chapter, the genetic 
architecture and SNP heritability of nsCL/P have important implications for analyses 
in later chapters and more generally, for the biological understanding of the trait 
aetiology. 
The primary aims of this chapter were to estimate the SNP heritability and 
explore the genetic architecture of nsCL/P; for example, evaluating the hypothesis 
that nsCL/P has a highly polygenic architecture. In the introduction to this chapter, I 
describe the different components of genetic architecture and the relevant methods 
for investigating these components. Possible implications for analyses in later 
chapters as well as previous research on nsCL/P are also discussed.  
3.2.1 Heritability 
The aetiological relevance of genetic factors to phenotypes can vary greatly 
across traits; height is highly genetic while an individual’s first language is largely 
non-genetic (for example, consider the scenario where two identical twins were 
separated at birth and one grew up in France and the other grew up in Germany). 
Heritability is defined as the proportion of phenotypic variation attributable to genetic 
variation. The broad-sense heritability, denoted H2, is the ratio of total genetic 
variance to total phenotypic variance 
𝑉𝐺
𝑉𝑃
, the narrow-sense heritability, denoted h2 
considers only additive genetic variance 
𝑉𝐴
𝑉𝑃
 while SNP heritability estimates include 
only additive genetic contributions from SNPs that are present on the assaying 
platform186.  
Heritability can be measured on the observed or liability scale. The observed 





Figure 4: Liability scale of phenotypic variation  
genetic factors across a population. Contrastingly, on the liability scale for heritability, 
phenotypic variation or disease liability is modelled as being continuous and normally 
distributed on a population level; individuals over the liability threshold have the trait 
and individuals under do not, with the proportion of the normal distribution over the 














For binary traits, the liability scale is typically preferred. This is because the 
phenotypic variation of a binary trait is dependent on the trait prevalence, and case-
control studies will often have a higher prevalence of cases than the general 





for heritability estimates for diseases with different prevalences to be compared, 
assuming that the liability model holds 187.  
3.2.2 Genetic architecture 
If genetic factors have a substantial role in a trait’s aetiology, it is important to 
consider the genetic architecture, which is defined as the characteristics of genetic 
variation contributing to the aetiology of a trait. These include; the number of relevant 
genetic variants, their effect sizes, their allele frequencies as well as interactions 
between genetic variants (epistasis) or between the genome and the environment 
146. Inferences about the components of genetic architecture for nsCL/P may have 
important implications for the PRS and MR analyses in later chapters. Here, I 
describe the different components of genetic architecture and their importance.  
3.2.2.1 Number of genetic risk variants 
Unlike Mendelian traits, which are determined by genetic variation at a single 
locus, a complex trait is characterised by having multiple distinct genetic risk loci. 
The number of risk loci varies between complex traits, but many complex traits are 
thought to be affected by hundreds or thousands of independent genetic variants. 
Indeed, there is evidence that association signals for many complex traits are spread 
across the majority of the genome, which prompted a proposed omnigenic model of 
complex traits where the majority of the genome is relevant to trait aetiology via 
interconnected gene regulatory networks 145. 
There are several important implications of the number of genetic risk variants 
influencing a trait which are pertinent to work in later chapters. Firstly, PRS which are 
used in later chapters to detect genetic overlap, are most effective for traits where 
many genetic variants contribute to trait aetiology. Secondly, for MR analyses, a 





testing for horizontal pleiotropy 147,148. Thirdly, the number of identified variants may 
support or oppose theories about the inheritance pattern of nsCL/P, e.g. the 
multifactorial liability or major risk gene models.  
3.2.2.2 Frequency of genetic risk variants 
Genetic variants vary in frequency across a population dependent on several 
factors including genetic drift, selection and the age of the variant. The frequency of 
disease predisposing genetic variants may be related to the disease prevalence. The 
common disease, common variant hypothesis 188,189 suggests that for prevalent 
complex traits, disease-causing alleles of small effect will be found commonly across 
the general population and that there is often only one disease-causing allele at a 
particular locus 190. A well characterised example, is the discovery of a single 
common allele in the APOE locus that increases risk of both Alzheimer’s and heart 
disease 191,192. Contrastingly, proponents of the common disease, rare variant 
hypothesis argue that substantial variation in common diseases is related to rare 
mutations 193.  
The frequency of relevant genetic risk variants can have important 
implications. Firstly, the frequency of genetic risk variants for a trait can be an 
important consideration for study design; standard genotyping chips have good 
coverage of common variation but mapping rare risk loci may require sequencing. 
Secondly, allele frequency is important for risk prediction screening. The effect of a 
variant on a population level is largely dependent on the allele frequency across the 
population of interest; a common variant with a small effect may be more useful for 





3.2.2.3 Magnitude of effect of genetic risk variants 
The effect of a genetic variant is determined by the variants effect on the DNA 
sequence. For example, a missense mutation refers to a base-pair change within a 
protein-coding region which alters the amino acid in a protein. A missense mutation 
in ADH1B, which is involved in the production of an enzyme involved in alcohol 
metabolism, has an effect on an individual’s alcohol behaviour. Genetic risk variants 
for the same trait can vary greatly in effect size; each risk allele of rs9939609 in FTO 
is associated with a 0.36 kg/m2 in BMI compared to an increase of 0.023 kg/m2 for 
each risk allele of rs657452 in AGBL4 194,195.  
Natural selection has important implications for the relationship between allele 
frequency and the effect of the variant. Selection pressure is dependent on the effect 
of the variant on fitness to sexually reproduce and the allele frequency, with the 
cumulative effect dependent on the age of the variant. Therefore, the cumulative 
effect of selection pressure is higher on common genetic variants, which are older, 
meaning that common genetic variants with a large effect on fitness are uncommon. 
Contrastingly, rare variants (which can be newer mutations), are under less selection 
pressure and so may be more likely to have large effects on fitness. However, 
whether this affects the allele frequency of risk loci for a phenotype depends on how 
the trait affects fitness to sexually reproduce.    
The effect size of genetic variants is important for several reasons. Firstly, the 
power of MR and PRS analyses depends on the proportion of phenotypic variation 
explained by relevant genetic variants. Secondly, for screening, variants of large 
effect are (dependent on allele frequency) desirable for risk prediction. Thirdly, from 
an evolutionary perspective, variants with large effects can have important 





rare in most populations, is strongly associated with increased BMI in Samoans. 
Each risk allele is associated with a 1.36-1.45 kg/m2 increase in BMI, an effect size 
approximately four times that of the previously described variant in FTO 196. This 
variant is thought to have been under positive selection in the past when food was 
scarcer but may now be under negative selection with rising obesity rates in the 
Samoan population.  
3.2.3 How to estimate the heritability and characterise the genetic architecture 
of nsCL/P 
The next step is to consider how one can estimate the heritability of nsCL/P 
and explore the different components of genetic architecture. There are several 
different study designs and methodologies that differ in terms of data requirements 
(e.g. genotype data or pedigrees without genotype data), output (e.g. some estimate 
heritability and some identify risk loci) and interpretation.  
Before I describe the relevant methodologies, it is pertinent to begin by 
introducing the concepts of identical by descent (IBD) and identical by state (IBS). 
Assuming two individuals share an identical stretch of DNA, if the stretch is inherited 
from a recent common ancestor it is said to be IBD while conversely if the stretch 
cannot be established as being inherited from a recent common ancestor, it is said to 
be IBS. Individuals with recent common ancestors will share IBD stretches of 
chromosomes (haplotypes); closely related individuals will share long segments of 
DNA while less closely related individuals will share smaller segments. 
3.2.4 Pedigree and twin studies 
One way of investigating the contribution of genetics to the aetiology of a 





phenotypic differences between related individuals in relation to the proportion of the 
genome shared between the relatives, i.e. the proportion of alleles that are IBD.  
Twins are especially useful for exploring heritability because certain 
characteristics allow for a design akin to a natural experiment. Monozygotic (MZ) 
twins are genetically IBD, sharing ~100% of alleles, while dizygotic (DZ) twins share 
around 50% of alleles that are IBD, but both types of twins can be assumed to share 
a common environment. Twin studies contrast the phenotypic concordance of a trait 
in monozygotic and dizygotic twins. In theory, a heritable trait will be more 
concordant in monozygotic twins than in dizygotic twins, which in turn will be more 
concordant than between unrelated individuals. An estimate of the narrow-sense 
heritability can be approximated by a function of the difference between the MZ/DZ 
phenotypic concordance. Similarly, sibling comparisons can be used to estimate the 
narrow-sense heritability, by comparing the trait recurrence rates between siblings to 
the trait incidence in the general population.  
Early twin studies demonstrated that nsCL/P is a highly heritable trait, with 
substantially higher concordance rates between MZ twins compared to DZ twins. In 
Brazilian and Scandinavian populations, twin heritability estimates ranged from 45 to 
over 90% 197-199. However, there are several potential limitations of heritability 
estimates from twin studies. Firstly, the shared environment may not be the same 
between MZ and DZ twins (MZ twins may be treated differently to DZ twins) and 
secondly, twin concordance can be difficult to measure if ascertainment is 
incomplete. The interpretation of heritability estimates from twin studies is complex 
because it is impossible to estimate the contribution of additive, dominance or 
environmental differences and it is therefore unclear whether the twin heritability 





Prior to the availability of genotype data, there was considerable 
disagreement between pedigree studies about the most likely inheritance pattern of 
nsCL/P. Carter first proposed a multifactorial model of inheritance 156 by arguing that 
the recurrence rates of nsCL/P are inconsistent with both recessive and dominant 
models of Mendelian inheritance 202. The existence of sub-phenotypes in unaffected 
family members and the results of some pedigree studies supported the 
multifactorial model 203-206, but the results of other pedigree studies suggested that 
the recurrence patterns were more consistent with autosomal major gene 
inheritance, potentially in conjunction with the environment 207-210. The possibility of a 
major nsCL/P susceptibility gene prompted the use of linkage analysis to identify the 
responsible gene, which I will discuss in the next section. 
3.2.5 Genotype-driven methods 
Genotyping refers to the examination of an individual’s DNA sequence; 
genotype data are commonly used to map genetic risk loci for traits by comparing 
the DNA sequence of different individuals but can also be used to estimate the 
heritability of genetic variants contained on the genotyping platform. The results of 
genetic mapping studies (e.g. the number of independent risk variants identified, the 
allele frequencies and the effect sizes) can be used to make inferences about the 
components of genetic architecture. A major caveat is that the different genetic 
mapping study designs have different strengths and weaknesses (e.g. linkage 
analysis within pedigrees is most effective for traits with a major susceptibility locus). 
Therefore, it is important to consider the results of the different study designs to 





3.2.5.1 Linkage analysis   
Linkage analysis is a genetic mapping method that exploits the IBD sharing 
within pedigrees to measure the co-segregation of segments of DNA with a trait. 
During meiosis, homologous pairs of chromosomes line-up and undergo crossing 
over, where the maternal and paternal chromosomes recombine so that the resulting 
chromosomes contain a mixture of maternal and paternal genetic variation. It is well 
characterised that recombination between two genetic loci is inversely related to the 
distance between the loci on the chromosome and so loci that are close together are 
often inherited together 14.  
Linkage was employed with some success to identify regions relevant to 
syndromic forms of cleft, e.g. Van der Woude syndrome and popliteal pterygium 
syndrome 15,16 but mapping risk loci for nsCL/P proved to be difficult. Multiple regions 
were found across different studies to co-segregate with nsCL/P, including loci on 
chromosome 6p23-24 (F13A) 17,18,211, chromosome 2p13-p14 and chromosome 
19q13.1 (BCL3) 19 but findings were not consistently replicated 20. Although effective 
at detecting rare alleles with high penetrance, linkage analysis has been shown to be 
largely ineffective at identifying higher frequency genetic variation with modest 
effects 14,212. The difficulties mapping loci for nsCL/P using linkage were inconsistent 
with the existence of a major nsCL/P susceptibility gene. 
3.2.5.2 Genome-wide association studies and Transmission Disequilibrium Test 
An alternative method for mapping genetic risk loci for complex traits is 
association testing, such as in a GWAS. Association testing involves quantifying the 
statistical association between genotyped genetic variants and a phenotype, 
requiring only that alleles are IBS 213. There are three possible reasons for an 





scenario is that the allele is a causal variant which directly affects disease 
susceptibility. The next best scenario is that, because some subjects share a recent 
common ancestor, the allele is in LD with a causal variant. The worst-case scenario 
is that the association is a false positive, potentially because of bias from population 
stratification or cryptic relatedness 214.  
As alleles are not required to be IBD in association testing, the majority of 
GWAS compare cases to unrelated controls. However, cases with related controls 
(i.e. parents or siblings) can also be used for genetic association testing. The 
Transmission Disequilibrium Test (TDT) 215,216 measures the over-transmission of 
heterogeneous alleles from parents to their unaffected offspring and so can be 
described as detecting linkage in the presence of association. Notable advantages of 
sampling trios are that parental environmental risk factors can be phenotyped, the 
TDT is robust to population stratification and that parent-of-origin effects can be 
investigated. The main disadvantage of trio designs is lower statistical power; a 
parent-offspring trio has roughly equivalent power to a single case and a single 
control from a case-unrelated control design 214,217.  
Both trios 21,30,71 and case-control 22,23 designs have been used for GWAS of 
nsCL/P. A primary reason for sampling trios is the interest in identifying maternal risk 
factors and gene-environment interactions relevant to nsCL/P. GWAS have been 
very successful in identifying risk loci for nsCL/P, with over 40 distinct genetic risk 
loci identified in studies across ethnically heterogeneous populations 9,21-24,27-30,218. 
The existence of many common risk variants for nsCL/P supports a multifactorial 
model of inheritance for nsCL/P, but interestingly, many of the identified risk variants 
have substantial effect sizes. For example, the risk allele of rs987525 (a major 





variant, is associated with substantially increased risk of nsCL/P (Relative risk > 2.0) 
24. Smaller but substantial effect sizes are observed for many other common nsCL/P 
risk loci, which may have implications for the selection pressure on nsCL/P related 
alleles.  
A point to consider when using GWAS results to make inferences about 
genetic architecture is that the number of genetic variants identified often increases 
with sample size. This is because the main criteria in a GWAS is usually whether a 
variant passes the genome-wide significance threshold. As sample sizes tend to 
infinity, a huge number of variants will pass the genome-wide significant threshold for 
polygenic traits with smaller and smaller effects (dependent on allele frequency). For 
example, a recent GWAS of height in 700,000 Europeans reports 700 loci at 
genome-wide significance 219. Therefore, the ability to make inferences about trait-
specific genetic architecture can be dependent on available data-sets; the rarity of 
nsCL/P means that current GWAS are still modestly sized. 
3.2.5.3 Using GWAS data to estimate SNP heritability and polygenicity 
Genotype data can also be used to estimate the heritability of markers on the 
genotyping chip (often referred to as the SNP heritability). There are currently 
several different methods for estimating the SNP heritability, including; Genetic 
relationship matrix restricted maximum likelihood (GREML) as implemented in 
Genome-wide Complex Trait Analysis (GCTA) software 220, the use of Bayesian 
linear mixed-model approaches as implemented in BOLT-Linear mixed models 
(BOLT-LMM) 221,  Linkage Disequilibrium Adjusted Kinship (LDAK) 222,223,  Additive 
Variance Explained and Number of Genetic Effects Method of Estimation 
(AVENGEME) 224 and  LD score regression 225, which utilises summary level GWAS 





polygenicity of a trait; the polygenic transmission disequilibrium test (PTDT) 
measures over-transmission of polygenic risk between unaffected parents and 
affected offspring 158. 
The SNP heritability of nsCL/P has been previously estimated to be around 
30% in a European population using GCTA, with 25% of the variance explained 
when restricting to 24 known risk loci 26. However, there is some evidence 
suggesting that the SNP heritability of nsCL/P may vary across different populations. 
In a Chinese population, 26 known risk loci were found to account for around 11% of 
the heritability of nsCLP which is substantially lower than the estimate from the 
European population 26,28, perhaps because of differences in LD structures between 
the different populations. It is worth noting that because some of the known risk loci 
were identified in the same study populations used for the heritability estimates, the 
variance explained by the known risk loci may be inflated by winner’s curse. 
Regardless, the variance explained by SNPs in the two populations suggests that 
common variation explains a large proportion of the phenotypic variation for nsCL/P. 
3.2.5.4 Missing heritability 
Although GWAS have identified thousands of risk loci across complex traits, 
SNP heritability estimates are consistently lower than heritability estimates 
generated from twin studies 226. Indeed, the SNP heritability estimate of 30% for 
nsCL/P is substantially lower than the twin study estimates of 45-90%. Different 
theories have been proposed for these differences, including; the role of LD and 
MAF 222; the role of rare variation 227,228; the effects of copy number variation 229; and 





3.2.5.5 Genomic imputation, whole exome and whole genome sequencing 
The lack of coverage of rare variation on a typical genotyping chip means that 
in general, the majority of variants identified in GWAS are relatively common in 
frequency. This means that GWAS results may under-represent the importance of 
rare variation in trait-specific genetic architecture. However, the number of identified 
low frequency risk variants is increasing with the use of sequencing and genomic 
imputation. Sequencing involves complete (or near-complete) genotyping of the DNA 
sequence in regions of interest, which is important for identifying rare variation 
missed by typical genotyping chips. Targeted sequencing involves sequencing a 
specific region of interest, whole exome sequencing involves sequencing the protein 
coding segments of the genome and whole genome sequencing involves 
sequencing of the majority of the genome 146. Large deeply-sequenced reference 
panels (described in Chapter 2) can be used in genomic imputation, where the 
genotypes of non-genotyped variants are estimated using LD and phase from a 
reference panel. The imputation of GWAS results allows further identification of 
lower-frequency genetic risk variants.  
Imputation and sequencing has led to increased discovery of low frequency 
and rare genetic variants for nsCL/P. Genomic imputation of a nsCL/P data-set 
identified 4 additional risk loci 26, suggesting that some lower frequency risk markers 
were missed by the original genotyping arrays. Targeted sequencing has identified 
rare genetic variation in known nsCL/P candidate genes that may contribute to 
disease aetiology 31,231 and whole exome sequencing has identified further candidate 
genes for nsCL/P, containing rare missense and deleterious variants 232,233. These 
findings suggest that rare genetic variation has an important aetiological role and 





better characterise the effects of rare variation on nsCL/P. One caveat is that many 
of the syndromic forms of CL/P are often phenotypically indistinguishable from 
nsCL/P, complicating the search for rare variation. Currently, rare variation is unlikely 
to be useful for PRS and MR analyses because variants identified in sequencing 
studies are unlikely to be commonly genotyped or imputed in other studies. 
3.2.6 Caveats and analysis plan 
The primary aim of this chapter was to use a variety of different methods to 
make inferences about the genetic architecture and heritability of nsCL/P. However, 
there are two major caveats that require further background. 
3.2.6.1 Construction of nsCL/P summary statistics 
Firstly, it was necessary to independently generate nsCL/P GWAS summary 
statistics, used in this chapter and later chapters, because the summary statistics 
from the largest previously published meta-analysis GWAS of nsCL/P in Europeans 
24 were not publicly available. This GWAS 24 was a meta-analysis of two previous 
studies, the ICC trios and the Bonn-II study 21,23. Although the meta-analysis 
summary statistics were unavailable, I had access to the individual level genotype 
data from the ICC and GWAS summary statistics from the Bonn-II study and 
therefore was able to use the data from these studies to generate meta-analysis 
nsCL/P summary statistics.  
Meta-analysing the results from the two studies requires careful consideration; 
the TDT design tests for linkage in the presence of association and commonly 
reports the proportion of transmitted risk alleles, while a case-control GWAS design 
tests for association and often reports an odds ratio (OR). However, OR of the 





as a function of the proportion of transmitted high-risk alleles 234, allowing for 
harmonisation of results between the two studies.  
3.2.6.2 Case-control matching 
The second caveat is that the ICC data-set consists of parent-offspring trios 
but many heritability estimation methods, e.g. GCTA, require samples consisting of 
cases and unrelated controls. To circumvent this issue, one possibility was to match 
nsCL/P cases with population controls, but this was likely to be a challenging task 
because the nsCL/P cases (from the ICC), even those of European descent, were 
sampled from different recruitment centres across Scandinavia and the US. This 
meant that matching on ancestry to a single homogeneous population study could 
lead to population stratification bias, where systematic population differences 
between cases and controls lead to differences in allele frequency. Differences in 
disease prevalence across study populations combined with population stratification 
can lead to genetic associations that are unrelated to genuine biological differences 
235. A proposed solution to the ancestral heterogeneity of the ICC data-set was to 
match nsCL/P cases with population controls from the UK Biobank, which sampled a 
large number of ancestrally heterogeneous individuals.  
Further considerations relevant to case-control matching are firstly, the 
possibility of batch effects between cases and controls, and secondly, the most 
appropriate way to match cases to controls. Batch effects are systematic genotyping 
differences caused by differences in the genotyping process, such as different 
genotyping chips, and can be difficult to distinguish from genuine biological 
differences. Batch effects are a particular problem in this instance as firstly, the ICC 





nsCL/P cases are on one genotyping chip and all of the proposed controls are on 
another. 
In terms of matching cases to controls, attempting to pair cases with 
ancestrally homogeneous controls is an obvious starting point. One method that can 
be used to explore ancestry is PCA. PCA is a commonly used adjustment to account 
for population stratification in genetic association studies, the principal being that 
genome-wide IBS sharing between individuals identifies recent common ancestry 
173,236. PCA has limitations, notably it has reduced effectiveness for highly 
admixtured populations with uneven sampling 237,238. In this instance, derived 
principal components from a merged ICC-UK Biobank sample are not necessarily 
measures of ancestry as they may pick up any form of systematic variation across a 
data-set such as batch effects.   
An alternative approach is to use previously derived markers of ancestry, 
ancestral informative markers (AIMs), to infer ancestry. Using AIMs to infer ancestry 
is less computationally intensive than PCA and may be more likely to pick up 
biogeographical substructure. AIMs have been previously identified for 9 different 
populations from the 1000 Genomes 163 and can be used to generate admixture 
components inferring the ancestry of genotyped individuals 239 240.  
3.2.6.3 Overview of analysis plan 
First, meta-analysis GWAS summary statistics were constructed using 
available data sources. Second, case-control matching was used to pair nsCL/P 
cases from the ICC with UK Biobank controls. Third, relevant genetic architecture 
and heritability methods were used to make inferences about nsCL/P. Relevant data-
sets and analyses are contained in Table 3 in the next section. In this chapter, I 





3.3 Materials and methods 
3.3.1 Study participants 
 In this chapter, I utilised several datasets; the ICC individual level trio 
genotype data, the Bonn-II study GWAS summary statistics and the UK Biobank 
controls. The three data-sets have been described previously in detail in Chapter 2.  
In brief, the ICC data-set consists of over 2,500 individuals with an OFC 
predominantly of European or Asian descent, with parental controls. The Bonn-II 
study was an nsCL/P case-control GWAS including 399 cases and 1,318 controls. 
The UK Biobank is a cohort study including 502,655 participants aged between 40-
69 years, sampled from across the UK. More information on analyses and relevant 
data-sets is contained in Table 3. 
Table 3: Different analyses and relevant data-sets as described in Chapter 2 
Analysis Datasets used 
nsCL/P meta-analysis 
summary statistics 
European ICC trios and Bonn-II summary statistics 
Matched nsCL/P-control 
sample 
European ICC nsCL/P cases and UK Biobank controls 
Polygenic transmission 
disequilibrium test 
European and Asian ICC trios with affected parents 
removed 
Sibling recurrence rate N/A (used estimates from literature) 
LD score regression nsCL/P meta-analysis summary statistics 
Genome-wide Complex Trait 
Analysis 
Matched nsCL/P-control sample 
AVENGEME Bonn-II summary statistics 
Matched nsCL/P-control sample 
 
3.3.2 Generation of nsCL/P meta-analysis summary statistics 
First, genetic loci identified with nsCL/P were identified using a TDT. PLINK 





of 638 parent-offspring trios and 178 parent-offspring pairs of European descent. 
TDT effect sizes were reported as OR. 
Second, the TDT summary statistics were meta-analysed with the Bonn-II 
summary statistics. In this instance, with only two studies to meta-analyse, and 
similar phenotyping and population structure in both datasets, a fixed effects model 
was assumed. METAL 241 was used to meta-analyse the OR from the TDT with the 
Bonn-II case-control GWAS 23 of 399 cases and 1,318 controls (Chapter 2) using a 
fixed-effects model. The final sample consisted of 1215 cases and 2772 controls, 
although it is worth noting that one parental control is not statistically equivalent to 
one unrelated control.  
As the meta-analysis nsCL/P GWAS summary statistics and their components 
have been described in previous publications 21,23,24, biological implications of the 
GWAS results are omitted. The results are instead validated by comparing the P-
values of the constructed GWAS summary statistics with the top hits from the 
published meta-analysis GWAS 24. 
3.3.3 Case-control matching 
3.3.2.1 Merging European nsCL/P cases and UK Biobank 
 Firstly, the 838 European ICC nsCL/P cases (Chapter 2.2.5.3) were merged 
with controls from the first genotype release of the UK Biobank (see Chapter 2.3). 
To increase computational speed when generating admixture components, the UK 
Biobank sample of over 150,000 individuals was split into 50 subsets at random. 
Each of the subset samples was then restricted to include only individuals of 
European ancestry, confirmed by PCA. The European nsCL/P and UK Biobank 
subsets samples were then filtered using a list of 130,025 AIMs from the GenoChip 





merged with each of the 50 UK Biobank subsets using PLINK. SNPs with 
mismatched alleles between the two data-sets or missingness greater than 2% 
across the combined sample were removed, leaving 69,219 AIMs to be used for the 
generation of admixture components. 
3.3.2.2 Generating admixture components 
Secondly, admixture components were derived in each of the merged 
nsCL/P-UK Biobank subsets. Admixture components were preferred over principal 
components because of the computational intensity of generating principal 
components and the possibility of picking up dimensions independent from ancestry 
in the combined sample. Nine admixture components, representing nine of the 1000 
Genomes 163 worldwide populations, were identified in each of the 50 combined 
samples (the nsCL/P cases and a subset of the UK Biobank controls) by applying 
ADMIXTURE v1.3 174 to the 69,219 AIMs. Admixture was applied in supervised 
mode against the nine previously curated gene pools 240. 
3.3.2.3 Propensity score matching 
Thirdly, each nsCL/P case was matched with 4 appropriate controls using 
propensity score matching which involves matching controls to cases, conditional on 
a defined set of covariates with an optimal matching defined as the matching with the 
minimum Euclidean distance 242. Propensity score matching 242 in R, using the 
nearest neighbour algorithm, was used to match the nsCL/P cases to UK Biobank 
controls with the nine admixture components as covariates. Analysis was performed 
separately for each of the 50 subsets and the best 4 matched controls, in terms of 
minimum Euclidean distance, for each case were then taken forward to the analysis 





3.3.2.4 Evaluating matching quality 
Finally, the quality of the matching in the nsCL/P cases/matched UK Biobank 
controls sample was evaluated using principal components. To generate the 
principal components, the European nsCL/P and UK Biobank samples were first 
filtered to include only HapMap3 SNPs 243. The files were then merged using PLINK, 
SNPs with mismatched alleles between the two data-sets were removed and the 
data-set was restricted to nsCL/P cases and matched UK Biobank controls. Strict 
QC was then performed, removing SNPs with MAF < 0.01, HWE P-value <0.01 and 
missingness >2%. Pairwise LD pruning was then used to generate an independent 
set of markers (markers within 10000 kilobases of an index variant were pruned if 
r2>0.1), and regions of high LD such as the HLA region were also removed. The first 
10 principal components were generated from this independent set of markers. Plots 
of the principal components were used to assess the quality of the matching.  
3.3.4 Exploring genetic architecture 
After the construction of the nsCL/P meta-analysis summary statistics and the 
matched case-control sample, several different methods were used to explore the 
genetic architecture of nsCL/P. These methods included; the PTDT, LD score 
regression, GCTA and AVENGEME. 
3.3.4.1 Polygenic transmission disequilibrium test (PTDT)  
The PTDT uses parent-offspring trios to infer the polygenic architecture of a 
trait or polygenic overlap between two independent traits. The PTDT detects over-
transmission of polygenic risk for a trait from unaffected parents to an affected child 
by constructing PRS from a training sample in an independent target sample of 





PRS were derived using summary statistics from the Bonn-II study 23 at a 
range of P-value inclusion thresholds from P<0.000001 to P≤1, i.e. including all 
SNPs in the summary statistics, (Thresholds: 0.000001, 0.000005, 0.00001, 
0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1), and then constructed 
in the imputed ICC nsCL/P European and Asian pedigrees, separately. The PRS 
included independent SNPs generated by LD clumping the summary statistics in 
PLINK (clumps were formed of an index variant and other SNPs within 250kb of the 
index variant with r2>0.1), using the relevant ICC pedigree (Asian or European) as 
the reference panel for LD. The standardised difference in PRS between the 
unaffected parental controls and the affected children was calculated and the PRS 
P-value inclusion threshold with the strongest evidence of over-transmission was 
determined using a t-test.  
A stratified PTDT was used to investigate the genetic architecture of nsCL/P, 
i.e. which allele frequency range contributes most to the aetiology of nsCL/P. It was 
decided to test this on all SNPs (i.e. the PRS with a P-value inclusion threshold of 1) 
and only in the European pedigrees. The 1000 Genomes (Phase 3) reference panel 
163, was used to stratify the LD pruned PRS, into 5 MAF bins (“0<x≤0.1”, “0.1<x≤0.2”, 
“0.2<x≤0.3”, “0.3<x≤0.4”, “0.4<x≤0.5”). The PTDT was then run separately on each 
of the 5 strata. 
3.3.4.2 Sibling recurrence rate 
A simplistic method of estimating heritability of a dichotomous trait, is to use 
the population prevalence and familial recurrence rate of a trait to estimate the 
narrow-sense heritability estimate 𝐻2. If we assume a population prevalence of 𝐾𝑃 
and a sibling recurrence risk of 𝐾𝑆𝐼𝐵, the contribution of additive genotypic variation 





difference between the sibling recurrence risk and the population prevalence: 𝛴 =
2𝐾𝑃(𝐾𝑆𝐼𝐵-𝐾𝑃) while the phenotypic variation across the population (represented by V) 
can be modelled as a function of the population prevalence: V=𝐾𝑃(1-𝐾𝑃). 𝐻2 can then 
be approximated by the variance in genotype divided by the variance in phenotype: 
𝐻2 = 𝛴/V. In this instance, sibling recurrence risk and population prevalence 
estimates for nsCL/P were taken from previous publications 244,245.  
3.3.4.3 Linkage Disequilibrium (LD) score regression 
LD between a variant of interest and a causal variant causes inflation of the 
test-statistic proportion to the degree of LD with the causal variant 225. It has been 
demonstrated that the SNP heritability of a trait can be estimated by a regression of 
the test statistic against LD-scores, which are generated from reference panels such 
as 1000 Genomes 163 and measure the amount of variation tagged by each variant in 
the genome for each variant 225. LD-score regression has further applications such 
as partitioning heritability into functional categories 246 and estimating genetic 
correlation 247. Advantages of LD-score regression are that it can be applied to 
summary data and that the method is automated in a curated web-interface 248. The 
main disadvantage of LD-score regression is that the method has lower statistical 
power compared to methods that use individual level data.  
The python package LDSC.py was used to run LD score regression on the 
summary statistics of the ICC TDT, the Bonn-II Study and the combined TDT/Bonn-II 
meta-analysis, using LD score files from the 1000 Genomes (Phase 3) CEU data. 
Observational heritability estimates were converted to the liability scale using a 
population prevalence from a previous publication 249 and the sample prevalence 





 The input parameters for LD score regression are the Z scores and sample 
sizes for each SNP, which is used to weight the contribution of each SNP to the 
heritability estimate. Sample sizes for each SNP are trivial to calculate for a case-
control design, but non-trivial for a TDT design because the TDT requires at least 
one parent to be heterozygous for the over-transmission of a SNP to be tested for 
that parent-offspring trio. Therefore, I tested the effect of changing the sample size 
parameter for the TDT study on the SNP heritability estimates. As the primary 
analysis, the sample size for each SNP was considered to be a function of the total 
number of transmitted and untransmitted alleles (each transmitted or untransmitted 
allele was assumed to be equivalent to 1 case and 1 control). As a comparative 
secondary analysis, the sample size for each SNP was considered to be the total 
number of individuals in the ICC sample (i.e. the number of offspring plus the 
number of parents).  
3.3.4.4 Genome-wide Complex Trait Analysis (GCTA) 
The first method proposed for estimating the SNP heritability was Genome-
wide Complex Trait Analysis (GCTA) 220. Genetic relationship matrices (GRM) are 
constructed that estimate the pairwise relatedness between individuals. The SNP 
heritability is then estimated using the GRM, LMM and restricted estimated 
maximum likelihood (REML). The underlying premise is that if individuals who are 
phenotypically similar are also genotypically similar, then the trait is likely to be 
heritable. Close relatives such as parents and siblings should be removed before 
running GCTA analysis because of the large genetic overlap, strong phenotypic 
similarities and shared environment of closely related individuals 220. An extension of 
GCTA, using a bivariate linear mixed model, can be used to estimate the genetic 





GCTA is widely used method for estimating SNP heritability when individual 
level data are available. However, there are several published criticisms of the 
method 222,223,251,252. The primary criticism is that the underlying model used in GCTA 
makes many strong assumptions that do not necessarily hold. These assumptions 
pertain to the relationship between the expected amount of heritability assigned to 
each SNP with respect to MAF and LD 222. 
The admixture-matched nsCL/P case-UK Biobank control sample was used to 
estimate the SNP heritability of nsCL/P using GCTA. First, GCTA was run on the 
initial matched sample adjusting for the first 10 principal components. A population 
prevalence, taken from a previous publication 245 and the sample prevalence 
(calculated from the data) were used to convert the observed scale heritability 
estimates to the liability scale. Second, GCTA was rerun after removing related 
individuals (>0.025 on the GRM). Third, the effect of removing ancestral outliers and 
poorly matched individuals on the heritability estimates was investigated, which were 
determined using arbitrary cut-offs from principal component plots.  
3.3.4.5 Additive Variance Explained and Number of Genetic Effects Method of 
Estimation (AVENGEME) 
AVENGEME 224 is a maximum likelihood method for estimating SNP 
heritability, genetic covariance and the proportion of null SNPs across the genome. 
These parameters are estimated using the relationship between different inclusion 
thresholds for PRS and the test statistic for association between phenotype. Scores 
are generated using summary data from a training sample and are constructed in an 
independent target sample of unrelated individuals 136,224.  
 PRS were derived using summary statistics from the Bonn-II study 23 at a 





0.00001, 0.00005, 0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3, 
0.35, 0.4, 0.45, 0.5, 1) and then constructed in the admixture matched nsCL/P case-
UK Biobank control sample. The PRS were generated by LD clumping the summary 
statistics in PLINK (clumps were formed of an index variant and other SNPs within 
250kb of the index variant with r2>0.1), using the admixture matched sample as the 
reference panel for LD. 
A logistic regression was then performed with case-control status as the 
binary outcome and the Bonn-II PRS as the explanatory variable. Analysis was run 
both unadjusted and after adjusting for the first 10 principal components. The Z 
scores from the logistic regression and other relevant parameters were used to 
estimate the SNP heritability using AVENGEME. Parameters in the calculation 
included: sample prevalences, population prevalence and the number of SNPs 
common to both samples. The sample prevalences and number of SNPs common to 
both samples were derived from the data while the population prevalence was taken 
from a previous publication 245. It was assumed that the genetic architectures in the 
two samples are identical, i.e. the phenotyping of nsCL/P and ancestry are 
consistent across the two datasets.  
3.3.5 AVENGEME simulations 
The sensitivity of the AVENGEME heritability estimates to batch-related 
systematic differences between cases and controls was tested. It was assumed that 
if the PRS themselves are not associated with the genotypic batch differences, then 
the heritability estimate may be unbiased.  
The AVENGEME analysis was repeated in the admixture matched sample, 





allocated a P-value and effect size from another SNP). If AVENGEME heritability 
estimates are biased by poor quality case-control matching, then randomly arranged 
summary statistics should generate a heritability estimate significantly distinct from 0.  
To test this, 100 simulations were run using AVENGEME on the rearranged 
Bonn-II summary statistics and the admixture matched case-control sample. It is 
important to note that in this instance, assuming; substantial standard error in each 
heritability estimate, heritability estimates constrained between 0 and 1, and no true 
genetic effect, one would expect the mean of the simulations to be non-zero. This is 
because if there is no true effect, approximately half of the PRS in the simulations 
will be positively associated with case-control status while the other half will be 
negatively associated. However, heritability estimates have a lower bound of 0, 
meaning the mean of all simulations will be greater than 0. 
 
3.4 Results 
3.4.1 Generation of nsCL/P meta-analysis summary statistics 
After performing the TDT on the European nsCL/P trios, I meta-analysed the 
results with the summary statistics from the Bonn-II GWAS. Although there were 
some slight differences, the P-values were highly concordant with the results of the 
previously published meta-analysis GWAS 24 which used the same data-sets with 









Table 4: Comparison of Ludwig et al with meta-analysis summary statistics 
SNP (Ludwig et al 2012) 
European only              
P-value 
TDT + Bonn-II Meta-
Analysis 
P-value 
rs560426 1.02 x 10-6 4.43 x 10-5 
rs861020 1.78 x 10-6 1.38 x 10-5 
rs987525 3.94 x 10-34 7.95 x 10-20 1 
rs7078160 2.81 x 10-8 3.99 x 10-7 
rs227731 4.26 x 10-8 4.50 x 10-7 
rs13041247 7.41 x 10-4 2.25 x 10-3 
rs742071 2.63 x 10-7 4.07 x 10-6 
rs7590268 4.05 x 10-8 2.17 x 10-6 
rs7632427 4.20 x 10-5 2.62 x 10-4 
rs12543318 1.02 x 10-6 1.49 x 10-5 
rs8001641 6.20 x 10-10 4.41 x 10-8 
rs1873147 2.81 x 10-8 4.22 x 10-7 













3.4.2 Case-control matching 
 Admixture components were derived in the joint sample of UK Biobank 
controls and nsCL/P cases. Propensity score matching was then used to construct a 
matched case-control sample. However, in the matched sample, evidence was found 
of large systematic genome-wide differences between the nsCL/P cases and the 
matched UK Biobank controls. Principal component plots suggested that the second 
principal component divides cases from controls and demonstrated the substantial 
ancestral heterogeneity across the nsCL/P cases (Figure 5).  A regression of 
principal components on case-control status suggested systematic differences 
between cases and controls, which extended across many of the first 10 principal 
















Figure 5: Principal component plots of admixture matched sample  





























3.4.3 Polygenic transmission disequilibrium test (PTDT) 
 nsCL/P PRS from the Bonn-II study were constructed in the ICC European 
and Asian nsCL/P parent-offspring trios. The PTDT demonstrated consistent over-
transmission of nsCL/P genetic risk scores across all inclusion thresholds in 
European trios. The strongest association was observed when using 17 SNPs with P 
< 0.00001; affected offspring had 0.32 (95% C.I. 0.25, 0.39) S.D. higher nsCL/P 
polygenic risk score than their unaffected parents (P = 3.5 x 10-18) (Table 6). 
In the Asian trios, there was similar evidence of over-transmission, but the 
magnitude was smaller than in Europeans and strong association was not observed 
across all inclusion thresholds. As in Europeans, the strongest association was 
observed using a P value threshold of 0.00001; affected offspring had 0.19 (95% C.I. 
0.12, 0.25) S.D. higher nsCL/P polygenic risk score than their unaffected parents (P 





Table 6: Polygenic Transmission of nsCL/P genetic risk variants in independent European and Asian trios 
P-value Inclusion 
Threshold 
European Trios (N = 2209) Asian Trios (N = 2593) 
Number of 
SNPs 
Beta (95% C.I.)1 P Value Number of 
SNPs 
Beta (95% C.I.)1 P Value 
0.000001 4 0.30 (0.23, 0.37) 1.8x 10-16 10 0.12 (0.05, 0.19) 8.0x 10-4 
0.000005 13 0.30 (0.23, 0.37) 1.1x 10-16 18 0.16 (0.09, 0.23) 7.0x 10-6 
0.00001 17 0.32 (0.25, 0.39) 3.5x 10-18 23 0.19 (0.12, 0.25) 1.7x 10-7 
0.00005 44 0.25 (0.18, 0.33) 1.0x 10-11 53 0.16 (0.09, 0.13) 1.1x 10-5 
0.0001 69 0.24 (0.17, 0.31) 2.1x 10-11 81 0.12 (0.05, 0.19) 0.001 
0.0005 222 0.17 (0.10, 0.23) 2.7x 10-6 244 0.06 (0.00, 0.13) 0.056 
0.001 405 0.15 (0.08, 0.22) 4.6x 10-5 437 0.08 (0.01, 0.14) 0.020 
0.005 1,626 0.19 (0.12, 0.26) 5.3x 10-8 1793 0.12 (0.05, 0.18) 3.5x10-4 
0.01 3,002 0.16 (0.09, 0.23) 9.2x 10-6 3,334 0.10 (0.04, 0.17) 0.002 
0.05 11,400 0.16 (0.10, 0.23) 1.7x 10-6 13,222 0.09 (0.02, 0.15) 0.009 
0.1 20,133 0.16 (0.10, 0.23) 2.2x 10-6 23,421 0.06 (-0.01, 0.12) 0.096 
0.5 64,727 0.17 (0.10, 0.24) 1.1x 10-6 74,832 0.03 (-0.03, 0.10) 0.31 
1 92,527 0.16 (0.09, 0.23) 2.6x 10-6 107,809 0.03 (-0.04, 0.10) 0.38 







 After stratifying SNPs by MAF, PTDT results suggested that high frequency 
nsCL/P variants on the genotyping chip may be over-transmitted more than lower 
frequency variants. The largest magnitude of over-transmission was observed for 
SNPs with a MAF greater than 0.4; Beta = 0.16 (95% C.I. 0.09, 0.23, P value = 
0.00002) with the lowest over-transmission observed for SNPs with a MAF less than 
0.1; Beta = 0.05 (95% C.I. -0.02, 0.13, P value = 0.16) (Table 7). 
Table 7: Polygenic Transmission of SNPs by minor allele frequency 
MAF Inclusion 
Threshold 
Number of SNPs Beta (95% C.I.)1 P Value 
0.0 < x < 0.1 29,034 0.05 (-0.02, 0.13) 0.16 
0.1 < x < 0.2 25,592 0.07 (0.01, 0.14) 0.03 
0.2 < x < 0.3 15,516 0.11 (0.04, 0.18) 0.001 
0.3 < x < 0.4 11,801 0.06 (-0.01, 0.13) 0.10 
0.4 < x < 0.5 10,313 0.16 (0.09, 0.23) 0.00002 
1 Standardised difference in genetic score between parents and offspring  
3.4.4 Narrow-sense heritability using sibling recurrence risk 
The narrow-sense heritability estimate of nsCL/P was crudely estimated using 
population prevalence and sibling recurrence estimates. The estimated population 
prevalence of nsCL/P is around 1 in a 1000 or 0.1% 249. The relative risk of sibling 
recurrence was estimated to be 32 in a Norwegian medical birth registry 244. 
Assuming a population prevalence of 0.1%, the sibling recurrence risk estimate is 
3.2%. Assuming these parameters and the equation detailed earlier in Chapter 
3.3.4.2, the narrow sense heritability estimate of nsCL/P is 6.2%.  
3.4.5 Linkage disequilibrium score regression 
In the primary analysis, (the sample size of each SNP was assumed to be a 
function of the number of untransmitted and transmitted alleles) the LD score 
regression SNP heritability estimate of the combined meta-analysis was 0.33 (95% 





estimates for the ICC-TDT and Bonn-II summary statistics, respectively 0.17 (95% 
C.I. 0, 0.62) and 0.19 (95% C.I. 0, 0.51) likely reflecting the smaller sample sizes 
(Table 8).  
Table 8: Linkage Disequilibrium Score Regression results of two independent 
samples and the combined meta-analysis 









0.04 [0, 0.23) 
2(U+T)2 0.17 [0, 0.62) 




0.19 [0. 0.51) 
Combined Meta-
analysis 
1209 cases and 2763 






2(U+T)2 0.33 (0.14, 
0.51) 
1 Total number of cases and controls 
2 In the TDT study, the sample size for each SNP was assumed to be double the number of U (untransmitted alleles) and T 
(transmitted alleles) 
The sample size parameter for the contribution of each SNP affected SNP 
heritability estimates. Although confidence intervals overlapped, the two methods of 
calculating the sample size parameter gave somewhat discordant effect estimates 
for both the ICC-TDT sample alone (0.04 and 0.17), and the meta-analysis summary 
statistics (0.20 and 0.33). Not accounting for the number of homozygous parents for 
each SNP resulted in a lower SNP heritability effect estimate. This reduction could 
be because lower MAF SNPs, where over-transmission was only tested within a 
small sample of trios, are given the same weighting as higher frequency SNPs.  
3.4.6 Genome-wide Complex Trait Analysis 
 GCTA was used to estimate the SNP heritability of nsCL/P using the matched 
838 nsCL/P cases and 3352 UK Biobank controls sample. The SNP heritability 





the liability scale SNP heritability estimates of 0.45-0.70. Removing poorly matched 
individuals and ancestral outliers, using the principal component plots, increased the 
liability heritability estimates, possibly because estimates are sensitive to sample 
prevalence, which decreased as outliers removed were predominantly cases (Table 
9). GCTA on a case-control sample is sensitive to sub-structure differences between 
cases and controls which have been shown to exist, and the inflated heritability 
estimates reflect these differences. It is worth noting that ordinarily removing cases 
or controls without removing their respective matches may induce bias because it 
ignores the case-control matching. However, given the poor quality of the matching 
in this instance (see Figure 5 shown previously), this is unlikely to have a negative 
effect. 
Table 9: GCTA estimates from Admixture-Matched sample with outlier removal 
Sample Size Heritability Estimate (95% C.I.) Description 
Observed Scale Liability Scale 
838 Cases and 
3352 Controls 
0.91 (0.79, 1] 0.50 (0.43, 0.57) 4 Biobank controls 
matched to each 
case 
792 Cases and 
3313 Controls 
0.79 (0.65, 0.93) 0.45 (0.37, 0.52) Relateds removed 
(>0.025 from GRM) 
684 Cases and 
3281 Controls 
0.80 (0.66, 0.94) 0.49 (0.40, 0.58) Extreme ancestral 
outliers removed 
446 Cases and 
3281 Controls 
0.84 (0.69, 0.99) 0.70 (0.57, 0.82) Largely unmatched 
cases removed 
 
3.4.7 AVENGEME heritability and simulation results 
 AVENGEME was used to estimate the SNP heritability of nsCL/P using the 
matched nsCL/P cases and UK Biobank controls sample. PRS from the Bonn-II 
study, at different inclusion thresholds, were constructed in the matched sample. The 





0.22) unadjusted and 0.16 (95% C.I. 0.14, 0.18) when adjusted for the first 10 
principal components.  
 Running simulations of randomly rearranged nsCL/P summary statistics 
showed that batch and ancestry differences have a minor effect on SNP heritability 
estimates using AVENGEME because the average estimates across simulations 
were very close to 0 despite being constrained between 0 and 1. Additionally the 
results suggested that adjusting for principal components may not necessarily 
improve accuracy; the median heritability estimate of the simulated data was 0.000 
(95% C.I., 0.000, 0.018) without adjusting for principal components and 0.000 (95% 
C.I., 0.000, 0.027) when adjusting (Table 10).    
 
Table 10: AVENGEME heritability estimates when using random effect sizes from 
100 simulations 
 Heritability estimate (h2) 
Unadjusted Adjusted for 10 PC 
Mean (95% C.I.) 0.017 (0.008, 0.036) 0.015 (0.006, 0.036) 
Median (95% C.I.) 0.000 (0.000, 0.018) 0.000 (0.000, 0.027) 
Maximum (95% C.I.) 0.139 (0.107, 0.173) 0.106 (0.078, 0.136) 
 
3.5 Discussion 
In this chapter, individual level genotypes and pedigree data were used to 
explore the genetic architecture of nsCL/P and estimate the proportion of heritability 
explained by common genetic variation captured by a genotyping chip. Triangulating 
the results from several different methods, strong evidence was found for a 
substantial role of common genetic variation in the aetiology of nsCL/P and a highly 
polygenic genetic architecture. These findings have several important implications 
for work in later chapters. Firstly, the evidence for polygenicity suggests that nsCL/P 





as genetic proxies for liability to nsCL/P. Secondly, the high effect sizes and allele 
frequencies of the known risk loci suggest that MR analyses with liability to nsCL/P 
as the exposure are likely to be well-powered. Finally, a polygenic architecture for 
nsCL/P is consistent with the proposed multifactorial liability model of inheritance.  
The PTDT showed consistent over-transmission of nsCL/P polygenic risk from 
unaffected parents to affected offspring across all P value thresholds in European 
trios and over some thresholds in Asian trios, supporting the notion that nsCL/P has 
a polygenic component driven by common genetic variation. The observation of sub-
clinical craniofacial phenotypes in individuals with nsCL/P and unaffected relatives, 
such as lip pits 93, orbicularis oris muscle defects 96,97 and dental anomalies 102, is 
consistent with a polygenic architecture for nsCL/P. The most predictive score in the 
PTDT including less than 20 SNPs, suggests that genetic risk for nsCL/P may be 
largely attributable to a modest number of common variants, consistent with the 
previous finding that the majority of the SNP heritability in Europeans is explained by 
24 known risk loci 26. A further important finding is that nsCL/P polygenic risk scores 
generated in Europeans are still predictive in Asian populations, albeit to a lesser 
extent, which is consistent with the difference in variation explained by known risk 
loci in European and Asian populations 26,28. MAF stratified PTDT analysis further 
supported the importance of high frequency genetic variation, although the extent to 
which lower frequency variation is tagged by SNPs on the genotyping chip is largely 
unclear. 
A modest narrow-sense heritability estimate of 6.2% using sibling recurrence 
risk and prevalence may be attributable to both the crudeness of the method and to 
the low population prevalence of nsCL/P (the magnitude of the denominator in the 





AVENGEME SNP heritability estimates of 33% and 20% respectively, further support 
the role of common variation, and are consistent with a previous SNP heritability 
estimate of 30% 26. 
Despite the efforts to match nsCL/P cases to controls from the UK Biobank on 
ancestry, there was strong evidence of systematic differences between cases and 
matched controls. These systematic differences could be attributable to the 
difficulties matching the ancestrally heterogeneous ICC nsCL/P cases, sampled from 
across the US and Scandinavia, to individuals in the UK Biobank. Alternatively, the 
differences may be caused by batch effects, i.e. differences in genotyping chips and 
related processes. The GCTA estimates of SNP heritability of 45-70% on the liability 
scale are higher than the estimates from other methods in this chapter and previous 
estimates 26,  but are likely inflated by the systematic differences in the matched 
sample. Contrastingly, simulations showed that any systematic differences in the 
matched sample are unlikely to have biased the AVENGEME heritability estimates.  
The findings of strong evidence for nsCL/P having a polygenic architecture 
and a substantial SNP heritability are highly concordant with previous findings. 
Previous estimates of the narrow-sense heritability of nsCL/P from twin and pedigree 
studies ranged between 40 and 90% 198,199, which are higher than our SNP 
heritability estimates, but this may be explained by narrow-sense estimates including 
the effects of rare variation. As discussed previously, a published SNP heritability 
estimate is also highly concordant with our findings 26.  
The major strength of the analysis is the thoroughness of evaluating many 
different heritability estimation methods (narrow-sense and SNP) for a complex trait 





both European and Asian trios which allowed for the evaluation of the effect of 
population differences in polygenic scoring methods. The analysis also featured 
some relatively novel approaches in exploring genetic architecture such as 
stratification on allele frequency in the PTDT. Finally, the systematic differences in 
the matched sample, although a limitation in most regards, revealed that methods 
using PRS such as AVENGEME may be largely unaffected by genotyping chip 
differences.  
The major limitation of the study is that the matched case-control samples 
used were not homogeneous; this had a sizeable effect on the heritability estimates 
from GCTA which are therefore likely unreliable. Despite the efforts to match cases 
to controls on ancestry, genotyping chip differences between cases and controls or 
genuine ancestral differences resulted in population substructure differences 
between the cases and controls in the matched samples. Although some nsCL/P 
cases mapped relatively well with the matched controls on principal component 
plots, the plots suggested that systematic differences between cases and controls 
were highly prevalent even after the removal of ancestral outliers. A possible reason 
for this is the heterogeneity between the European nsCL/P cases; the cases are 
sampled from different populations including Denmark, Norway and the USA. 
Another limitation is that of statistical power, the number of nsCL/P cases used in the 
analyses was relatively low; LD score regression recommends sample sizes greater 
than 3000 and this was reflected by large confidence intervals. Statistical power may 
be lowered further by phenotypic heterogeneity within the nsCL/P phenotype; there 
is increasing evidence that nsCLP and nsCLO may have distinct aetiologies 8,13,27,253. 





phenotype in our analyses may have resulted in measurement error, as the genetic 
architecture and SNP heritability may differ between the nsCL/P subtypes.  
To conclude; the PTDT demonstrated that nsCL/P is a highly polygenic trait 
and AVENGEME / LD score regression analyses estimated that common genetic 
variation explains between 20 and 33% of the phenotypic variance in nsCL/P. These 
findings, in conjunction with previous findings, imply that both PRS and MR can be 
utilised effectively in an epidemiological context to explore causal relationships 
involving liability to nsCL/P. AVENGEME has been shown in this instance to give 
heritability estimates largely unaffected by batch and could be the most appropriate 
heritability method to use in samples affected by batch. The difficulties with matching 
cases to controls on ancestry across samples with different genotyping chips was 
also shown to be a non-trivial undertaking and should be considered carefully, 














Chapter 4: Epigenetics and nsCL/P 
4.1 Abstract 
 Many nsCL/P genetic risk variants identified in GWAS reside in non-protein-
coding regions with an unclear function. One possibility is that genetic risk variants 
influence susceptibility to nsCL/P through gene expression pathways, such as those 
involving DNA methylation.  
 MR and joint likelihood mapping were used to identify putative loci where 
genetic liability to nsCL/P may be mediated by variation in DNA methylation, using 
nsCL/P GWAS summary data and methylation data from four studies. The primary 
analyses used DNA methylation in blood, so the correlation between DNA 
methylation in blood and more appropriate tissues (lip/palate) was estimated for 
relevant CpG sites.  
Evidence was found at three independent loci, VAX1 (10q25.3), LOC146880 
(17q23.3) and NTN1 (17p13.1), that liability to nsCL/P and variation in DNA 
methylation might be driven by the same genetic variant. Follow up analyses using 
DNA methylation data, derived from lip and palate tissue, and gene expression 
catalogues provided further insight into possible biological mechanisms. Genetic 
variation may increase liability to nsCL/P by influencing DNA methylation and gene 
expression at VAX1, LOC146880 and NTN1.  
 
4.2 Introduction 
4.2.1 Epigenetics, gene expression and nsCL/P 
GWAS have identified around 40 distinct genetic risk variants for nsCL/P in 





protein coding regions and so their functional relevance remains unclear. One 
possibility is that genetic risk variants for nsCL/P may act through gene regulation 
pathways. For example, a previous study demonstrated that a major nsCL/P risk 
locus, a non-coding interval at 8q24, regulates gene expression in the developing 
murine face, suggesting similar mechanisms in humans 32.  
Epigenetics refers to mitotically (and perhaps, controversially meiotically) 
heritable changes in gene expression that are not explained by changes to the DNA 
sequence 255. Epigenetic processes, which include DNA methylation, histone 
modification and non-coding RNAs, can effect gene expression by influencing 
transcription 256. There is increasing evidence that epigenetic mechanisms, such as 
DNA methylation, play a role in the development of OFCs 33-36, potentially via 
changes to gene expression.   
4.2.2 DNA methylation 
DNA methylation, the most widely-studied epigenetic mechanism is a 
reversible modification of DNA, typically involving the addition of a methyl group to a 
cytosine base in the base-pair sequence CpG. The CpG pairing has been shown to 
have a lower than expected frequency throughout the genome but occurs more 
frequently in regions known as CpG islands 256. CpG islands are found in the coding 
regions of around half of all transcribed genes and are thought to play a major role in 
gene expression 256. DNA methylation can influence gene expression by silencing 
transcription; one possible mechanism is that methylation can block interactions 
between the DNA and proteins involved in transcription 257,258.   
DNA methylation has been proposed as a potential mediator of environmental 
effects on disease risk because it can be altered by exogenous stimuli and these 





exposure causes changes in methylation 260 and there is some evidence that these 
changes may mediate the effects of maternal smoking on reduced birthweight in the 
offspring 261. 
Two groups of diseases where DNA methylation has been shown to be highly 
relevant are X-linked Mendelian syndromes and cancer. The importance of DNA 
methylation in development is illustrated by the effect of mutations in the MECP2 
gene, which codes for a protein involved in the binding of methylated DNA. 
Mutations in MECP2 can cause Rett syndrome, Angelman syndrome and non-
specific X-linked mental retardation 262. An aetiological link between methylation and 
cancer is suggested by the differential methylation of malignant tumour cells 
compared to healthy cells 263.  
4.2.3 Investigating the role of DNA methylation  
The association between DNA methylation at CpG sites across the genome, 
and complex traits can be investigated using EWAS. However, the direction of effect 
between DNA methylation and a phenotype is difficult to determine, as epigenetic 
marks are susceptible to both confounding and reverse-causation. Unlike germline 
DNA, methylation can vary across the life course and so can be affected by the 
presence of disease as well as many potential common confounders from 
observational epidemiological studies, such as an individual’s age 264,265.  
Further potential confounders when investigating a possible causal role of 
DNA methylation are batch effects 165 and cellular heterogeneity 178. Batch effects 
between different samples can be caused by variation in chips, pre-processing 
methods or assaying. Cell counts are another potential confounder as DNA 
methylation varies greatly across different cell types and cellular heterogeneity has 





similar vein to cellular heterogeneity, methylation can vary greatly between different 
tissue types and it is therefore important to measure methylation in an appropriate 
tissue 92.  
4.2.4 Genetics of DNA methylation and epigenetic MR 
 A substantial proportion of the variation in DNA methylation is explained by 
variation in the germline genome, such variants are referred to as methylation 
quantitative trait loci (mQTL). mQTL can affect methylation in cis, i.e. affect the 
methylation of nearby areas, or in trans, affecting sites further away 266.  
 mQTL can be used as instruments for DNA methylation in an MR framework 
to more formally investigate the relationship between DNA methylation and a 
phenotype 259. If a SNP, which is a mQTL, is also associated with nsCL/P, there are 
several distinct possibilities. The first possibility is that the effect of the SNP on 
nsCL/P is mediated by DNA methylation, i.e. the SNP affects DNA methylation which 
then in turn affects the phenotype (vertical or mediatory pleiotropy). The second 
possibility is that the SNP affects the phenotype through a pathway independent of 
DNA methylation, and liability to nsCL/P causes differences in methylation. In some 
instances, this reverse direction could be thought of as reverse-causation; for 
example, if atherosclerosis (often a precursor to more serious heart disease 
symptoms) causes changes in methylation. However, in this instance the 
interpretation of liability to nsCL/P causing differences in methylation as reverse 
causation is less clear. The third possibility is that the causal SNP influencing 
methylation at a probe is in strong LD with another SNP that independently affects 
the risk of nsCL/P (linkage disequilibrium). The fourth possibility is that nsCL/P and 
DNA methylation are influenced by the same SNP, but via independent pathways 





Figure 6: Possible explanations for an association between mQTL and nsCL/P. In 
this chapter, I attempted to identify loci where genetic influences on nsCL/P are 









The principles of MR and joint likelihood co-localization can be used to 
determine the most likely of the four possibilities at each locus. The main advantage 
of using an MR approach is that the germline genome is fixed from birth, alleviating 
the possibility of reverse-causation, and may also be less susceptible to 
confounding. However, one limitation is that it is currently difficult to differentiate 
between mediation and horizontal pleiotropy because the majority of CpGs are 
instrumented by a single genetic variant 259,267,268. 
4.2.5 Chapter aims 
In this chapter, genetic and epigenetic data from several different cohorts 
were used to investigate if DNA methylation mediates the effect of genetic risk 
variants for nsCL/P. The four possibilities, outlined previously, were evaluated using 
bidirectional MR and joint-likelihood co-localisation. It was not possible to distinguish 






mQTL relevant to putative mediating CpGs were investigated with regards to 
overlap with gene expression (a potential functional mechanism) using publicly 
available databases. Putative CpGs were compared with the results of a previous 
nsCL/P EWAS, derived from whole blood in a Brazilian population, to determine if 
they were differentially methylated between nsCL/P cases and controls.  
Given that primary analyses used DNA methylation derived in blood, which 
might not be representative of the developing orofacial tissues 36, correlations 
between DNA methylation in blood and lip/palate tissue in the same individuals were 
estimated. Additionally, considering the growing evidence that different subtypes of 
OFCs have distinct aetiologies 8, it was investigated whether putative CpGs are 
differentially methylated in blood samples from children with different OFC subtypes. 
In this chapter, Dr Gemma Sharp performed analyses that involved the Cleft 
Collective data and the methWAS cohort. I performed all other described analyses.  
4.3 Materials and methods 
4.3.1 Study participants 
4.3.1.1 ICC and Bonn-II 
The nsCL/P meta-analysis GWAS summary statistics derived in Chapter 3 
were used for information on nsCL/P genetic risk variants. In brief, the meta-analysis 
summary statistics included ICC TDT results from 638 parent-offspring trios and 178 
offspring duos of European descent, meta-analysed with GWAS summary results on 
399 cases and 1,318 controls from the Bonn-II study. 
 LiftOver 269 was used to convert the genome positions in the nsCL/P 
summary statistics to the most recent genome build 37. Finally, PLINK 161 was used 





within a 250 kb region around each index variant, and to generate a set of 
independent SNPs for the pipeline. 
4.3.1.2 ALSPAC  
To identify mQTL (SNPs associated with DNA methylation), data were used 
from ALSPAC 270,271. Genome-wide DNA methylation and genotype data are 
available for ARIES, a subset of ALSPAC 164, which has been described in more 
detail in Chapter 2. These data have previously been used to generate a database 
of mQTL (http://www.mqtldb.org/) 266. The database contains summary statistics for 
all mQTL with a P-value <1x10-7 for the association between SNP and CpG. 
 For the purposes of this study, mQTL identified in cord blood samples 
collected at birth were most relevant (the closest available time point to the orofacial 
developmental period). For one analysis (the reverse two-sample MR), specific CpG-
SNP associations were required that were unavailable from mQTLdb.org. Therefore, 
for required CpGs, the methods from the original study were replicated: individuals 
with missing genotype or covariate data were excluded, leaving 787 children. The 
methylation data were then rank-normalised to remove outliers and covariates, 
potential batch effects and the influence of cell heterogeneity were controlled for by 
regressing data points on sex, the first 10 ancestry principal components, bisulfite-
converted DNA batch and blood cell proportions estimated using the Houseman 
method 178,179. Residuals were then calculated, which were used as the outcome 
variable in a linear regression model in PLINK161 to calculate the relevant CpG-SNP 
associations.  
Finally, any mQTL acting in trans (i.e. any SNP associated with a CpG site 





potentially problematic, (for example, cross-hybridising probes) according to a 
previous publication, were removed 272.  
4.3.1.3 GOYA 
mQTL of interest, identified in ALSPAC, were followed up for replication using 
genotype and cord blood DNA methylation data from the GOYA cohort 177. More 
information on GOYA is contained in Chapter 2.  
Genotype and cord blood DNA methylation data were available for 1000 
children. The methods described above for ALSPAC were replicated. Individuals with 
missing genotype or covariate data were excluded, leaving 889 children. SNPs with 
missingness (>5%) were also removed using PLINK. As in ALSPAC, the methylation 
data were rank-normalised to remove outliers and covariates, potential batch effects 
and the influence of cell heterogeneity were adjusted for by regressing data points 
on sex, the first 10 ancestry principal components, DNA batch and blood cell 
proportions estimated using the Houseman method 178,179. Residuals were then used 
as the outcome variable in a linear regression model in PLINK to calculate the 
relevant CpG-SNP associations. 
4.3.1.4 Expression quantitative trait loci (eQTLs) databases 
To identify eQTL (SNPs associated with gene expression), two gene 
expression databases were used. The GTEx database 182,183 and the NNC eQTL 
Catalog 184. More information on these databases is contained in Chapter 2.  
4.3.1.5 methWAS cohort 
To assess whether methylation at nsCL/P-associated CpGs (identified 
through MR) differs between nsCL/P cases and controls, relevant CpGs were looked 





in 67 non-familial, nsCL/P cases and 59 age- and sex-matched controls from a 
Brazilian population. More information on the methWAS cohort is contained in 
Chapter 2.  
4.3.1.6 The Cleft Collective 
To explore whether methylation at nsCL/P-associated CpGs differs by OFC 
subtype, the mean methylation values in blood were compared with matched 
lip/palate tissue samples from 150 children from the United Kingdom, enrolled in the 
Cleft Collective birth cohort study. More information on the Cleft Collective is 
contained in Chapter 2. 
4.3.2 Testing for mediation: Mendelian randomization of the effect of 
methylation on liability to nsCL/P 
The nsCL/P meta-GWAS summary statistics for 543,150 SNPs were LD-
pruned (r2<0.001) to 17,090 independent SNPs using ALSPAC as the reference 
panel for the LD. These independent SNPs were then merged with 127,215 mQTL 
from the ALSPAC mQTL database. After removing potentially problematic CpGs and 
CpGs acting in trans (which may increase the likelihood of horizontal pleiotropy), 
there were 7,091 independent CpG-SNP pairings for 6,425 distinct CpGs. 
The MR-base R package 273 was then used to perform two-sample MR on all 
CpGs, using mQTL as the exposure variables and nsCL/P as the outcome. In initial 
analyses, CpGs with one mQTL were tested using the Wald test which is a method 
of estimating the causal effect when there is only a single valid SNP for the 
exposure. The causal estimate is estimated as the effect of the SNP on outcome 
divided by the effect of the SNP on the exposure, and can be interpreted as the unit 





 CpGs associated with more than one independent mQTL were tested using 
the Inverse Variance Weighted (IVW) method, an extension to the Wald Ratio 
method when there are multiple SNPs. The IVW estimates the causal effect by 
combining the Wald ratios for each variant in a fixed-effects or random-effects meta-
analysis 275. To account for possible residual LD between mQTL, CpGs with more 
than one mQTL, were retested adjusting for LD between the SNPs using a 
likelihood-based method 276. Pair-wise SNP LD was computed using the CEU and 
GBR populations from the 1000 Genomes in LDlink 277. As a sensitivity analysis, 
replication of the SNP-CpG associations with a Bonferroni-corrected MR P-value 
<0.05 was attempted in GOYA.  
4.3.3 Testing for reverse causation: Mendelian randomization of the effect of 
liability to nsCL/P on methylation 
To assess the possibility that liability to nsCL/P causes changes in DNA 
methylation, MR-Base was used to conduct the reverse two-sample MR. Six SNPS, 
previously found to be genome-wide significant in Europeans 24, were used as the 
exposure, proxying for liability to nsCL/P. mQTL from ALSPAC were used as proxies 
for the methylation outcomes. The IVW method was used as the primary analysis.  
4.3.4 Testing for linkage: joint-likelihood mapping to assess co-localisation 
Joint likelihood mapping is a method of testing for co-localisation, where two 
phenotypes are being affected by the same causal variant in a region of interest 
rather than two independent causal variants affecting each of the phenotypes 
separately. The likelihood of co-localisation is estimated by exploring the shape of 
the association curves over a region. Co-localisation can suggest vertical pleiotropy 
where a genetic variant affects a phenotype which in turn has a downstream effect 





The Joint Likelihood Mapping (JLIM) package in R (jlim.R) 278 was used to test 
the possibility that liability to nsCL/P and methylation are driven by the same causal 
effect in each region of interest. To distinguish between separate causal variants, we 
set the limit of genetic resolution in terms of r2 to 0.8 (LD). The CEU data from the 
1000 Genomes 163 (Phase 3) was used as the reference dataset for LD. The majority 
of CpGs were associated with only one independent mQTL, so it was not possible to 
distinguish between mediation/vertical pleiotropy (top left-hand panel of Figure 6) 
and horizontal pleiotropy (bottom right-hand panel of Figure 6). 
4.3.5 Comparison with gene expression 
The previous steps identified CpGs that potentially mediate the effect of 
genetic variation on susceptibility to nsCL/P. Further evidence for a functional effect 
would be provided if implicated mQTL also affect gene expression. Therefore, 
relevant SNPs were looked up in two eQTL databases (GTEx 183 and NESDA NTR 
Conditional eQTL Catalog 184) and the estimated effect sizes and P-values for eQTL 
in various tissues were noted.  
4.3.6 Comparison to methWAS EWAS results 
At implicated CpGs, data from the methWAS cohort were used to explore 
differential methylation between nsCL/P cases and controls from the Brazilian 
methWAS EWAS study. The estimated direction of effect and P-values obtained 
using the observational EWAS and MR approaches were compared. 
4.3.7 Tissue and cleft-subtype-specific variation 
At identified CpGs, data from the Cleft Collective were used to explore 1) the 
correlation between methylation in blood and methylation at the site of the cleft 





CPO or CLP). One-way ANOVA was used to compare the mean methylation of 
subtypes, adjusting for sex and surrogate variables designed to capture technical 
batch and cell composition effects.  
4.4 Results 
4.4.1 Testing for mediation: Mendelian randomization of the effect of 
methylation on liability to nsCL/P 
Two sample MR was used to identify CpGs where methylation may mediate 
genetic liability to nsCL/P by performing an MR analysis of methylation on nsCL/P. 
mQTL from ALSPAC data were used as genetic instruments for methylation at 
different CpG sites (exposures) and SNPs from the nsCL/P GWAS meta-analysis 
summary statistics were used as genetic instruments for liability to nsCL/P 
(outcome). Evidence was found for an effect of methylation on liability to nsCL/P at 
26 CpGs after a Bonferroni correction for 6,425 tests (Bonferroni-corrected P-value 
<7.8x10-6, corresponding to an uncorrected P-value <0.05). Of these 26 CpGs, 20 
were instrumented by single mQTL and six were instrumented by two mQTL each. 
When the six CpGs with two mQTL each were re-tested, accounting for the LD 
between the SNPs, only one (cg02598441 at LOC146880) survived correction for 
multiple testing. These 21 mQTL were therefore taken forward to the reverse-
causation step. 
As a sensitivity analysis, all 21 of the ALSPAC mQTL were investigated in 
data from the GOYA cohort. 17 of the 21 CpG-SNP pairings passed QC and were 
present in the GOYA data, of which 16 replicated as mQTL in the same direction 

















































































































































































0.57, 8.7*10-11 N/A (didn’t 
have SNP) 
N/A 
1 ALSPAC regression coefficients are on rank-normalised data 
4.4.2 Testing for reverse causation: Mendelian randomization of the effect of 
genetic liability to nsCL/P on methylation 
Next, we tested if the association between the mQTL and liability to nsCL/P 
arose because liability to nsCL/P, a latent measure of nsCL/P, affects methylation. 
Two sample MR was used to test this possibility, with liability to nsCL/P as the 
exposure and methylation as the outcome. No evidence was found for liability to 
nsCL/P influencing variation in methylation at the 21 CpGs (Table 12). However, it 
should be noted at this point that this step is very likely to be limited by statistical 
power. 
 
4.4.3 Testing for linkage: joint-likelihood mapping to assess co-localisation 
Next, a co-localisation method was used to assess if there was evidence that 
methylation and liability to nsCL/P are driven by the same causal effect at each 
locus. Of the 20 CpGs instrumented by one mQTL each, evidence was found for co-
localisation at four CpGs (cg11398452, cg01862363, cg02481697 and cg16107528). 
With the addition of the CpG site associated with two mQTL (cg02598441), evidence 
was found that methylation at five CpGs are putative mediators of genetic liability to 
nsCL/P at four different SNPs (Table 12).  
Of these four SNPs, three were available and tested in the imputed GOYA 
data (rs807647, rs1808191 and rs4752028). Two of the SNPs (intergenic rs8076457 





third SNP, rs4752028, replicated as an mQTL for two out of three CpG sites but did 
not replicate for the CpG-SNP pairing (rs4752028/cg11398452) where there was 
evidence of co-localisation (Tables 11 and 12). 
Table 12: Results of the forward (methylation  nsCL/P) and reverse (nsCL/P  




























































































































































































































1 This region was too sparsely genotyped to apply the co-localisation analysis 
2This CpG had two mQTL, so we did not apply the co-localisation analysis 
 
4.4.4 Comparison between methylation and gene expression 
In a look-up of the four identified SNPs in the GTex and NESDA NTR 
Conditional eQTL databases, strong evidence was found for rs4752028 at SHTN1 
being an eQTL for SHTN1. There was also strong evidence that both rs1808191 at 
PLEKHM1P1 and rs1991401 at CEP95/DDX5 are eQTL for six nearby genes, 
including CEP95 and DDX5, which were identified through both databases. There 
was no strong evidence that the intergenic SNP rs8076457 is associated with gene 
expression in either database which only included pairings meeting a certain 

















GTex: Gene, tissue, 




Catalog: Gene, tissue, 





SHTN1, whole blood, 
0.35, 1.4*10-15 























exposed skin, -0.29, 
1.5*10-11 
PLEKHM1P, sun 





DDX5, whole blood, -
0.30, 1.8*10-19 
CEP95, whole blood, 
0.14, 2.3*10-7 
MILR1, whole blood, 
0.24, 1.4*10-5 
DDX5, whole blood, -
0.22, 6.2*10-108 











4.4.5 Comparison to methWAS EWAS results 
At cg02598441 (LOC146880), the direction of effect estimated in our first 
(forward) MR analysis was concordant with that in the methWAS EWAS study, with 
an EWAS P-value (2.4x10-3) that survived Bonferroni correction for five tests. The 
direction of estimated effect was also concordant between studies at the three CpGs 
at NTN1, but the smallest EWAS P-value was 0.12. At cg11398452 (VAX1), the 
direction of estimated effect was discordant between our MR analysis and the 
methWAS EWAS, with a small EWAS P-value (9.4x10-3) (Table 14). 
4.4.6 Tissue and cleft-subtype-specific variation in the Cleft Collective 
At most of the five identified CpGs, there was evidence of weak correlation 
between methylation in blood, lip and palate tissues (correlation coefficients ranged 
from -0.11 to 0.32), particularly between blood and lip tissue. Weak evidence was 
found for the mean methylation values in any of the three tissues differing between 
the OFC subtypes. However, the analysis was likely underpowered to give precise 
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1 Effect size for forward MR can be interpreted as the difference in risk of nsCL/P per S.D. increase in methylation beta value. 
2 Effect size for the methWAS EWAS can be interpreted as the difference in mean methylation beta value in participants with 






In this study, a previously devised framework was employed to explore 
putative mediation of genetic influences on nsCL/P by DNA methylation. Five CpG 
sites were identified, in three independent regions (VAX1, LOC146880, NTN1), 
where either bidirectional MR and co-localisation analyses suggested that the same 
variant affects both methylation and nsCL/P, or where evidence was found that two 
independent variants affect both nsCL/P and methylation (see Figure 6).  
Lower methylation at the CpG at VAX1 (cg11398452) was associated with the 
nsCL/P risk allele C of the SNP rs4752028 at SHTN1. This SNP is strongly 
associated with lower expression of SHTN1 according to two eQTL databases. 
VAX1 is a homeobox containing gene that has been shown to be expressed in the 
developing brain 279,280 and SNPs in VAX1 have been shown to be associated with 
nsCL/P in multiple independent GWAS across distinct populations 13,23,29,281,282. 
VAX1 knock-out mice have been shown to develop a cleft palate (CP), suggesting 
VAX1 has a potentially important role in nsCL/P aetiology 13. SHTN1, sometimes 
known as KIAA1598, codes for the protein (shootin1) that is involved in neuronal 
polarization 283 and has also been reported to be relevant to the aetiology of nsCL/P 
in several studies 29,284,285. It is difficult to discern the locus more relevant to nsCL/P 
between the VAX1 and SHTN1 genes because of their close proximity and similar 
expression profiles in mice and it is unclear which is the functional gene in the area 
29,280,285,286. The association between methylation at cg11398452 and rs4752028 was 
not replicated in the GOYA data, but the SNP was strongly associated with 
methylation at nearby probes. Similarly, the direction of association between 
cg11398452 methylation and nsCL/P was discordant between the MR analysis and a 





Higher methylation at the CpG at LOC146880 (cg02598441) was associated 
with the G allele of rs1991401 in DDX5 and the C allele of rs1808191 in PLEKHM1P. 
rs1991401 in DDX5 was associated with reduced expression of DDX5 and increased 
expression of CEP95 and MILR1 while rs1808191 in PLEKHM1P was associated 
with increased expression of SMURF2 but decreased expression of PLEKHM1P, 
RP13-104F24.3 and has-mir-6080. However, there was weak evidence that the 
SNPs affected expression of the same genes. DDX5 is involved in RNA helicase 
processes that are highly relevant to important cellular processes while PLEKHM1P 
and LOC146880 are pseudogenes 280. There is no robust evidence from previous 
literature to support an association between genetic variation of these genes and 
nsCL/P. The SNP in PLEKHM1P replicated as an mQTL in the GOYA dataset but 
there was not sufficient data to test the SNP in DDX5.  
Lower methylation at three CpGs at NTN1 was found to be associated with 
the nsCL/P risk allele T of the SNP rs8076457, an intergenic SNP close to NTN1. 
rs8076457, the mQTL for cg08162363, cg02481697 and cg16107528, is not known 
to be strongly associated with gene expression levels in two datasets. The function 
of NTN1 is still largely unknown but is thought to be involved in cell migration during 
development 280. NTN1 has been previously discussed as a strong candidate gene 
for nsCL/P 30; NTN1 may affect liability to nsCL/P via epistatic interactions, there is 
some evidence that NTN1 knock-out mice show consistency with the CP phenotype 
and NTN1 expression is localised to the palate 30,31. rs8076457 replicated as an 
mQTL across all relevant CpGs in the GOYA dataset. 
Previous work has identified many functional possibilities for genetic risk 
variants for nsCL/P 31,32,231 but this study adds to the current evidence for DNA 





study include the integration of multiple data sources, such as ALSPAC, which 
provided access to detailed phenotype, genotype and epigenetic data. The nsCL/P 
GWAS summary statistics allowed a comprehensive genome-wide analysis in a 
large dataset. The methWAS cohort EWAS results allowed a comparison of the 
influence of methylation on nsCL/P between observational and MR studies. The use 
of the GOYA replication cohort allowed triangulation of evidence for mQTL across 
different studies. Finally, the Cleft Collective data allowed us to compare genome-
wide DNA methylation in different tissues and subtypes of cleft.  
There are, several limitations to this study. First, methylation and expression 
in the studied tissues (postnatal cord blood, whole blood, lip and palate tissue) are 
unlikely to accurately reflect that in the developing orofacial tissue where epigenetic 
processes could feasibly influence susceptibility to nsCL/P. However, a previous 
study has identified a high correlation between blood and lip tissue, both taken at the 
time of first surgery in a UK cohort of patients with non-familial nsCL/P 36. Previous 
analysis looking for tissue-specific signals for nsCL/P did not find evidence of 
enrichment and concluded that this may be due to tissue type differences 254.  
Second, CLO and CLP cases were analysed together as one group in the GWAS, 
MR analyses and the previously published EWAS. Increasingly, evidence suggests 
that these subtypes are molecularly and aetiologically distinct and should be 
analysed separately 8,254, but the analysis was limited by the data available from 
previous studies. Although no evidence was found for differential methylation 
between subtypes at our five identified CpGs, there may be other loci where 
methylation mediates genetic influences on more specific cleft subtypes. Third, 
although efforts were made to select only non-syndromic cases for the Cleft 





and children with syndromes may have very different methylation profiles. Fourth, a 
major limitation of this study is that some of the steps, particularly the reverse MR, 
are likely to be statistically underpowered. Fifth, as the majority of mQTL were 
instrumented by just a single genetic variant, it was not possible to distinguish 
between mediation and horizontal pleiotropy and therefore proposed mediation is 
putative. Finally, the comparisons between ALSPAC and other cohorts may be 
affected by technical differences, tissue differences (cord blood vs whole blood), 
ancestral differences between cohorts, age of participants (newborns vs children 
over six years old), a lack of statistical power giving rise to spurious associations or 
the enrichment of GOYA for overweight and obese mothers, which may introduce 
selection bias. Indeed, although mQTL were largely concordant between ALSPAC 
and GOYA, the mQTL and CpG site (in SHTN1) found to co-localise with liability to 
nsCL/P in ALSPAC did not replicate in GOYA. Similarly, the CpG site cg11398452, 
close to SHTN1, was directionally discordant between the analysis in ALSPAC and 
the results of a methWAS EWAS. 
In conclusion, analyses identified three putative loci where DNA methylation 
may mediate genetic susceptibility to nsCL/P. Future work, determining the function 
of these genes and the epigenetic modulation of their expression relevant to prenatal 
orofacial development could provide important aetiological insights. One possibility, 
warranting further investigation, is that identified DNA methylation differences are 








Chapter 5: Investigating the shared genetics of 
nsCL/P and facial morphology  
5.1 Abstract 
There is increasing evidence that genetic risk variants for nsCL/P are also 
associated with normal-range variation in facial morphology. However, previous 
analyses are mostly limited to candidate SNPs and findings have not been 
consistently replicated.  
In this chapter, PRS were used to test for genetic overlap between nsCL/P 
and seven biologically relevant facial phenotypes. Where evidence was found of 
genetic overlap, bidirectional MR was used to test the hypothesis that genetic liability 
to nsCL/P is causally related to implicated facial phenotypes.  
Across 5,804 individuals of European ancestry from two studies, strong 
evidence was found, using PRS, of genetic overlap between nsCL/P and philtrum 
width; a 1 S.D. increase in nsCL/P PRS was associated with a 0.10 mm decrease in 
philtrum width (95% C.I. 0.054, 0.146; P = 0.00002). Follow-up MR analyses 
supported a causal relationship; genetic variants for nsCL/P homogeneously cause 
decreased philtrum width. The results support a liability threshold model of 
inheritance for nsCL/P, related to abnormalities in development of the philtrum.  
5.2 Introduction 
Facial morphology in the general population has been shown to be highly 
polygenic; genome-wide significant loci have been found for multiple facial 
phenotypes across diverse ethnic populations 95,287-290. In some cases, the genes 
associated with normal-range variation in facial shape have also been implicated in 





overlap between nsCL/P risk loci and facial phenotypes in the general population 
288,291,292. For example, the strongest nsCL/P GWAS signal, intergenic variant 
rs987525 on chromosome 8q24, was found to be associated with more than half of 
the 48 facial phenotypes studied in a European population 288 while in a Han 
Chinese population, rs642961 in IRF6 (a major nsCL/P-associated gene) strongly 
predicted lip-shape variation in females 292. Shared genetic aetiology between 
nsCL/P and normal-range in facial variation is further supported by the observation 
of sub-clinical differences in facial morphology and the increased incidence of lip 
defects in unaffected relatives of nsCL/P cases 93,96-98. However, associations 
between nsCL/P genetic variants and facial morphology have not been consistently 
replicated, possibly because of methodological differences in measuring facial 
phenotypes or population differences between cohorts 287.  
The use of individual markers to demonstrate genetic overlap between two 
phenotypes has notable limitations; a large number of statistical tests are introduced, 
and interpretation is difficult when some SNPs show an association and others do 
not. In Chapter 3, evidence was found of over-transmission of nsCL/P PRS between 
unaffected parents and affected offspring, which suggests that PRS can be used 
effectively to test for genetic overlap between nsCL/P and normal-range facial 
morphology.  
Interpreting genetic overlap between nsCL/P and a facial phenotype is difficult 
because the development of the face and development of an OFC are largely 
synchronous. One possibility is that differences in the facial phenotype are a sub-
phenotypic manifestation of genetic liability to nsCL/P (see Figure 7). The 
inheritance of dichotomous traits can be modelled on the liability scale, where every 





genes, environment and chance. Individuals above a liability threshold develop the 
trait, while increased liability may cause related phenotypic differences in individuals 
without the trait 156,204,293. A highly relevant example is that increased liability to 
developing a CP has been hypothesised to be associated with delayed movement of 
the palatal shelf, which may in turn result in a CP, dependent on other factors such 
as shelf and head width 204. Bidirectional MR can be used to test the hypothesis that 



















Figure 7: Liability threshold model for nsCL/P 
 
Shown is an illustration of a liability threshold model for nsCL/P. Every individual has 
a normally distributed liability to nsCL/P, determined by genes, environment and 
chance. Individuals over the liability threshold develop nsCL/P, with the area under 
the curve past the threshold equal to the trait incidence. We are hypothesising that 
liability to nsCL/P, specifically genetic liability to nsCL/P, may be associated with 


















The genetic overlap between nsCL/P and normal-range facial morphology in 
the general population was investigated using nsCL/P PRS. Then, in the instance of 
genetic overlap, bidirectional MR was used to explore the relationship between 
nsCL/P and implicated facial phenotypes. In this chapter, Mr Myoung Keun Lee from 
the University of Pittsburgh performed the polygenic risk scoring analysis in the 
3DFN study which required individual level data. Another member of the Pittsburgh 
group generated the GWAS summary statistics for philtrum width in their cohort. I 
performed all other described analyses, including the analysis of the 3DFN summary 
data. 
5.3 Methods 
5.3.1 Study participants  
5.3.1.1 ICC and Bonn-II 
 The nsCL/P meta-analysis GWAS summary statistics, previously described in 
Chapter 3, were used for information on nsCL/P genetic risk variants. In brief, the 
meta-analysis summary statistics included ICC TDT results from 638 parent-
offspring trios and 178 offspring duos of European descent, meta-analysed with 
GWAS summary results on 399 cases and 1,318 controls from the Bonn-II study. 
5.3.1.2 ALSPAC 
 Primary analyses used participants from ALSPAC 164. The cohort and 
genotyping have previously been described in Chapter 2. 
Face-shape data are available for a subset of the cohort. ALSPAC children 
were invited to a clinic at the age of 15 years and 5,253 attended, where two high-
resolution 3D facial images were taken by Konica Minolta Vivid 900 laser scanners. 
4,747 individuals had usable images (506 individuals did not complete the 





coordinates of 22 facial landmarks were derived from the scans and Euclidean 
distances between landmarks were calculated for relevant distances. To alleviate 
multiple testing issues, I tested 7 distances that were either tested previously or have 
biological relevance to nsCL/P (Table 15). Facial distances used in the analysis are 
shown in Figure 8. 
Table 15: Biologically plausible facial phenotypes 
Facial phenotype Justification for inclusion  
Nasal width Boehringer et al (EJHG 2011) – looked for 
association between phenotype and 
nsCL/P SNPs. 
Nasal lip height Relevance to cleft lip 
Lip width Relevance to cleft lip 
Philtrum width  Relevance to cleft lip 
Lip height Relevance to cleft lip 
Lip chin height Weinberg et al (Orthodontics & 
craniofacial research 2009) – compared 
phenotype between parents of nsCL/P 
children and control parents. 
Inter-palpebral width  Weinberg et al (Orthodontics & 
craniofacial research 2009) – compared 
phenotype between parents of nsCL/P 














Figure 8: Facial morphological distances of interest 
 
This figure shows the 12 facial landmarks that were used to generate the facial 
phenotypes tested for association with the nsCL/P PRS. Facial phenotypes were 
defined as the 3D Euclidean distance between the following landmarks (Nasal width: 
1-2, Nasal-lip distance: 3-7, Lip width: 4-5, Philtrum width: 6-8, Lip height: 7-9, Lip-





















5.3.1.3 3D Facial Norms Study (3DFN) 
Replication analyses used data on participants from the 3DFN 185 which has 
been described in Chapter 2. In brief, the 3DFN includes 2,454 unrelated individuals 
of recent European descent, aged between 3 and 40 years, which were recruited 
from 4 sites across the USA and screened for a history of craniofacial conditions. 
3D-derived anthropometric measurements, 3D facial surface images and genotype 
data were derived from each study participant.  
In collaboration with the Center for Inherited Disease Research (CIDR), 2,447 
subjects in the 3DFN database were genotyped using a genome-wide association 
array including 964,193 SNPs from the Illumina OmniExpress+exome v1.2 array and 
an additional 4,322 SNPs from previous craniofacial genetic studies. The genotype 
dataset was imputed using the 1000 Genomes reference panel (phase 3) 185.  
3DFN study participants had their facial surfaces captured via 3D stereo-
photogrammetry using either a two-pod 3dMDface or a multi-pod 3dMDcranial 
system. Captures were inspected to ensure 3D surface quality and additional 
captures were obtained if necessary. Similar to ALSPAC, a set of standard facial 
landmarks were collected from each 3D facial image and linear distances were 
calculated between the landmark coordinates. 
5.3.2 Polygenic risk score construction and analysis 
5.3.2.1 PRS construction 
 The nsCL/P meta-analysis GWAS summary statistics were used to construct 
nsCL/P PRS. The PTDT results from Chapter 3 were used to inform the most 
predictive PRS. The P-value inclusion threshold, which was P<0.00001, was 





 Using ALSPAC as a reference panel for linkage disequilibrium, PLINK was 
used to prune and clump the nsCL/P meta-analysis summary statistics (r2<0.1 and 
250 kb) using the most predictive P-value threshold. The PRS were then constructed 
in the ALSPAC sample. Information on the SNPs in the PRS is contained in Table 
16. 
Table 16: nsCL/P Polygenic risk score SNPs 










rs742071 1:18979874 T G 0.2927 0.0573 3.3 x 10-
7 
rs560426 1:94553438 T C -0.2574 0.0564 5.1 x 10-
6 
rs4147812 1:94575043 A C 0.3234 0.0606 9.4 x 10-
8 
rs12057415 1:94829769 T C -0.2786 0.0572 1.1 x 10-
6 
rs861020 1:209977111 A G 0.3218 0.0660 1.1 x 10-
6 
rs7590268 2:43540125 T G -0.3428 0.0650 1.3 x 10-
7 
rs1650504 5:158029550 A G 0.2585 0.0584 9.5 x 10-
6 
rs12543318 8:88868340 A C -0.288 0.0594 1.3 x 10-
6 
rs6470648 8:129716308 A G 0.3081 0.0636 1.3 x 10-
6 
rs11989880 8:129872982 T C 0.4993 0.0586 1.5 x 10-
17 
rs12548036 8:129947882 T G 0.5416 0.0585 2.1 x 10-
20 
rs1372452 8:130029034 A G 0.5244 0.0778 1.6 x 10-
11 
rs3138512 9:92222453 A G 0.3085 0.0690 7.9 x 10-
6 
rs4752028 10:118834991 T C -0.4046 0.0703 8.8 x 10-
9 
rs9545330 13:80699166 A G 0.432 0.0684 2.6 x 10-
10 
rs1258763 15:33050423 T C 0.3049 0.0629 1.2 x 10-
6 






rs8076457 17:8943929 T C 0.3175 0.0620 3.1 x 10-
7 
rs227731 17:54773238 T G -0.3148 0.0564 2.5 x 10-
8 
rs1808191 17:62784028 A C -0.3307 0.0707 2.9 x 10-
6 
rs3746101 19:2050823 T G 0.4474 0.0980 5.0 x 10-
6 
1 CHR:BP – Chromosome and Base Pair Position on the HumanGenome19 build 
  
5.3.3.2 PRS power calculations 
Power calculations for PRS analysis were performed using AVENGEME 
136,224. Assuming 80% power and an alpha level of 0.05, we estimated the minimum 
genetic covariance required between nsCL/P and the 3D face-shape distances for 
an association between the PRS and the face-shape distances to be detectable. 
Parameters used in power calculations are contained in Table 17. The genetic 
covariance estimates were then converted to genetic correlation estimates using 
GCTA 220 heritability estimates of the facial morphology variables derived in 
ALSPAC. 
Table 17: Parameters in Polygenic Risk Score analysis power calculations 
Parameter  Value Source 
Sample size of training sample 3972 determined from data 
Prevalence of nsCL/P in 
training sample 
0.305 determined from data 
Population prevalence of 
nsCL/P 
0.001 IPDTOC Working Group. 
"Prevalence at birth of 
cleft lip with or without cleft 
palate: data from the 
International Perinatal 
Database of Typical Oral 
Clefts (IPDTOC)." (2011). 
Number of independent SNPs 
common to both arrays (r2<0.1) 
75,737 determined from data 
h2 of nsCL/P 0.2 AVENGEME estimate 






5.3.3.2 Polygenic risk score association with facial phenotypes in ALSPAC 
Of the 4,747 ALSPAC children with face-shape scans, 3,941 individuals had 
genotype data. GCTA 220 was used to prune these individuals for relatedness (GRM 
< 0.05) and the final sample with complete covariates included 3,707 individuals. The 
associations between facial phenotypes and the nsCL/P PRS were measured in the 
final sample using a linear regression adjusted for sex, age at clinic visit, height at 
clinic visit and the first four principal components. Effect sizes were reported per S.D. 
increase in PRS.  
5.3.3.3 Replication in 3D Facial Norms Database 
 Distances with some evidence of an association (P < 0.05) in the ALSPAC 
children were followed up for replication in an independent cohort (3DFN). 2,429 
3DFN individuals had genotype and face-shape data. 332 individuals were removed 
due to missing SNPs in the PRS or missing covariates. The final sample consisted of 
2,097 individuals. The association between implicated facial measurements and the 
nsCL/P PRS was measured using a linear regression adjusted for sex, age, height 
and the first 4 principal components. Effect sizes were reported per S.D. increase in 
PRS. 
5.3.4 Exploring possible mechanistic direction 
5.3.4.1 Bidirectional Mendelian randomization analysis 
A bidirectional two-sample MR analysis was performed using the 
TwoSampleMR R package 273 , testing both the forward direction (the effect of 
genetic risk variants for nsCL/P on implicated facial measurements) and the reverse 
direction (the effect of genetic risk variants for implicated facial measurements on 





The IVW method was used as the primary analysis (previously described in 
Chapter 4). Several sensitivity analyses were performed to test the assumptions of 
MR. Cochran’s Q test for heterogeneity was used to test for balanced pleiotropy by 
testing the heterogeneity of the Wald estimates across each SNP 294,295.  MR Egger 
was used to test for directional pleiotropy; the MR Egger regression estimate 
provides an estimate for the true causal effect even if all genetic variants are invalid 
but assumes that instrument strength and pleiotropic effects are independent (the 
INSIDE assumption).  
The weighted median 148 and weighted mode estimates 149 were used to 
further examine the consistency of the causal estimate under certain assumptions. 
Assuming that at least half of the genetic instruments are valid, the weighted median 
provides a causal estimate, allowing for violation of the second and third IV 
assumptions. An advantage of the weighted median is that it generates more precise 
causal estimates than MR Egger 148. Assuming that the modal estimate (the largest 
grouping of similar causal effect estimates) is valid, the weighted mode method 
estimates the causal effect even if all other instruments are invalid. The weighted 
mode is generally less precise than the weighted median but more precise than MR-
Egger 149.  
 Leave-one-out analysis, where the IVW analysis is rerun after removing each 
SNP in turn, was used to identify potential outlying SNPs that are driving the overall 
effect estimate. The Steiger test of directionality 296 was used to determine the likely 
direction of effect using GWAS summary statistics data. The test is particularly 
useful, compared to a bidirectional MR, when the biology of instruments is unknown 





5.3.4.2 GWAS summary statistics for nsCL/P and implicated facial phenotypes 
MR analyses required relevant SNP association information with respect to 
both nsCL/P and implicated facial measurements. SNP information relevant to 
nsCL/P was extracted from the nsCL/P meta-analysis summary statistics, previously 
described in Chapter 3.  
For implicated facial phenotypes, GWAS were performed using PLINK 161 in 
both ALSPAC (3,707 individuals) and the 3DFN study (2,429 individuals with 
genotype and face shape data), using the same covariates as previously described 
in the PRS analysis. Summary statistics were then meta-analysed using METAL 241, 
with the combined sample including 6,136 individuals. SNP information relevant to 
implicated facial phenotypes was then extracted from the ALSPAC/3DFN meta-
analysis summary statistics.  
The ALSPAC/3DFN meta-analysis GWAS summary statistics of implicated 
facial phenotypes were subsequently analysed and functionally annotated 297 with 
the potential overlap between implicated facial phenotype associated SNPs and 
eQTL investigated using the GTEx catalogue, described previously in Chapter 2 183. 
5.3.4.3 Genetic risk variants for nsCL/P and implicated facial phenotypes 
For the forward direction, relevant SNPs are variants strongly associated with 
nsCL/P. Six of twelve genome-wide significant SNPs from a previous study were 
used as nsCL/P SNPs 24. The study was a meta-analysis of both European and 
Asian data and these six SNPs were genome-wide significant in the European only 





Table 18: nsCL/P Mendelian randomization SNPs 












rs7590268 2:43540125 T/G -0.328 0.065 0.0537 0.0505 
rs987525 8:129946154 A/C 0.829 0.0909 -0.1045 0.0517 
rs7078160 10:118827560 A/G 0.400 0.0704 0.0806 0.0572 
rs8001641 13:80692811 A/G 0.357 0.0581 -0.0021 0.0432 
rs1873147 15:63312632 A/G -0.352 0.0621 0.0491 0.0483 
rs227731 17:54773238 T/G -0.315 0.0564 0.0929 0.0434 
1 CHR:BP – Chromosome and Base Pair Position on HG19 
For the reverse direction, relevant SNPs are variants strongly associated with 
the implicated facial phenotypes. The ALSPAC/3DFN meta-analysis summary 
statistics were LD clumped (r2<0.001 within 500KB) to generate independent 
instruments for the MR analysis. LD proxies (r2>0.9) were used for SNPs 
unavailable in the nsCL/P summary statistics and were generated using LDlink and 
LDproxy 277 using the 1000 Genomes CEU/GBR populations as the reference panel 
163.  
5.3.4.4 Interpretation of bidirectional MR analysis 
The results of the bidirectional MR and relevant sensitivity analyses were 
used to infer the likelihood of the liability-related sub-phenotype model. Three distinct 
possibilities were considered to explain the association between nsCL/P PRS and 






Figure 9: Interpretation of bidirectional MR 
(A) SNPs associated with nsCL/P have a homogeneous effect on the facial 
phenotype with weak evidence for the reverse direction MR. We would conclude that 
genetic liability to nsCL/P causes both increased liability to nsCL/P (in conjunction 
with the environment and chance) and changes in the facial phenotype.  
(B) SNPs associated with nsCL/P have a heterogeneous effect on the facial 
phenotype. In this instance, there is weak evidence for genetic liability to nsCL/P 
causing changes in the facial phenotype because liability assumes a consistent 
effect. We would conclude that an unknown confounder Y affects the facial 
phenotype and liability to nsCL/P independently. 
 (C) SNPs associated with nsCL/P have a homogeneous effect on the facial 
phenotype AND SNPs associated with the facial phenotype cause increased liability 
to nsCL/P. In this instance, there are two possibilities. The first possibility is that the 
genetic instruments for the facial phenotype are weak (e.g. only one SNP) and so 
the causal effect estimate of the facial phenotype on liability to nsCL/P is imprecise. 
The second possibility is that nsCL/P and the facial phenotype have a substantial 
genetic correlation, which would require further investigation. Here, the results of the 
Steiger test are useful, as they can infer the most likely direction of effect between 




















5.4.1 The prediction of facial morphology using PRS for nsCL/P 
 Prior to testing the performance of our nsCL/P PRS on predicting facial 
morphology, the minimum genetic correlations required to detect an association 
between the PRS and the facial phenotypes were calculated using AVENGEME. 
Across the facial phenotypes, the minimum genetic correlation required ranged from 
0.17 to 0.28 with differences attributable to the different heritability estimates across 
the facial phenotypes (Table 19). 
 























0.045 0.18 (0.04, 0.33) 0.24 (0.18, 0.50) 
Philtrum width 
cphL_cphR 
0.045 0.20 (0.05, 0.35) 0.23 (0.17, 0.45) 
Lip height 
ls_li 
0.045 0.18 (0.03, 0.32) 0.24 (0.18, 0.58) 
Nasal width 
alL_alR 




0.045 0.34 (0.19, 0.49) 0.17 (0.14, 0.23) 
Distance between 
lip and chin 
li_pg 
0.045 0.21 (0.06, 0.35) 0.22 (0.17, 0.41) 
Distance between 
lip and nose 
sn_ls 
0.045 0.34 (0.19, 0.49) 0.17 (0.14, 0.23) 
 











The performance of the nsCL/P PRS for prediction of seven facial 
morphological traits was evaluated. Evidence was found of an association between 
the nsCL/P PRS and philtrum width in the ALSPAC children, where a 1 S.D. 
increase in nsCL/P PRS was associated with a 0.07 mm decrease in philtrum width 





















3D facial Euclidean distances 
in ALSPAC 
 
ALSPAC children (N=3707) 
Beta (95% C.I.) 
Per 1 S.D. increase in 
PRS 
P-value 
Distance between subnasale 
and labiale superius 
 (Nasal-lip)  
-0.25 (-2.16, 1.65) 0.79 
Distance between labiale 
inferius and pogonion 
(Lip-chin) 
-0.02 (-0.10, 0.06) 0.64 
Distance between left and 
right palpebrale inferius (Mid-
point of eyes) 
-0.08 (-0.17, 0.01) 0.09 
Distance between left and 
right alare (Nasal width) 
-0.01 (-0.08, 0.06) 0.75 
Distance between labiales 
inferius and superius 
(lip height) 
0.02 (-0.05, 0.10) 0.53 
Distance between left and 
right crista philtri 
(philtrum width) 
-0.07 (-0.13, -0.02) 0.014 
Distance between left and 
right cheilion  
(lip width) 





Replication for this finding was attempted in the 3DFN study and a consistent 
effect of 1 S.D. increase in nsCL/P PRS being associated with a 0.14 mm decrease 
in philtrum width (95% C.I. 0.07, 0.21; P = 0.00017) was found. Meta-analysing these 
results; indicated that a 1 S.D. increase in nsCL/P PRS is associated with a 0.10 mm 
decrease in philtrum width (95% C.I. 0.054, 0.146; P = 0.00002). 
5.4.2 GWAS of philtrum width 
To generate SNP-philtrum width association information for MR analyses, 
GWAS of philtrum width in both ALSPAC and 3DFN were performed separately 
before meta-analysing. The combined sample included 6,136 individuals of recent 
European descent. Two novel chromosomal regions associated with philtrum width 
with genome-wide significance were identified at 5q22.2 (lowest P value for 
rs255877, P=3.8x10-10), within the non-coding RNA intronic region of an 
uncategorised gene ENSG00000232633, and 7p15.2 (rs2522825, P=1.4x10-8), an 
intergenic SNP near HOXA1. There was evidence of possible heterogeneity between 
ALSPAC and 3DFN with regards to the association between rs2522825 and philtrum 
width. Although the direction of effect was consistent between the two studies, 











Table 21: Independent philtrum width trait loci derived from the ALSPAC/3DFN 
summary statistics 























































Some evidence was found that the two lead SNPs may be eQTL for nearby 
genes (Table 22). The two lead SNPs of the genome-wide significant loci, rs255877 
and rs2522825, were used as genetic variants associated with philtrum width in 













Table 22: Philtrum width associated SNPs in GTex 





rs255877 (G) YTHDC2 -0.32 (3.4x10-9) 
-0.11 (2.1x10-6) 
-0.14 (2.4x10-5) 
Brain – Cerebellum 
Thyroid 
Lung 
CTD-2201G3.1 0.23 (3.6x10-5) Skin – sun exposed 
(lower leg) 
rs2522825 (T) SKAP2 0.20 (3.2x10-14) Whole blood 
HOXA4 0.43 (2.2x10-9) Whole blood 
HOXA-AS2 0.41 (7.0x10-9) Whole blood 
HOTAIRM1 0.35 (3.1x10-8) Whole blood 
HOXA2 0.37 (4.4x10-8) Whole blood 
HOXA5 0.31 (4.0x10-6) Skin – not sun 
exposed 
(suprapubic) 
HOXA1 0.33 (1.2x10-5) 
0.24 (2.1x10-5) 
Whole blood 
Skin – sun exposed 
(lower leg) 




5.4.3 Bidirectional MR 
MR was used to investigate the possible causal mechanism that would give 
rise to the genetic overlap between nsCL/P and philtrum width. 
Firstly, it was determined whether genetic variants contributing to liability of 
nsCL/P affect philtrum width, by testing SNPs strongly associated with nsCL/P for 
association with philtrum width. A 1-unit log odd increase in liability to nsCL/P was 





width. Sensitivity analyses suggested there was weak evidence for pleiotropy or 
heterogeneity and validated the consistency of the instrument. Leave-one-SNP-out 
analysis showed consistent effect estimates after exclusion of each SNP (Table 23).  
Table 23: Causal estimates of genetic liability for nsCL/P on philtrum width using 
Mendelian Randomization and sensitivity analyses.  











Balanced pleiotropy N/A 0.36 




-0.01 (-0.11, 0.10) 0.93 
Regression 
estimate1 
-0.10 (-0.33, 0.13) 0.43 
Weighted median Consistency1 -0.12 (-0.21, -0.04) 0.0043 
Weighted mode Consistency1 -0.12 (-0.21, -0.03) 0.049 
Leave-one out 
rs1873147 
Additive model1 -0.11 (-0.20, -0.02) 0.017 
Leave-one out 
rs227731 
Additive model1 -0.10 (-0.16, -0.03) 0.007 
Leave-one out 
rs7078160 
Additive model1 -0.13 (-0.20, -0.06)  0.0001 
Leave-one out 
rs7590268 
Additive model1 -0.11 (-0.20, -0.02) 0.013 
Leave-one out 
rs8001641 
Additive model1 -0.13 (-0.21, -0.04) 0.0030 
Leave-one out 
rs987525 
Additive model1 -0.10 (-0.22, 0.01)  0.084 
1 Units: mm change in philtrum width per 1-unit log odd increase in liability to nsCL/P 
2 Units: Average pleiotropic effect of a nsCL/P genetic variant on philtrum width 
 
Secondly, it was determined whether genetic variants associated with philtrum 
width also affect liability to nsCL/P, by testing two independent SNPs associated with 
philtrum width at genome-wide significance (derived in the ALSPAC and 3DFN 





evidence was found of an association between philtrum width-associated variants 
and liability to nsCL/P. A 1 mm increase in philtrum width was associated with a 0.30 
log-odd unit increase in nsCL/P (95% C.I. -0.26, 0.86; P = 0.30). The direction of 
effect was discordant to the PRS analysis and the MR analysis with liability to 
nsCL/P as the exposure, where the results suggested that increased liability to 
nsCL/P is associated with decreased philtrum width. Sensitivity analyses for 
pleiotropy were limited, with only 2 SNPs. 
Table 24: Proxy SNPs (for philtrum width associated variants) in nsCL/P summary 
statistics  























5:112722855 T/C 0.20 0.032 0.0088 0.058 
rs2522825 rs2712248 / 
0.95 
7:27120689 T/C -0.18 0.039 -0.11 0.061 
 
Thirdly, the MR-Steiger test of directionality was used to test the direction of 
effect between philtrum width and liability to nsCL/P. The results suggested that the 
true direction of effect is that genetic variants contributing to liability to nsCL/P cause 
changes in philtrum width (P <10-10). 
5.4.4 Interpretation of Bidirectional Mendelian randomization 
Strong evidence was found for genetic liability to nsCL/P causing decreased 





in the forward-MR, and weak evidence was found for the reverse-MR of philtrum 
width-associated variants on liability to nsCL/P. Therefore, the most likely 
explanation for the genetic overlap between nsCL/P and philtrum width is that 
genetic liability to nsCL/P is causally related to decreased philtrum width. 
 
5.5 Discussion 
In this chapter, strong evidence has been found for genetic overlap between 
nsCL/P and normal-range variation in philtrum width. Furthermore, genetic risk SNPs 
for nsCL/P have been shown to consistently cause decreased philtrum width in the 
general population. Notably there was weak evidence for genetic overlap between 
nsCL/P and upper lip width despite the observational correlation between the widths 
of the upper lip and philtrum.  
There are two main implications of these results. First, the findings 
demonstrate the aetiological relevance of the formation of the philtrum to nsCL/P. 
The medial nasal and maxillary processes are responsible for development of the 
upper lip and philtrum 2. Developmental anomalies within these processes may 
result in a cleft lip (CL) 3 and the findings show that even when there is successful 
fusion, as in our study populations, the genetic variants which give rise to a CL/P 
cause decreased philtrum width. Secondly, the additive effect of common nsCL/P 
risk variants, on a related phenotype in the general population, showing little 
evidence for effect heterogeneity, supports a polygenic threshold model of 
inheritance for nsCL/P.  
Although previous studies have looked at nsCL/P related sub-phenotypes, the 





the relationship. The identification of phenotypic differences related to nsCL/P liability 
are consistent with previous studies 93,96-98,102,298 observing sub-clinical facial 
phenotypes in individuals with nsCL/P and their unaffected family members, 
particularly a previous study which observed reduced philtrum width in unaffected 
parents of individuals with nsCL/P 98. A polygenic threshold model of inheritance 
related to development of the philtrum is consistent with a previously proposed 
mechanism for the inheritance of CP 204, the identification of numerous common 
nsCL/P genetic risk variants 24-28 and estimation of a substantial SNP heritability for 
nsCL/P 26. Previously reported associations between nsCL/P and other facial 
morphological dimensions found in previous studies 98,288,291 using candidate SNPs 
were not replicated. However, polygenic risk score methods are methodologically 
distinct and are used to investigate a different research question to single SNP 
analyses. 
The investigation of the association between nsCL/P and facial morphology 
was extended in two important ways. The association was shown to be present not 
only in unaffected family members but also in the general population, and MR was 
used to demonstrate that this relationship is present on the liability scale. 
Conventionally MR is used to test possible causal effects of a modifiable continuous 
exposure such as cholesterol or alcohol on disease outcomes 154,155. Here the 
principles of MR were exploited to test the threshold hypothesis, by inferring a causal 
relationship between genetic variants contributing to liability of nsCL/P and philtrum 
width in a non-clinical population. The evidence of a causal relationship suggests 
that a smaller philtrum width is a sub-phenotypic manifestation attributable to the 





In addition to investigating the relationship between facial morphology and 
nsCL/P, I also performed the first GWAS of philtrum width, and identified two novel 
genome-wide significant loci. Notably one of the loci, rs2522825 at 7p15.2, was 
associated with gene expression at several nearby genes in the homeobox gene 
family, which are known to play important roles in embryonic development 299,300. 
The causal inference made in this chapter was achieved through the use of 
two independent cohorts as discovery and replication samples which greatly reduces 
the risk of false positives and demonstrates that results can be generalised to 
different populations. Detailed facial phenotyping data on a large number of 
individuals in our cohorts along with other detailed phenotype and genotype data 
enabled us to identify philtrum width as being the most relevant facial morphological 
feature from amongst seven biologically likely candidates. Statistical power does limit 
the detection of other features that may have mechanistic relationships with smaller 
effect sizes. 
In this study, I combined CLP and CLO, however there is evidence suggesting 
that there are distinct aetiological differences between these traits, 8,9,27 which could 
reduce our statistical power, and complicates interpretation. For example, the 
philtrum may be more related to CLO, but I did not have sufficient data to compare 
nsCL/P subtype differences. An additional limitation is that there are few well-
characterised genetic risk loci for philtrum width, so the MR analysis testing if genetic 
variants associated with a narrow philtrum width also affect liability of nsCL/P, may 
be underpowered. Additionally, one of the two novel identified genome-wide 
significant SNPs for philtrum width in the meta-analysis had non-overlapping 
confidence intervals between the two data-sets. This suggests heterogeneity and the 





 The conclusion of this chapter is that genetic liability to nsCL/P is causally 
related to variation in philtrum width. This finding supports a polygenic threshold 
model of inheritance for nsCL/P, related to abnormalities in development of the 
philtrum. Further research looking at the relationship between genetic liability for 

















Chapter 6: nsCL/P and adverse 
developmental outcomes 
6.1 Abstract 
Syndromic OFC cases often present with other developmental abnormalities 
in addition to the facial cleft structure while nsCL/P cases do not commonly present 
with other clinical symptoms. However, there is evidence to suggest that nsCL/P 
cases may be at increased risk for adverse outcomes such as low birth-weight, 
dental anomalies, behavioural outcomes, speech disorders and middle-ear disease. 
The increased incidence of adverse outcomes may only be in OFC cases or it may 
be present in individuals with a high number of nsCL/P genetic risk variants, for 
example; in unaffected family members. If genetic variants for nsCL/P are also 
associated with an adverse outcome, one possibility is that the underlying liability to 
nsCL/P causes changes in the outcome.  
In this chapter, nsCL/P PRS were used to test for genetic overlap between 
nsCL/P and speech, hearing and anthropometric-related outcomes but there was 
insufficient power to test for an association with dental variables. Across all 
phenotypes tested, weak evidence was found of genetic overlap between nsCL/P 
and speech, anthropometric measures and hearing, although analyses may have 
been underpowered to detect modest genetic correlation. The results are consistent 
with the adverse outcomes being caused by an OFC or related surgical procedures 
rather than being related to genetic liability.  
6.2 Introduction 
OFC cases caused by a Mendelian syndrome can often present with other 





common in nsCL/P cases, there is substantial evidence that individuals with nsCL/P 
may be at increased risk for a range of adverse developmental outcomes relating to 
anthropometrics, tooth formation, hearing, behavioural outcomes and speech. The 
increased risk of these adverse outcomes means that individuals with nsCL/P may 
have a reduced quality of life 13,91 and more alarmingly, individuals with nsCL/P have 
been shown to have higher mortality up to the age of fifty-five 92.  
Determining the aetiological factors resulting in increased risk of these 
adverse outcomes could have important implications for treatment, interventions and 
biological understanding. I start by reviewing the epidemiological literature, discuss 
possible causes of the adverse outcomes and propose the use of genetics for 
disentangling the aetiology. 
6.2.1 Anthropometric and dental outcomes 
 There is some evidence suggesting that individuals with OFCs may differ in 
terms of physically observable phenotypes (independent from the OFC) compared to 
the general population. Phenotypic differences include reduced weight, height and 
head circumference at birth 99-101, and higher incidence of dental anomalies such as 
hypodontia or a crossbite 102-109. Over time, the anthropometric differences are 
thought to attenuate, with some evidence for catch-up growth 99,101. The same genes 
may affect dental anomalies and OFCs independently 301; e.g., a nonsense mutation 
in MSX1 has been previously shown to be associated with both OFCs and tooth 
agenesis in a Dutch family 302. 
6.2.2 Speech and hearing 
There is also evidence that individuals with an OFC may have increased risk 





sounds, is an important outcome in OFC patients because an unoperated CP can 
result in severely disordered speech, with problems also potentially persisting even if 
the CP is surgically corrected 115. Common speech disorders affecting OFC children 
include abnormal nasality, low speech quality and abnormal consonant production 
114-116. Eustachian tube dysfunction is common in children with a CP and can lead to 
increased risk of middle ear disease and impaired hearing. In particular, otitis media 
with effusion (OME) is more common with increased severity and a longer duration 
110-113.  
6.2.3 Behavioural outcomes and education attainment 
Children with OFCs may also be more likely to exhibit behavioural problems, 
such as anxiety, depression and hyperactivity 117-120 and perform worse academically 
than their peers 121. Possible reasons for these differences include; difficulties with 
speech, hearing and facial differences; increased incidence of being bullied and 
increased absence from school for treatment. These factors may lead to lower self-
esteem and impaired emotional development 117.  
6.2.4 Possible causes of adverse developmental outcomes 
One possible cause of the increased risk of adverse outcomes in nsCL/P 
cases is the binary (OFC or control) phenotype itself. The physical presence of an 
OFC could directly affect outcomes, such as the presence of a CP affecting sound 
production 114-116. Alternatively, the related surgical procedures that individuals with 
an OFC may undergo (e.g. palatoplasty and pharyngeal flap surgery) could have 
adverse effects. Surgery may affect maxillofacial growth 303 which could have a 





Another possibility is that the increased risk of adverse developmental 
outcome is related to an individual’s underlying liability to nsCL/P, independent of 
whether they have an OFC. Although nsCL/P is treated as a binary phenotype, sub-
phenotypes may exist in individuals without an OFC, such as unaffected family 
members. The possibility that liability to nsCL/P may directly cause the increased 
incidence of these outcomes, can be explored by testing the association between 
nsCL/P genetics variants and the outcome in individuals that do not have an OFC. If 
nsCL/P genetic variants are associated with adverse outcomes in the general 
population this supports the notion that the outcome is directly related to a 
continuous nsCL/P phenotype. Conversely, if nsCL/P genetic variants are not 
associated with tested outcomes, this suggests that previously discussed factors 
such as the physical presence of an OFC or related surgery may be more 
aetiologically relevant to these specific outcomes. Determining the most likely 
aetiological factors for adverse outcomes may have implications for both surgery and 
the follow-up of patients post-surgery. A similar approach has been previously 
demonstrated in Chapter 5, where strong evidence was found suggesting that 
increased genetic liability to nsCL/P is associated with decreased philtrum width in 
the general population.  
6.2.5 Chapter aims 
In this chapter, I decided to focus on potential genetic overlap between 
nsCL/P and speech, hearing, dental and anthropometric-related outcomes in 
analyses. Given the vastly different sample sizes for the different outcomes, power 
calculations were initially performed to determine which outcomes were feasible to 
investigate with available data-sets. The genetic overlap between nsCL/P and 





of evidence of genetic overlap, bidirectional MR was used to explore the relationship 
between nsCL/P and implicated outcomes. In this chapter, I performed all described 
analyses. 
6.3 Methods 
6.3.1 Study participants 
6.3.1.1 ICC and Bonn-II 
 The nsCL/P meta-analysis GWAS summary statistics, previously described in 
Chapter 3, were used for information on nsCL/P genetic risk variants. In brief, the 
meta-analysis summary statistics included ICC TDT results from 638 parent-
offspring trios and 178 offspring duos of European descent, meta-analysed with 
GWAS summary results on 399 cases and 1,318 controls from the Bonn-II study. 
6.3.1.2 ALSPAC 
Analyses in this chapter used ALSPAC 164 participants with genotype data 
and phenotype data relevant to anthropometric measures, dental outcomes, speech 
and hearing. The cohort and genotyping have previously been described in Chapter 
2.  
Anthropometric measures (e.g. birthweight and head circumference) were 
obtained from 8,677 new-borns registered in the cohort by trained ALSPAC staff. 
Dental outcomes were measured in ALSPAC children at the Children in Focus 
clinics. A small sub-sample of ALSPAC were invited to attend specialist clinics at 3 
different time-points (31 months, 43 months and 61 months). The earliest time-point 
of 31 months was used as it had the largest sample size for the dental phenotypes. 
A binary variable was derived for crossbite status. If an individual had a left or right 
posterior crossbite they were classified as having a crossbite. If an individual had 





variable was derived for missing lateral incisor status. If an individual was missing 
the upper right lateral incisor and/or the upper left incisor they were classified as 
having a missing lateral incisor. If both teeth were non-missing they were classified 
as a control.  
ALSPAC children were invited to a clinic at the age of 8 years and 7,390 
attended and completed a speech and language assessment. Speech samples were 
recorded digitally during an expressive language task and listener judgement on the 
extracted phonetic speech, transcription and comparison with controls was used to 
diagnose persistent speech disorder (PSD). Participant children were divided into a 
PSD group (n=263), a group demonstrating common clinical distortions (e.g. 
problems with r’s and s’s), a sub-clinical PSD group (n=582), children who presented 
with a range of speech errors but did not reach the threshold for PSD (n=141) and 
the rest of the cohort (n=6,399) 304-306.  For the purposes of analyses, two binary 
variables were constructed from the classifications. Firstly, controls (N=6399) were 
compared to children diagnosed with PSD (N=263). However, the modest sample 
sizes with diagnosed PSD meant statistical power was likely to be low. Therefore, 
secondly, PSD cases were combined with children presenting with a range of 
speech errors below the PSD threshold (N=141) and these children (N=404) were 
compared to the same control group (N=6399). These two derived PSD-related 
speech variables were used in analyses. 
ALSPAC children were invited to clinics at the ages of 9.5 and 11.5 years, 
7,725 and 7,159 children attended respectively. At these clinics, air conduction 
audiometry and tympanometry were used to assess hearing frequency thresholds 
and the function of the middle ear. Air conduction audiometry (at 11 years) and 





of ALSPAC children. The ear with the lowest threshold for each frequency was used 
to generate a measure of pure tone low frequency hearing by averaging across the 
0.5, 1 and 2 kHz thresholds and a measure of pure tone high frequency hearing by 
averaging across the 3, 4 and 8 kHz thresholds 307,308. In the tympanometry, middle 
ear pressure (MEP) was measured in both ears; the ear with the lowest MEP was 
used in analyses. Low MEP could suggest reduced Eustachian tube dysfunction, a 
risk factor for middle ear disease 308. Variables pertaining to pure-tone high-
frequency hearing, pure-tone low frequency hearing and MEP were used in 
analyses. 
6.3.2 Polygenic risk score construction and analysis 
6.3.2.1 PRS construction 
 As in Chapter 5, the most predictive PRS from Chapter 3, which includes LD-
clumped SNPs with P-value< 0.0001 was used as a genetic proxy for nsCL/P. Using 
ALSPAC as a reference panel for LD, PLINK 161 was used to LD prune and clump 
the nsCL/P meta-analysis summary statistics (r2<0.1 and 250 kb) using the most 
predictive P-value threshold. The PRS were then constructed in the ALSPAC 
sample. SNPs contained in the PRS are listed in Table 16 in Chapter 5. 
6.3.2.2 PRS power calculations 
 Power calculations for PRS analysis were performed using AVENGEME 
136,224. Initially, AVENGEME was used to estimate the minimum genetic covariance 
detectable with 80% power at P<0.05. Parameters included in calculations were the 
sample sizes of both the training and target samples, sample and population 
prevalences of nsCL/P, the number of SNPs common across both samples, a 
heritability estimate of nsCL/P and an estimate of the proportion of null markers that 





Table 25: Parameters in PRS analysis power calculations 
Parameter  Value Source 
Sample size of training sample 
(nsCL/P) 
3987 determined from data 




determined from data 
Prevalence of nsCL/P in 
training sample 
0.305 determined from data 
Prevalence of outcome (if 
binary) in target sample 
Dependent on 
outcome 
determined from data 
Population prevalence of 
nsCL/P 
0.001 IPDTOC Working Group. 
"Prevalence at birth of 
cleft lip with or without 
cleft palate: data from the 
International Perinatal 
Database of Typical Oral 
Clefts (IPDTOC)." (2011). 
Population prevalence of 
outcome (if binary) 
Dependent on 
outcome 
determined from data 
Number of independent SNPs 
common to both arrays (r2<0.1) 
75,737 determined from data 
h2 of nsCL/P 0.2 AVENGEME estimate in 
Chapter 3 
Proportion of null markers 0.992 AVENGEME estimate in 
Chapter 3 
 
However, it is difficult to directly compare the genetic covariance estimates 
between different phenotypes as the outcomes may differ in heritability. Therefore, 
as in Chapter 5, the genetic covariance estimates were transformed to genetic 
correlation estimates using the following formula:  






 The AVENGEME heritability estimate of nsCL/P from Chapter 3 was used for 
nsCL/P. GCTA 220 was used to estimate the heritability of adverse outcomes of 





intervals overlap both 0 and 1), a SNP heritability of 0.2 for the related outcome was 
assumed for power calculations.  
6.3.2.3 PRS association testing 
The sample-size of ALSPAC children with both genotype and phenotype data 
varied across the different outcomes of interest from 661 to 5260. Therefore, power 
calculations were used to inform whether there was sufficient power to test the 
nsCL/P PRS for association with an outcome. Phenotypes with insufficient power 
(less than 80% power to detect a genetic correlation of 0.5) were removed from 
analyses.  
For outcomes passing the power calculations, the associations between the 
nsCL/P PRS and the phenotypes were then estimated using a linear regression 
adjusted for the first four principal components. Effect sizes were reported per S.D. 
increase in PRS.  
6.4 Results 
6.4.1 Power calculations 
 Power calculations demonstrated that statistical power varied greatly across 
the different outcomes of interest. For anthropometric phenotypes, e.g. birthweight, 
there was sufficient power to detect small to moderate genetic correlation. 
Contrastingly, for dental outcomes there was insufficient power to detect even 
substantial genetic correlations. Worth nothing is that power calculations assumed a 
statistical significance threshold of P<0.05 and therefore do not consider statistical 
adjustment for the testing of multiple phenotypes which would further reduce power 


























(Using 95% C.I. 
from h2 estimates) 








4887 0.039 0.23 (0.10, 
0.35) 
0.18 (0.15, 0.28) 
Missing lateral 
incisor 
724 controls  
134 cases 
0.150 N/A2 (0.2) 0.75 




N/A2 (0.2) 0.93 
PSD1 / Controls 4606 controls  
187 cases 
0.095 N/A2 (0.2) 0.48 
Sub-clinical 
PSD1 or PSD1 / 
Controls 
4606 controls  
296 cases 
0.082 N/A2 (0.2) 0.41 
Middle Ear 
Pressure 
5260 0.038 0.07 [0, 0.19) 0.32 (0.19, 1] 
High frequency 
hearing 
5122 0.039 0.04 [0, 0.15) 0.44 (0.23, 1] 
Low frequency 
hearing 
5115 0.039 0.12 (0.00, 
0.24) 
0.25 (0.18, 1] 
1 PSD: Persistent speech disorder 
2 GCTA estimates were not reported if the confidence intervals overlapped both 0 and 1. A h2 of 0.2 was assumed for 
conversion to genetic correlation estimates. 
 
6.4.2 The prediction of developmental phenotypes using PRS for nsCL/P 
6.4.2.1 Anthropometric outcomes 
 There was little evidence for an association between the nsCL/P PRS and 
birthweight (Beta: -1.9g; 95% C.I. -12.6, 16.5; P = 0.79) or with head circumference 
at birth (Beta = -0.01 cm2; 95% C.I. -0.05, 0.04; P =0.78). The confidence intervals 
suggested that there was unlikely to be substantial genetic correlation between these 





6.4.2.2 Speech and hearing outcomes 
There was little evidence for an association between the nsCL/P PRS and 
persistent speech disorder (OR 1.05; 95% C.I. 0.90, 1.21; P=0.54). The result was 
consistent when sub-clinical cases were also included (OR 1.02; 95% C.I. 0.90,1.21 
P=0.75). The wide confidence intervals suggest that the available data-set may be 
insufficient to rule out substantial genetic overlap (Table 27). 
Similarly, no strong evidence was found of an association between the 
nsCL/P PRS and middle ear pressure at age 9 (Beta: 0.32 daPa; 95% C.I. -1.6, 2.3; 
P = 0.75), low frequency pure-tone hearing at age 11 (Beta: -1.9g; 95% C.I. -12.6, 
16.5; P = 0.79) and high frequency pure-tone hearing at age 11 (Beta: -1.9g; 95% 
C.I. -12.6, 16.5; P = 0.79). Again, confidence intervals suggested that substantial 
genetic overlap was unlikely (Table 27). 
Table 27: Association between Cleft PRS & developmental outcomes 
Phenotype Increase in units 
per 1 SD increase 
in nsCL/P PRS 
(95% C.I.) 
P value  
Anthropometric: 
Head circumference at birth (cm2) N=4887 
Birthweight (g) N=4887 
 
-0.01 (-0.05, 0.04) 





PSD diagnosis (OR compared to control) N=4793 
Sub-clinical PSD/PSD (OR compared to control) N=4902 
 
1.05 (0.90, 1.21) 





Middle ear pressure at 9 years (daPa2) N=5260 
Low frequency hearing at 11 years (dB3) N=5122 
High frequency hearing at 11 years (dB3) N=5115 
 
 
0.32 (-1.6, 2.3) 
-0.06 (-0.20, 0.09) 






1 PSD: Persistent speech disorder 
2 daPa: decapascals a measure of air pressure 







In this chapter, a nsCL/P PRS was found to be weakly associated with 
anthropometric measures, persistent speech disorder and hearing variables in a 
sample representative of the general UK population. The statistical power to detect 
genetic overlap varied across the different phenotypes; the large sample sizes and 
low effect sizes for the anthropometric and hearing variables (e.g. 1.9 grams or -0.06 
decibels) suggest that for these outcomes, the true effect is unlikely to be of clinical 
significance. However, the wide confidence intervals for the speech variables 
suggested that strong conclusions cannot be made about genetic overlap between 
nsCL/P and speech.  
In general, these findings imply that there are likely alternative causes of 
these adverse developmental outcomes in OFC cases distinct from genetic liability. 
Previously discussed possibilities, such as the physical presence of an OFC or 
complications of surgery, may be responsible for the differences in speech, hearing 
and anthropometric outcomes. For example, a CP often results in differences in the 
size and shape of the oral nasal and pharyngeal cavities and the velopharyngeal 
valve. These differences affect the physical production of sounds, which may 
increase the risk of speech disorders 309. Similarly, the function of the Eustachian 
tube may be affected by the presence of a CP, which could lead to impaired hearing 
110. Lower birth weight in nsCL/P cases may be related to the increased risk of 
preterm birth in children with congenital malformations 310. 
In Chapter 5, strong evidence was found for an aetiological link between 
nsCL/P and facial morphology, and previously identified sub-phenotypes in nsCL/P 
cases and unaffected relatives have been largely craniofacial phenotypes (lip pits, 





suggests that, of the outcomes considered in this chapter, dental outcomes may 
have been the most likely to be related to genetic liability to nsCL/P. Indeed, 
previous studies have found evidence of some genetic overlap 301; MSX1 is a risk 
locus for both nsCL/P and dental anomalies 65,302,311,312. This is also supported by the 
genetic overlap between nsCL/P and OFC syndromes which can present with dental 
anomalies. For example, distinct genetic variation in IRF6 is associated with nsCL/P 
and causes Van der Woude syndrome 93. However, the available data were 
insufficiently powered to test the nsCL/P PRS for association with dental 
phenotypes.  
There are several strengths of analyses described in this chapter. Firstly, the 
richness of ALSPAC as a data source; high quality phenotype data, for speech, 
anthropometric and hearing variables (which were derived by specialists), and 
genotype data were available for a large proportion of the cohort. Secondly, given 
that nsCL/P PRS were previously shown to be associated with philtrum width in 
Chapter 5, the method has been demonstrated to be effective at detecting genetic 
overlap and nsCL/P. Thirdly, the use of genetic methods to disentangle the possible 
causes of adverse outcomes in nsCL/P cases is a relatively unique design that 
bypasses the effects of surgery and the physical presence of an OFC. 
Nevertheless, there are multiple limitations that need to be considered. Firstly, 
the heterogeneity of OFC subtypes complicates interpretation. In this study a PRS 
for nsCL/P was used but although nsCL/P is often treated as a single phenotype in 
epidemiological and genetic studies, distinct from CPO, there is emerging evidence 
that CLO and CLP have aetiological differences 8,254. The phenotypic heterogeneity 
is a limitation as a CP may be the most relevant OFC to speech and hearing. In 





more predictive than the nsCL/P PRS. A second limitation is that statistical power 
was potentially low for speech-related phenotypes, meaning that modest to 
moderate effects cannot be ruled out. Thirdly, it is possible that low frequency or rare 
genetic variation not tagged by the nsCL/P PRS may be causally related to both 
nsCL/P and the increased risk of outcomes tested. However, this is unlikely to 
explain the consistent risk increase of adverse outcomes across all nsCL/P cases, 
and common genetic variation has been previously shown to play a major 
aetiological role for nsCL/P in both Chapter 3 and in previous publications 24-28. 
 To conclude, weak evidence was found for genetic overlap between nsCL/P 
and speech, hearing and anthropometric outcomes. These results suggest that 
genetic liability to nsCL/P is unlikely to play a causal role in the increased risk of 
these adverse outcomes in children with nsCL/P. Therefore, these outcomes are 
likely to be related to if an individual has an OFC or related surgical procedures. 
Further research using larger samples are necessary to test the possibility of genetic 









Chapter 7: Estimating the genetic overlap 
between nsCL/P and oral cavity/ 
oropharyngeal cancer 
7.1 Abstract 
Observational studies suggest that individuals with birth defects, including 
nsCL/P, may have increased risk of cancer. An association between nsCL/P and 
cancer is further supported by several genes (e.g. CDH1 and AXIN2) implicated in 
the aetiologies of both traits. However, the genetic overlap between nsCL/P and 
OC/OPC, which affect similar anatomical regions, has not been previously 
investigated. 
nsCL/P PRS were constructed at different P-value inclusion thresholds in a 
sample of 5,048 OC/OPC cases and 5,450 controls of European ancestry. PRS 
analyses were followed up by MR analysis to test a possible causal relationship 
between liability to nsCL/P and risk of OC/OPC.  
Strong evidence was found for an association between a 1 S.D. increase in 
nsCL/P PRS (including SNPs with P<0.1) and increased odds of OC/OPC (OR 1.09: 
95% C.I. 1.04, 1.13 P = 5.3 x 10-5). MR analyses found weak evidence for a causal 
effect of liability to nsCL/P on OC/OPC.  
In follow-up analyses in the UK Biobank, weak evidence was found for an 
association between the nsCL/P PRS and tobacco smoking or alcohol behaviour 
phenotypes, two known risk factors for OC/OPC. Additionally, the association 
between the nsCL/P PRS and OC/OPC did not replicate in the UK Biobank sample 
of 687 cases and 408,282 controls (OR 1.01: 95% C.I. 0.93, 1.09 P=0.86). However, 





overlapped with the initial analyses. The implications of the results from the two 
studies are that nsCL/P and OC/OPC may have shared genetic aetiology, unrelated 
to alcohol or tobacco intake.  
7.2 Introduction 
Evidence from epidemiological population-based studies suggests that 
individuals with birth defects may have increased risk of developing cancer, 
particularly childhood cancers 313-316. For example, individuals with chromosomal 
aneuploidies such as Down syndrome have been shown to have increased 
incidence of leukaemia 313-315. However, the epidemiological evidence for increased 
incidence of cancer in nsCL/P cases is largely inconsistent. Some studies have 
reported increased incidence of cancer amongst OFC cases and unaffected relatives 
123,313,317, but other studies have reported weak evidence for an association 122,314,315. 
There are several limitations of an epidemiological approach for investigating the 
relationship between nsCL/P and cancer. Firstly, statistical power is limited by the 
modest number of individuals with both nsCL/P and cancer. Indeed one study 
reported findings from a data-set including 89 OFC cases, of which 2 had cancer 317. 
Secondly, cancer is a highly heterogeneous phenotype; the aetiologies of childhood 
leukaemia and colorectal cancer are likely highly distinct, and subtype stratification 
would further reduce power 318,319. Thirdly, depending on the available data, it can be 
difficult to differentiate between syndromic and non-syndromic OFCs, which have 
highly different aetiologies. For example, Patau syndrome 320, which can present with 
an OFC, is caused by trisomy, a known risk factor for leukaemia 313-315.  
An alternative approach for disentangling the relationship between nsCL/P 
and cancer is to investigate their shared genetics; genetic overlap may suggest that 





biological pathways. Previous studies suggest that nsCL/P and cancer have shared 
genetic risk factors; several genes have been identified that are relevant to the 
aetiologies of both nsCL/P and cancer 127, notably CDH1 128,129,321 which is 
implicated in gastric and breast cancer 322, and AXIN2 129,323-325 which is linked to 
colorectal cancer and tooth agenesis 326 327.  
Cancers affecting the oral cavity and pharynx are a strong candidate for 
shared genetic aetiology with nsCL/P because both phenotypes affect similar 
anatomical sites. The main risk factors for OC/OPC relate to alcohol consumption, 
tobacco use or HPV infection 328. However, OC/OPC has been shown to have a 
substantial genetic component, with 8 independent genetic risk loci identified in a 
previous GWAS 328 (although important to note that this includes a SNP in ADH1B 
known to be strongly associated with alcohol consumption 329). Potential shared 
genetic aetiology between nsCL/P and OC/OPC has not been previously 
investigated, possible due to the relative rarity of both phenotypes. 
As demonstrated in previous chapters, nsCL/P PRS can be used effectively to 
detect genetic overlap between nsCL/P and heritable phenotypes. Genetic overlap 
between nsCL/P and OC/OPC could suggest common risk factors or biological 
pathways involved in the aetiologies of both traits. A distinct possibility is that risk of 
OC/OPC is causally related to liability to nsCL/P. As in Chapter 5, the principles of 
MR can be used to test the possibility of this causal relationship. 
To explore the shared genetics of nsCL/P and OC/OPC; firstly, nsCL/P PRS 
were used to explore potential genetic overlap between nsCL/P and OC/OPC. 
Secondly, in the instance of genetic overlap, MR was used to test a possible causal 





instance of genetic overlap, the association between nsCL/P PRS and OC/OPC was 
tested for replication in the UK Biobank and the PRS was investigated for 
association with known risk factors (alcohol and smoking intake) for OC/OPC. In this 
chapter I performed all described analyses. 
7.3 Methods 
7.3.1 Study participants 
7.3.1.1 ICC and Bonn-II 
The nsCL/P meta-analysis GWAS summary statistics, previously described in 
Chapter 3, were used to construct nsCL/P PRS. In brief, the meta-analysis summary 
statistics included ICC TDT results from 638 parent-offspring trios and 178 offspring 
duos of European descent, meta-analysed with GWAS summary results on 399 
cases and 1,318 controls from the Bonn-II study. 
7.3.1.2 OC/OPC GWAS data-set 
The OC/OPC GWAS data-set 328 has been previous described in Chapter 2, 
including relevant information on how OC/OPC cases were identified (using ICD 
codes) and genotyping. In brief, the data-set consists of 12 epidemiological studies 
from North America, South America and Europe, comprising 6,034 OC/OPC cases 
and 6,585 controls. For the purposes of analyses, the data-set was restricted to 
5,048 cases and 5,450 controls of recent European ancestry, which were split into 
studies from North America and studies from Europe. 
7.3.1.3 UK Biobank 
 The UK Biobank has been previously described in Chapter 2, including 
information on genotyping. In brief, the UK Biobank is a large-scale cohort study of 





chapter, relevant phenotypes were OC/OPC case-control status and self-reported 
alcohol consumption/tobacco smoking variables. 
 ICD10 hospitalisation codes were used to identify OC/OPC cases in the UK 
Biobank using the same classification codes as in the OC/OPC GWAS data-set 328. 
Oral cavity cancer (C02.0–C02.9, C03.0–C03.9, C04.0–C04.9, C05.0–C06.9), 
oropharyngeal (C01, C02.4, C09.0–C10.9), hypopharyngeal (C13.0–C13.9) and 
overlapping (C14). The number of cases was not sufficient for stratification by 
subtype, so all cases were grouped together. 
Self-reported alcohol consumption data were collected at baseline using a 
questionnaire. Participants were asked for their alcohol drinking status (current, 
former, never) and for estimates of their average weekly intake of a range of different 
alcoholic beverages (red wine, white wine, champagne, beer, cider, spirits, fortified 
wine). From these variables, an average intake of alcoholic units per week was 
derived by summing the estimated intakes of the different alcoholic beverages 
consumptions across the seven drink types, as in a previous study 330. The 
questionnaire used the following measurement units for each of the five alcoholic 
drink types: measures for spirits, glasses for wines and pints for beer/cider which 
were estimated to be equivalent to 1, 2 and 2.5 units respectively. Individuals 
reporting current intake frequency of “one to three times a month”, “special 
occasions only” or “never” (for whom this phenotype was not collected), were 
assumed to have a weekly alcohol consumption volume of 0.  
Self-reported tobacco smoking data were also collected at baseline using a 
questionnaire. Participants were asked their tobacco smoking status; current, former, 





day and the age they started smoking which was used to generate a pack years 
measure. Similarly, former smokers were asked to estimate the number of cigarettes 
smoked per day previously, the age they started smoking and the age they stopped 
smoking, to generate a pack years measure. Individuals reporting their tobacco 
smoking status as “never smokers” were assumed to have tobacco pack years of 0. 
The mean and S.D. for weekly alcoholic consumption volume and tobacco 
pack years were calculated; individuals more than five S.D. away from the mean 
were removed from relevant analyses. Note that although under certain conditions 
(described above), an individual’s missing alcoholic volume and pack year 
phenotype data were assumed to be 0, the mean and the S.D. were calculated in the 
original sample reporting non-missing data.  
7.3.2 Polygenic risk score construction and analysis in OC/OPC data-set 
The 1000 Genomes (Phase 3) 163 CEU sample was used as a reference 
panel to LD clump (r2<0.1 and 250 kb) the nsCL/P meta-analysis summary statistics 
at 11 different P-value inclusion thresholds (0.000001, 0.000005, 0.00001, 0.00004, 
0.0001, 0.0005, 0.001, 0.005, 0.01, 0.05, 0.1). In previous chapters a single PRS 
threshold (P<0.00001) was used to test for genetic overlap with multiple phenotypes 
but given the focus on a single phenotype (and subtypes), it was decided to test a 
range of thresholds for a more comprehensive exploration of shared genetic 
aetiology.  
Next, the nsCL/P PRS, at the 11 different P-value inclusion thresholds, were 
constructed separately in the European and North American OC/OPC case-control 
samples. The associations between the nsCL/P PRS and OC/OPC case-control 





cases only and oropharyngeal cases only (OPC) using logistic regression. For the 
comparison of OC/OPC subtypes, cases and controls with less than 70% CEU 
ancestry were removed. Covariates in the model were the first 10 genetic principal 
components, sex and age in both samples. METAL 241 was then used to meta-
analyse the effect sizes, standard errors and P-values from the two sub-samples 
using a fixed-effects model.  
7.3.3 Mendelian randomization analysis in OC/OPC data-set 
In the instance of genetic overlap between nsCL/P and OC/OPC, Mendelian 
randomization (MR) was used to investigate a possible causal relationship between 
liability to nsCL/P and risk of OC/OPC. As in Chapter 5, six genome-wide significant 
SNPs for nsCL/P, taken from a previous publication 24, and listed in Table 18 were 
used as a genetic instrument for liability to nsCL/P. The SNP-liability to nsCL/P 
information was extracted from the nsCL/P meta-analysis GWAS summary statistics. 
The European and North American OC/OPC GWAS summary statistics 328 were 
meta-analysed using METAL 241. The relevant SNP-risk of OC/OPC information was 
extracted from this meta-analysis. 
In a bidirectional MR approach, the reverse direction would also be tested (i.e. 
the effect of liability to OC/OPC on risk of nsCL/P). However, of the eight genome-
wide significant SNPs, four were specific to oral cavity cancer, a further two had 
obvious issues with pleiotropy (a SNP in ADH1B associated with alcohol 
consumption and a SNP in the HLA region) and one variant was a rare intronic 
deletion. The reverse direction MR analysis was not performed because of the 





7.3.4 Testing PRS for replication in the UK Biobank and for association with 
environmental risk factors  
 The UK Biobank was used to follow-up results from the OC/OPC GWAS data-
set to firstly, attempt to replicate results and secondly, to investigate the association 
of nsCL/P PRS with known environmental risk factors for OC/OPC. Firstly, the UK 
Biobank data-set of 487,409 individuals was restricted to a subset of 409,700 
individuals of recent European descent. Individuals of non-European descent were 
removed based on a k-means cluster analysis on the first 4 genetic principal 
components 331.  
Secondly, the nsCL/P PRS most strongly associated with case-control status 
from analyses described in Chapter 7.3.2 was constructed in the sample. Finally, the 
nsCL/P PRS was tested for association with OC/OPC case-control status, alcoholic 
units consumed per week and tobacco smoking pack years adjusting for sex, age 
and the first 10 genetic principal components.  
7.4 Results 
7.4.1 The prediction of OC/OPC risk using PRS for nsCL/P 
 After meta-analysing the North American and European results, strong 
evidence was found for an association between nsCL/P PRS and increased risk of 
OC/OPC. A 1 S.D. increase in nsCL/P PRS (including independent SNPs with 
P<0.1) was associated with increased odds of OC/OPC (OR 1.09; 95% C.I. 1.04, 
1.13; P=0.000053). PRS with more liberal inclusion thresholds (e.g. P < 0.05 and P < 
0.1) which included thousands of SNPs were more strongly associated with risk of 





Table 28: Association of nsCL/P PRS with risk of OC/OPC 






All OC/OPC subtypes against controls 
(5048 Cases and 5450 Controls) 
OR (95% C.I.) 
Per 1 S.D. increase in PRS 
P 
0.000001  10 1.01 (0.97, 1.05) 0.64 
0.000005  15 1.02 (0.98, 1.07) 0.27 
0.00001  18 1.02 (0.98, 1.07) 0.27 
0.00005  48 1.01 (0.97, 1.05) 0.71 
0.0001 78 1.01 (0.97, 1.05) 0.58 
0.0005 238 1.01 (0.97, 1.05) 0.71 
0.001 424 1.01 (0.96, 1.05) 0.79 
0.005 1,607 1.05 (1.01, 1.09) 0.021 
0.01 2,777 1.03 (0.99, 1.08) 0.10 
0.05 8,620 1.06 (1.02, 1.11) 0.0026 
0.1  12,614 1.09 (1.04, 1.13) 0.000053 
 
Similarly, there was strong evidence for an association between the nsCL/P 
PRS and the two main OC/OPC subtypes, oropharyngeal and oral cavity cancer. A 1 
S.D. increase in nsCL/P PRS (P<0.1) was associated with increased odds of both 
oropharyngeal cancer (OR 1.10; 95% C.I. 1.04, 1.16; P=0.00079) and oral cavity 
















Oropharyngeal cases only 
(2297 Cases and 5182 Controls) 
Oral cavity cases only 
(2463 Cases and 5182 Controls) 
OR (95% C.I.) 
Per 1 S.D. increase 
in PRS 
 
P OR (95% C.I.) 




0.000001 1.03 (0.97, 1.08) 0.37 1.01 (0.96, 1.07) 0.58 
0.000005 1.04 (0.98, 1.09) 0.19 1.02 (0.97, 1.07) 0.54 
0.00001 1.03 (0.98, 1.09) 0.25 1.02 (0.97, 1.07) 0.44 
0.00005 1.02 (0.96, 1.07) 0.51 1.02 (0.97, 1.08) 0.35 
0.0001 1.03 (0.97, 1.08) 0.38 1.03 (0.98, 1.09) 0.20 
0.0005 1.01 (0.96, 1.07) 0.62 1.03 (0.98, 1.08) 0.23 
0.001 1.02 (0.97, 1.08) 0.45 1.02 (0.97, 1.08) 0.35 
0.005 1.04 (0.99, 1.10) 0.11 1.07 (1.02, 1.13) 0.0061 
0.01 1.04 (0.99, 1.10) 0.12 1.05 (1.00, 1.10) 0.073 
0.05 1.07 (1.02, 1.13) 0.011 1.09 (1.04, 1.15) 0.00053 
0.1 1.10 (1.04, 1.16) 0.00079 1.12 (1.06, 1.17) 0.000016 
 
7.4.2 Mendelian randomization 
The follow-up MR analysis testing the causal effect of liability to nsCL/P on 
risk of OC/OPC (using the 6 SNPs previously used in Chapter 5 and listed in Table 
18) found weak evidence for a causal relationship. A 1-unit log odd increase in 
liability to nsCL/P was weakly associated with decreased odds of OC/OPC (OR 0.98; 
95% C.I. 0.91, 1.05; P = 0.53). MR sensitivity analyses generated similar effect 









Table 30: MR analysis of liability to nsCL/P on OC/OPC risk 
















0.03 (-0.06, 0.11) 0.60 
Regression 
estimate1 
0.93 (0.77, 1.13) 0.49 
 
Weighted median Consistency1 0.96 (0.90, 1.03) 0.30 
Weighted mode Consistency1 0.95 (0.88, 1.03) 0.30 
1 Units: Odds ratio for OC/OPC per 1-unit log odd increase in liability to nsCL/P 
2 Units: Average pleiotropic effect of a nsCL/P genetic variant on odds of OC/OPC 
7.4.3 Testing PRS for replication in the UK Biobank and for association with 
environmental risk factors 
In the follow-up analysis in the UK Biobank, weak evidence was found that the 
nsCL/P PRS (P<0.1), previously found to be associated with OC/OPC in the GWAS 
data-set, is associated with OC/OPC (OR 1.01; 95% C.I. 0.93,1.09; P=0.85). 
However, this may be because of the smaller sample sizes in the UK Biobank (687 
cases compared to 5,048). Indeed, the confidence intervals overlapped with the 
previous estimate. Additionally, there was no strong evidence for an association 
between the nsCL/P PRS and self-reported alcohol consumption or lifetime cigarette 
smoking. The confidence intervals for alcoholic units per week (-0.09 to 0.03 
alcoholic units per week) and pack years (-0.08 to 0.02 pack years) suggested any 
true effect, if one exists, is modest and unlikely to explain the association between 





Table 31: Association of nsCL/P PRS (P<0.1) with OC/OPC, alcohol and smoking in 
the UK Biobank 
Phenotype (Units) N Effect size (95% C.I.) 








1.01 (0.93, 1.09) 0.85 
Alcohol consumption 
(Units per week) 




123,685 -0.03 (-0.08, 0.02) 0.31 
 
7.5 Discussion 
 In this chapter, nsCL/P PRS were found to be associated with increased risk 
of OC/OPC, with concordant results from subtype analyses, but follow-up MR 
analyses found weak evidence for a causal effect of liability to nsCL/P on risk of 
OC/OPC. These results imply that the most likely possibility is that nsCL/P and 
OC/OPC have shared genetic aetiology. Although the relationship is non-causal, 
genetic overlap suggests that individuals with nsCL/P and other individuals with high 
genetic liability to nsCL/P (e.g. unaffected family members) may have slightly 
elevated risk of developing OC/OPC because of shared genetic risk factors.  
However, the specific biological pathways that the nsCL/P PRS is proxying 
for, relevant to both nsCL/P and OC/OPC, are currently unclear. Well-powered 
analyses in the UK Biobank suggested that alcohol and cigarette smoking behaviour 
are unlikely to explain the genetic overlap. The interpretation of what exactly a 
nsCL/P PRS is tagging becomes increasingly complex as more and more SNPs are 
included. Indeed, the nsCL/P PRS most strongly associated with OC/OPC included 
over 10,000 SNPs. One possibility is that the genetic overlap may be attributable to 





CDH1 gene, known to be related to nsCL/P and cancer subtypes, has been shown 
to be related to both axonal growth and patterning in the developing murine brain 332, 
and tumour suppression 333.   
Another possibility is that, although the maternal environment is the route to 
exposure for nsCL/P, the nsCL/P PRS may be proxying for environmental 
exposures. The maternal genotype is correlated with the foetal genotype suggesting 
that the nsCL/P PRS may be a weak proxy for maternal genetic risk factors. 
Furthermore, both the foetal and maternal genotype may both play important roles in 
the effect of environmental exposures on risk of OFCs. For example, there is some 
evidence that the maternal and foetal ADH1C haplotype may modify the association 
between maternal alcohol consumption and risk of OFCs via alcohol metabolism 334.  
Previous epidemiological and genetic studies have not investigated the 
relationship between nsCL/P and OC/OPC. However, the findings in this chapter are 
consistent with previous genetic studies that have identified genetic variation 
associated with nsCL/P and various cancer subtypes 127-129,321,323-325. It is difficult to 
compare the results to the epidemiological literature as the majority of studies 
focused on childhood cancers but the results are consistent with the reported effect 
size from a previous study, investigating the risk of adult-onset cancers in nsCL/P 
cases, which was likely underpowered to detect a modest effect 122.    
 There are several strengths of analyses in this chapter. The usage of PRS as 
a genetic proxy for nsCL/P has advantages over the candidate gene or candidate 
SNP approaches used in previous studies 127-129,321,323-325 because it both reduced 
the number of statistical tests, and more generally, extended the evidence for 





strength is the focus on OC/OPC cancer; previous epidemiological and genetic 
studies have looked more generally at the relationship between nsCL/P and all 
cancers but cancers arising from different organs may be highly aetiologically 
heterogeneous. Although similar results were found in analyses for the OC and OP 
subtype analyses, it is important to note that these subtypes may also be 
aetiologically heterogeneous 328. Finally, the study design is a considerable strength; 
the construction of nsCL/P PRS derived from a modestly sized GWAS in a much 
larger OC/OPC GWAS data meant that analyses were well-powered to detect 
modest genetic overlap. Similarly, the use of the UK Biobank cohort allowed well-
powered exploration of possible biological mechanisms.   
Nevertheless, there are several limitations of analyses. Firstly, the absence of 
replication of the association between the nsCL/P PRS and OC/OPC in the UK 
Biobank weakens the argument for genetic overlap between the two phenotypes. 
However, this may be because of the modest number of OC/OPC cases in the UK 
Biobank, confidence intervals overlapped with the estimates from the OC/OPC 
GWAS data-set. Secondly, the OC/OPC GWAS data-set was highly ancestrally 
heterogeneous and included samples from 12 different epidemiological studies, 
including a case-only study (the Head and Neck 5000). Therefore, it is possible that 
allele frequency differences between cases and controls relating to population 
differences could result in spurious associations with the nsCL/P PRS, although this 
is unlikely given the number of SNPs in the PRS. Thirdly, available genetic 
instruments were insufficient to test the hypothesis that liability to OC/OPC is 
associated with risk of nsCL/P, so this possibility cannot be ruled out. Finally, as in 
previous chapters, treating heterogeneous nsCL/P subtypes (CL/P, CLO) 8,9,27 as a 





site, the oropharynx includes the soft palate while the oral cavity includes the lips 
and hard palate, suggesting that the different nsCL/P subtypes may have different 
mechanistic relationships with the OC/OPC subtypes.  
 To conclude, nsCL/P and OC/OPC likely have shared genetic risk factors that 
are unrelated to alcohol or tobacco intake. nsCL/P cases and unaffected family 
members may also have slightly increased risk of OC/OPC. Further work is required 
to more formally investigate common biological pathways and shared environmental 















Chapter 8: Discussion 
8.1 General discussion 
A recurring theme throughout this thesis is the use of PRS and/or MR to 
explore the causes and consequences of nsCL/P. The modest sample sizes of the 
available nsCL/P GWAS data meant that, in general, analyses investigating liability 
to nsCL/P as an exposure, in conjunction with larger outcome data-sets, were more 
statistically viable than analyses considering nsCL/P as the outcome. For this 
reason, the hypothesis that the inheritance of many binary traits such as nsCL/P is 
determined by a continuous, normally distributed variable, i.e. liability, was integral to 
many analyses. An interesting possibility is that an individual’s underlying liability to 
nsCL/P could have causal effects on nsCL/P-related phenotypes in individuals 
without nsCL/P. 
The liability threshold model was proposed as an explanation for the mode of 
inheritance of binary traits that did not follow Mendelian inheritance patterns 
156,202,293,335. Indeed, Carter first proposed a multifactorial model of inheritance for 
nsCL/P in the late 1960’s 202. However, geneticists of the past did not have access to 
the abundance of genotype data, which are now currently available, and so were 
limited by their reliance on pedigree-recurrence rates methods. Indeed, several 
pedigree studies incorrectly concluded that the segregation patterns of nsCL/P were 
inconsistent with a multifactorial model of inheritance 207-210, which may have been 
the reason that linkage analysis was utilised to map a theoretical major nsCL/P gene 
17-20,211. The difficulties mapping a major nsCL/P susceptibility gene using linkage 
were followed by the subsequent identification of many independent nsCL/P risk loci 
in association studies 9,21-24,27-30,218, and a multifactorial model of inheritance for 





In Chapter 3, I extended previous work on the genetics of nsCL/P by using 
several different genotype-driven methods to further explore the genetic architecture 
of nsCL/P and estimate the SNP heritability. Limitations of the available data-sets 
and case-control matching meant that GCTA SNP heritability estimates were inflated 
but estimates from other methods such as AVENGEME and LD-score regression 
were less susceptible to these limitations. Triangulating results from the different 
methods suggested, firstly; that nsCL/P has a SNP heritability of between 20 and 
33%, highly consistent with a published GCTA estimate of 30% 26 and secondly; that 
nsCL/P has a highly polygenic architecture. These findings supported the use of 
nsCL/P PRS in subsequent chapters, to detect genetic overlap between nsCL/P and 
phenotypes of interest. Furthermore, the abundance of well-characterised nsCL/P 
risk loci with large effect sizes, suggested that an MR framework could be used 
effectively to test causal effects of liability to nsCL/P. The premise that liability to 
nsCL/P could have phenotypic effects in the general population was tested in the 
four subsequent results chapters.  
In Chapter 4, MR and joint-likelihood co-localisation were used to test the 
hypothesis that the effect of nsCL/P genetic risk variants on disease liability is 
mediated by DNA methylation. Three putative loci at VAX1, LOC146880 and NTN1 
were identified where genetic variation may affect nsCL/P via DNA methylation. 
Functional follow-up found that two of the loci were also associated with gene 
expression of nearby genes. However, there were several limitations meaning that 
identified loci are merely putative. Firstly, the methylation GWAS data-set was even 
smaller than the nsCL/P GWAS data-set, meaning MR analyses were insufficiently 
powered to test the causal effect of liability to nsCL/P on methylation. Secondly, with 





and horizontal pleiotropy. Thirdly, although results were compared with DNA 
methylation data derived from lip and palate, primary analyses used DNA 
methylation in blood as a proxy for more relevant tissues. Nevertheless, the work in 
this chapter extended previous work investigating the role of DNA methylation in 
nsCL/P 8,34-36. The use of a previously-devised bioinformatics-based framework 
267,268, publicly available GWAS summary data and the principles of MR, allowed a 
greater focus on causal relationships between DNA methylation and nsCL/P than 
previous studies.   
The focus of Chapter 5 was unravelling the shared genetics between nsCL/P 
and normal-range variation in facial morphology. Starting with seven facial 
phenotypes, the width of the philtrum was found to be the most relevant facial 
phenotype to nsCL/P. nsCL/P PRS were found to be strongly predictive of philtrum 
width in the general population, across around 6,000 individuals of European 
ancestry from two studies. Follow-up MR analyses suggested that increased genetic 
liability to nsCL/P results in decreased philtrum width. These findings suggested that 
the inheritance of nsCL/P may be related to the additive effect of nsCL/P genetic risk 
variants on the development of the philtrum. Furthermore, these results 
demonstrated that genetic liability to nsCL/P has phenotypic effects in individuals 
without nsCL/P, validating the use of similar methods in later chapters.  
 Chapter 6 focused on potential genetic overlap between nsCL/P and a range 
of phenotypes for which nsCL/P cases are thought to have increased risk of adverse 
outcomes than controls, such as speech and hearing. The idea was to determine if 
the adverse outcomes are caused by the binary status of having nsCL/P, i.e. related 
to surgery or the physical presence of a cleft, or are on a continuum, related to 





genetic effects between nsCL/P and adverse outcome phenotypes, but some 
analyses may have been limited by statistical power. The lack of genetic overlap 
suggests that the adverse outcomes tested are more likely to be related to 
complications of having an OFC rather than to an individual’s genetic liability to 
nsCL/P. 
Chapter 7 used a similar approach to disentangle possible genetic overlap 
between nsCL/P and cancer. Cancers can be highly heterogeneous so the 
relationship between nsCL/P and a grouping of cancers affecting a similar 
anatomical region, OC/OPC, was investigated. nsCL/P PRS including thousands of 
SNPs were found to predict increased risk of OC/OPC but MR analyses suggested 
that the increased risk is unrelated to genetic liability to nsCL/P. Follow-up analyses 
found weak evidence that the genetic overlap was related to smoking or tobacco 
use, and the exact reason for the shared genetic overlap remains unclear. The 
implications of these findings are that nsCL/P and OC/OPC have shared genetic 
aetiology that could be related to shared environmental risk factors or common 
biological processes.  
The five results chapters investigated the same phenotype and used very 
similar methods but attempted to answer very different questions. nsCL/P was 
shown to be highly polygenic with a substantial SNP heritability, DNA methylation 
and the philtrum were both shown to have aetiological relevance to nsCL/P, nsCL/P 
and a cancer subtype were shown to have genetic overlap while contrastingly, weak 
evidence was found for genetic overlap between nsCL/P and several developmental 





8.2 Future work 
8.2.1 Extensions to my thesis work 
There are many possible extensions to the work in this thesis. Firstly, relevant 
to the work in Chapter 3; GWAS have been very effective at picking up high 
frequency genetic risk variants for nsCL/P with modest sample sizes but the 
contribution of low frequency and rare variants to the aetiology of nsCL/P is less 
clear. Increased sample sizes and methodological advances, such as imputation and 
sequencing, will allow increased opportunity to identify lower frequency risk variation 
for nsCL/P. 
A recurring limitation throughout analyses in this thesis is the phenotypic 
heterogeneity of nsCL/P. As discussed previously, there is a growing body of 
evidence suggesting aetiological differences between nsCL/P subtypes (CLO and 
CLP) 8,28,254.  As the sample sizes of nsCL/P GWAS increase, there will be more 
power to test for subtype differences for genetic risk factors. Unravelling the genetics 
of CPO, which is not included within the nsCL/P subtype, and has an incidence of 
around 1 in 2,500 336 is also important. CPO has been previously shown to have 
almost no polygenic overlap with nsCL/P and is thought to be more related to rare 
genetic variation 26. To date, a single functional missense variant has been identified 
in a relatively small GWAS 336, larger efforts may identify additional risk loci.  
Although the functional relevance of some nsCL/P risk variants is known, this 
is not the case for many identified loci. In Chapter 4, I investigated the possibility of 
genetic risk variants acting via DNA methylation. As DNA methylation, gene 
expression and other omics databases increase in size there is increased potential 
to use bioinformatics approaches to unravel biological pathways and improve 





difficult because the relevant tissue cannot be extracted during development, when 
an OFC forms. The increased sampling of more aetiologically relevant tissues such 
as lip and palate tissues over blood will improve the design of studies investigating 
the role of epigenetic mechanisms in the aetiology of nsCL/P.  
An argument could be made that investigating the genetic architecture of 
other congenital multifactorial defects such as pyloric stenosis, a gastrointestinal 
defect leading to severe vomiting, and neural tube defects, defects of the spinal cord, 
could lead to improved understanding of congenital malformations in general, 
including nsCL/P. This is because of the possibility that different congenital defects 
may share genetic risk factors and involve common developmental pathways. A 
previous modestly sized GWAS 337 identified three risk loci for pyloric stenosis but 
there have not been large genetic studies for many other congenital defects likely 
because of the rarity of many multifactorial birth defects. Future work could 
investigate the possibility of genetic overlap between different congenital defects, 
although recruiting the necessary samples is likely to be a challenge.  
In Chapter 5, a relationship between liability to nsCL/P and philtrum width 
was demonstrated but genetic overlap between nsCL/P and other facial phenotypes 
is also possible, including phenotypes tested in my analyses. Larger sample sizes 
and improved facial phenotyping, such as the recent global and local facial variation 
measures may allow further investigation of the shared genetics of nsCL/P and facial 
morphology 338.  
The relationship between genetic liability to nsCL/P and philtrum width 
highlighted the potential aetiological relevance of the philtrum to the development of 





and the severity of an OFC, a dose-response effect would further support the liability 
threshold model.  
Of the adverse outcomes considered in Chapter 6, dental anomalies were 
possibly the most biologically plausible to have genetic overlap with nsCL/P but there 
wasn’t sufficient power to test for an association. Combining genetic data on dental 
anomalies from multiple cohorts would allow for this potential relationship to be 
investigated in future studies. 
In Chapter 7, genetic overlap between nsCL/P and OC/OPC was 
demonstrated but the shared genetic risk factors are currently unclear. Further work 
could investigate common biological processes or shared environmental risk factors 
between the two phenotypes. Additionally, further work is necessary to determine if 
there is genetic overlap between nsCL/P and cancers of other anatomical regions, or 
if the genetic overlap is specific to OC/OPC. It is possible that some genetic risk 
variants are shared by nsCL/P and all cancer subtypes, which would suggest a 
general link between nsCL/P and cancer. Alternatively, if the genetic overlap is 
specific to OC/OPC this would suggest more localised tissue specific effects. If 
strong evidence is found of genetic overlap between nsCL/P and all cancer subtypes 
this could be translated to additional follow-up of nsCL/P cases. 
8.2.2 Maternal environmental risk factors for nsCL/P 
A planned thesis analysis was to use a MR framework to investigate possible 
maternal environmental risk factors for nsCL/P, identified from the observational 
epidemiological literature. However, there were several notable limitations of using 
the available data-sets to infer causality of maternal risk factors using MR which 





data-set, the importance of using MR to investigate maternal risk factors for nsCL/P, 
the theoretical required data-sets and further considerations   
8.2.2.1 Limitations of the ICC data-set for investigation of maternal environmental 
risk factors 
A major limitation was that the ICC data-set, consisting of parent-offspring 
trios, was missing a suitable control group for comparison with the mothers of cases. 
Matching to population controls and using paternal controls were both considered 
but these methods were potentially susceptible to a range of biases including, 
population stratification, batch effects, a causal effect of offspring genotype and 
assortative mating 339. In particular, the difficulties of matching across different 
studies and genotyping chips were demonstrated in Chapter 3.  
A second limitation was that many of the exposures of interest from the 
epidemiological literature have only one or two genetic risk variants identified at 
genome-wide significance (e.g. zinc 340). Relaxing the inclusion threshold and using 
GWAS summary statistics to construct allele scores would be one possibility to 
increase power 341. Another possibility would be to use the MR-RAPS estimator, a 
profile score based method which benefits from the inclusion of many SNPs, even 
weakly associated SNPs 342. However, more than half of the ICC sample was non-
European, and there is an absence of GWAS data for many of the exposures of 
interest in non-European populations. The use of genetic instruments derived in 
Europeans in an Asian population, without appropriate testing, could reduce power 
or even bias causal estimates.  
A final limitation is that even in the best case scenario, MR power calculations 
343 demonstrated that the available sample sizes are insufficient to detect modest to 





the variation in both European and Asian populations are available, and each 
nsCL/P mother could be successfully matched to 4 controls, the data-set has 80% 
power to detect an OR of 1.38 (Table 32). Previous meta-analyses of 
epidemiological studies suggested that for possible maternal risk factors for nsCL/P, 
the magnitude of effect (if there is a causal effect) is likely to be small to moderate 
57,67. 
 





























0.01 2.31 4.26 1.88 2.69 
0.02 1.91 2.85 1.61 2.03 
0.03 1.73 2.36 1.49 1.79 
0.04 1.63 2.11 1.42 1.66 
0.05 1.56 1.95 1.38 1.57 
 
8.2.2.2 Importance of MR to test maternal risk factors for nsCL/P? 
Given that the available data-sets have insufficient sample sizes for MR 
analyses of environmental risk factors for nsCL/P, it is first important to consider the 
importance of identifying maternal risk factors for nsCL/P and the advantages of 
specifically using MR.  
Importance is highly subjective, but from an epidemiological perspective, 
direct translation of MR results for prevention of nsCL/P is likely to be difficult given 
the probable modest effects of exposures and the relative rarity of nsCL/P. However, 





for nsCL/P. Firstly, determining causal relationships and exploring the biological 
mechanisms can lead to increased aetiological understanding of nsCL/P and 
potentially other congenital anomalies. Secondly, if an exposure that is already 
known to have intra-uterine effects (e.g. maternal folate) is shown to be aetiologically 
relevant to nsCL/P, this would strengthen the argument for public health 
interventions on folate levels during pregnancy.  
The use of MR to evaluate the potential causality of maternal exposures for 
nsCL/P may have advantages over both observational epidemiological studies and 
candidate gene approaches (e.g. using a single variant in MTHFR, a gene implicated 
in folate metabolism). Furthermore, comparing and contrasting the evidence from 
different methodologies, which have different sources of bias, can help to strengthen 
conclusions 344.  
8.2.2.3 Required data-sets? 
The next consideration is the required data-set for well-powered and non-
biased testing for MR analyses. A major challenge is recruitment because the ideal 
data-set would have genetic data for affected offspring, both of their parents and the 
mothers of controls 339. Power calculations suggest that even with relatively strong 
genetic instruments, much larger datasets than the ICC are required for MR 








Table 33: What sample sizes are required to investigate maternal risk factors for 
nsCL/P? 
True OR per 1 S.D. 
increase in exposure 
Proportion of variance 
explained in exposure by 
genetic instruments (R2) 
Number of cases 
required 
(Assuming 1 case paired 
with 4 controls) 
1.1 0.01 101,918 nsCL/P mothers 
0.02 50,959 nsCL/P mothers 
0.03 33,973 nsCL/P mothers 
0.04 25,480 nsCL/P mothers 
0.05 20,384 nsCL/P mothers 
1.2 0.01 26,373 nsCL/P mothers 
0.02 13,187 nsCL/P mothers 
0.03 8,791 nsCL/P mothers 
0.04 6,594 nsCL/P mothers 
0.05 5,275 nsCL/P mothers 
1.3 0.01 12,092 nsCL/P mothers 
0.02 6,046 nsCL/P mothers 
0.03 4,031 nsCL/P mothers 
0.04 3,023 nsCL/P mothers 
0.05 2,419 nsCL/P mothers 
 
Assembling samples of these sizes would be a substantial undertaking as 
OFCs are relatively uncommon; with an estimated incidence of 1 in 700 for all non-
syndromic OFCs and 1 in a 1000 for nsCL/P 1. The need for such large study 
samples could be alleviated by the derivation of stronger genetic instruments for the 
maternal exposures. The use of non-specific allele scores consisting of thousands of 
variants, not necessarily reaching genome-wide significance, could further increase 
power 341. However, whether genetic instruments explaining more than 5% of the 
variation in an exposure can be derived for exposures of interest is largely 
dependent on the genetic architecture and heritability of the exposure, and therefore 
may not be possible in some instances. 
8.2.2.4 Further considerations 
Assuming the availability of appropriate data-sets, there are several further 





proposed maternal exposure may also increase the risk of miscarriage. If children 
with nsCL/P have increased frailty (and so are at increased risk of miscarriage) and 
an exposure is associated with miscarriage, then there is potential for survival bias. 
Secondly, depending on the study population, gene-environmental interactions may 
distort the interpretation. For example, in the US, folate fortification is now mandatory 
and so in an MR analysis, the true effect of folate on nsCL/P may be 
underestimated. Another example is that if alcohol behaviour during pregnancy 
differs across different cultural groups, the maternal alcohol SNPs in an MR analysis 
may not be associated with expected outcomes in the offspring (i.e. alcohol SNPs 
will not be associated with outcomes in groups who do not drink alcohol for cultural 
reasons). Thirdly, many of the proposed risk factors may have complex interlinked 
relationships. Both, maternal smoking and adiposity have been explored as risk 
factors but these relationships are complicated by the fact that smoking is known to 
cause weight loss 345. Similarly, disentangling the relationship between the different 
phenotypes in the one-carbon metabolism folate pathway may require more complex 
modelling. Multivariable MR could be one approach used to tackle this issue 346.  
8.3 Summary 
The results presented in this thesis are a starting point for the use of PRS and 
MR to unravel the causes and consequences of nsCL/P. Notable successes of this 
preliminary work included demonstration of shared genetics between nsCL/P and the 
philtrum, evidence for DNA methylation mediating the effects of nsCL/P genetic risk 
variants and evidence of genetic overlap between nsCL/P and a cancer subtype. 
Future work, with larger sample sizes, will have improved power to explore the 
aetiology of nsCL/P, unravel subtype heterogeneity and test the phenotypic 
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